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Preface   
 
Preface 
 
This work is based on three health care-related observational studies conducted 
and/or analysed by the author. All three were primarily analysed using conventional 
multivariate regression methods, where the term conventional is used in the sense of 
not fully taking into account the hierarchical or multiple membership structure of the 
underlying datasets. In an additional step, re-analyses of all three datasets were 
performed using multilevel modelling, a novel statistical technique taking hierarchical 
data structures into account. 
 
The thesis is structured as follows. An introduction (chapter 1) sketches the fields of 
research addressed by the author and establishes the rationale for taking hierarchical 
(multilevel) data structures into account when doing research work in these fields. 
Different ways of dealing with multilevel data are briefly compared. The introduction 
is followed by a brief section summarising overall objectives (chapter 2). 
 
A general methods section (chapter 3) identifies the common statistical principles 
applied to the conventional analyses performed, and describes the approach to 
multilevel re-analysis. The issue of predictive ability is addressed in this context and 
a framework for comparing the results of the conventional regression analyses vs. 
multilevel analyses is described. 
 
The designs, methodological details and conventional-based results of the empirical 
studies which form the basis of this work have been reported and discussed in peer-
reviewed publications. These publications constitute the first three out of four results 
chapters (chapters 4-6). The fourth (chapter 7) summarises the results of multilevel 
re-analysis and compares these with the conventional-based findings. 
 
Adopting a broader viewpoint, the overall discussion (chapter 8) addresses the 
contribution of the three observational studies reported, and of the multilevel 
modelling-based results in particular, to current knowledge in the respective fields of 
research. Multilevel vs. conventional results are put into perspective and some 
conclusions are drawn with respect to the use of multilevel modelling in health care-
related research. 
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Three appendices describe details of the multilevel re-analyses, of the cross-
validation techniques applied, and of the characteristics, advantages and 
disadvantages of the statistical software used for these purposes. 
 
As chapters 4-6 of this thesis were previously published, it was decided to leave their 
counting of tables and figures untouched. Consequently, tables and figures are 
numbered chapter-wise. A list of tables and a list of figures are contained after the 
table of contents. All references are listed in alphabetical order at the end of the 
thesis. In addition, the references lists of the peer-reviewed publications were 
retained, but adjusted to the same format and numbering as in the main references 
list. Journal names were abbreviated according to the List of Journals Indexed for 
MEDLINE (2005; formerly Index Medicus). Journal names not contained in this list 
were not abbreviated. 
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Summary   
 
Summary 
 
In health care-related research, many studies circle around the problem of identifying 
risk factors for clinical events of interest, with a potential for economic consequences, 
or risk factors for increased health care costs. Multivariate regression methods are 
typically used to analyse such studies and have become central for an efficient 
control of confounding and assessment of effect modification. 
 
However, most of the data used for this type of research are characterised by 
hierarchical (multilevel) data structures (e.g., patients are frequently nested within 
treating physicians or study centres). Standard multivariate regression methods tend 
to ignore this aspect and it has been shown that this may lead to a loss of statistical 
efficiency and, in some cases, to wrong conclusions. Multilevel regression modelling 
is an emerging statistical technique which claims to correctly address this type of 
data, and to make use of their full potential. 
 
The author conducted and/or analysed three observational studies of factors 
associated with clinical events or cost endpoints of interest. In all cases, conventional 
regression methods were primarily used. In a second step, multilevel re-analyses 
were performed and the results were compared. 
 
The first study addressed the effect of exacerbation status, disease severity and 
other covariates on the disease-specific health care costs of adult Swiss asthma 
patients. Among other factors, the occurrence of asthma exacerbations was 
confirmed to be independently associated with higher costs, and to interact with 
disease severity. 
 
The second study addressed the impact of gatekeeping, a technique widely used to 
manage the use of health care resources, on the health care costs accrued by a 
general Swiss population. In a situation characterised by ambiguous research 
findings, the author's study indicated substantial cost savings through gatekeeping as 
opposed to fee-for-service based health insurance. 
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  Summary 
Finally, a combined dataset of six retrospective audits of breast cancer treatment 
from several Western European countries was used to estimate, for common 
chemotherapy regimen types, the frequency of chemotherapy-induced neutropenic 
events and to identify or confirm potential neutropenic event risk factors. Neutropenic 
events were shown to occur frequently in routine clinical practice. Several factors, 
including age, chemotherapy regimen type, planned chemotherapy dose intensity, 
and planned number of chemotherapy cycles, were shown to be potentially important 
elements of neutropenia risk models. 
 
Multilevel re-analysis showed higher level variation (i.e., variation at the level of the 
treating physicians or study centres) to be present in the asthma dataset and in the 
neutropenia dataset, but not in the gatekeeping dataset. In the first-mentioned cases, 
multilevel modelling allowed to quantify the amount of higher level variation; to 
identify its sources; to identify spurious findings by analysing influential higher level 
units; to achieve a gain in statistical precision; and to achieve a modest gain in 
predictive ability for out-of-sample observations whose corresponding higher level 
units contributed to model estimation. The main conclusions of the conventional 
analyses were confirmed. 
 
Based on these findings and in conjunction with published sources, it is concluded 
that multilevel modelling should be used systematically where hierarchical data 
structures are present, except if the higher level units must be regarded as distinct, 
unrelated entities or if their number is very small. Erroneous inferences will thus 
become more unlikely. Moreover, multilevel modelling is the only technique to date 
which allows to efficiently test hypotheses at different hierarchical levels, and 
hypotheses involving several levels, simultaneously. In the authors opinion, multilevel 
analysis is of particular interest where characteristics of health care providers, and 
clinical practice patterns in particular, may impact on health outcomes or health 
economic outcomes. It is only another facet of the same argument that multilevel 
modelling should also be used in multi-centre studies (including randomised clinical 
trials) to take into account study centre-specific characteristics and behaviours. 
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In many instances, the use of the technique will be tentative and rule out the 
presence of substantial higher level variation. If so, simpler methods can again be 
used. 
 
Besides some technical issues, the main disadvantage of multilevel modelling is the 
complexity involved with the modelling process and with correctly interpreting the 
results. A careful approach is therefore needed. Multilevel modelling can be applied 
to datasets post hoc, as the author has done, but superior results can be expected 
from studies which are planned with the requirements of multilevel analysis (e.g., 
appropriate sample size, collection of relevant covariates at all hierarchical levels) in 
mind. 
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Chapter 1 
 
Introduction 
 
In modern epidemiology and health care-related research, many studies circle 
around the problem of identifying factors associated with the occurrence of clinical 
events of interest, which will often have a potential for severe medical and/or 
substantial economic consequences. Goals may include to describe and identify 
such factors as a basis for further analysis, to establish causality between these 
factors and the events of interest (i.e. to establish them as true risk factors), to 
develop statistical models predicting individual or group-level risk, and ultimately to 
design new interventions for the betterment of the underlying health problems 
[100:10-3·176]. In other studies using very similar methodology, the endpoint may not 
be clinical event occurrence but cost in a population with a given disease of interest, 
or in a general population. In populations with chronic diseases, identifying correlates 
of cost, together with clinical findings, may help targeting further research and 
resources efficiently and, moreover, provide important input information for health 
economic evaluation studies (i.e., cost-effectives and cost utility analyses) [208]. 
Where general populations are regarded, the interest typically is in the ability of 
health care financing or health systems interventions to contain or reduce health care 
costs (without affecting quality of care). 
 
Where randomised trials are not feasible for ethical or practical reasons, e.g. in the 
study of treatments which are generally believed to be effective, of health risks and 
health behaviours, or of large-scale health system interventions, such research is 
often based on prospective or retrospective observational data collections. This 
thesis is based on three distinct studies falling into this group. 
 
Cost of illness of asthma 
The first study is a cost of illness analysis of adult Swiss asthma patients. Numerous 
studies have been conducted to describe the absolute and relative contribution of 
different cost items (e.g., medication costs, inpatient costs, indirect costs due to lost 
working days, etc.) to the cost of asthma, mostly in industrialised countries [11·79]. In 
17 
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contrast, the patient, disease, and treatment characteristics associated with high 
asthma costs were rarely and less systematically addressed. Based on a 
retrospective, medical charts-based dataset collected in 1996/1997, the author 
assessed correlates of direct medical asthma costs, with a special focus on the 
impact of disease severity and asthma control (chapter 4). 
 
Gatekeeping vs. fee-for-service based health insurance 
In the last three decades, most if not all industrialised countries were confronted with 
a situation where health care expenditures grew faster than gross domestic products 
[152]. This pronounced rise, caused by a mix of demand-side factors (e.g., 
demographic change, increased standard of living, enhanced access to information) 
and supply-side factors (new products and technologies) was rapidly perceived as a 
problem and a search for cost-saving interventions in the fields of health care 
financing, regulation, and organisation began [17·37]. The rise of managed care in 
the USA is the most widely known result of this process [155]. Various types of 
financial incentives, such as capitation, and techniques of utilisation management, 
such as utilisation review and gatekeeping, were newly introduced in a variety of 
countries [17·219]. Research addressing the impact of such interventions on health 
care costs and on quality of care gained in importance in parallel, but had to deal with 
several methodological challenges. In general populations, person-level health care 
costs vary widely, show a complex distribution, and are influenced by a multitude of 
health plan beneficiary characteristics (resulting in substantial differences in case-
mix) and provider characteristics [51]. Where studies focus on a limited set of 
diseases or types of service, generalisability may be substantially reduced. 
Moreover, in most real-life settings, several interventions and techniques are applied 
jointly in various combinations [194]. This makes it difficult to separate out the effects 
of single techniques of interest and confronts the researchers with changing 
comparators. 
 
Gatekeeping is one the most frequently used techniques of utilisation management 
[17·194]. In typical health plan-level gatekeeping arrangements, patients select a 
primary care physician who must authorise specialist referrals, expensive diagnostic 
procedures, and hospital admissions [194]. The primary aims are to improve 
coordination, to avoid wasteful use of resources, to protect patients from redundant 
18 
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or harmful treatments, and to foster continuity of care [68·73·137]. The author had the 
opportunity to compare a Swiss gatekeeping solution, one of the few worldwide 
where gatekeeping is used as stand-alone technique, with a classical fee-for-service 
plan (chapter 5). 
 
Neutropenic events in breast cancer chemotherapy 
Chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) are regarded 
as the most common dose-limiting toxicities of modern anticancer chemotherapy. 
They may impact on short-term as well as long-term treatment outcomes 
[23·119·153·191]. Research addressing the incidence and risk factors of CIN, FN, 
and subsequent events (i.e., chemotherapy dose delays, chemotherapy dose 
reductions, hospitalisations) has gained in importance during the last 15 years. 
Related sources of information include 
• clinical trials of anticancer treatments where CIN and FN are reported as adverse 
events [47]; 
• clinical trials of myelopoietic growth factors (colony-stimulating factors; CSFs), 
undertaken to assess the anti-neutropenic effects of this class of substances and 
typically performed under tightly controlled conditions (defined chemotherapy 
regimens; narrow eligibility criteria) [88·102·157·213·218]; 
• observational studies, undertaken prospectively or retrospectively, with the 
primary aims of assessing neutropenic event incidence in clinical practice and 
related risk factors, and with the ultimate goal of developing clinically applicable 
risk models [38·123·132·185]; 
• clinical trials specifically undertaken (very rarely) to confirm neutropenic event risk 
factors or validate risk models [171]. 
 
Despite some substantial efforts, no final conclusions have yet been reached in this 
field. (See Lyman et al. for a recent review [132]). The author used six retrospective 
audits of breast cancer treatment from several Western European countries to 
estimate neutropenic event incidences for the chemotherapy regimen types used, 
and to extract any information considered suitable to contribute to the discussion 
around neutropenic event risk factors. The audits used were essentially reflecting 
routine clinical practice, but had some limitations in terms of data availability (chapter 
6). 
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Multivariate regression methods and multilevel data structures 
Various types of multivariate regression techniques, appropriate for different types of 
response variables, have become standard methods in the analyses of observational 
and, increasingly, experimental data. Since computers have become available to 
rapidly execute estimation algorithms, their importance for an improved control of 
confounding and assessment of effect modification has become paramount. 
Consequently, such regression methods were also used in the primary analysis of 
the above-introduced studies. 
 
However, most conventional regression methods, inclusive of multiple least squares 
regression, logistic regression, and generalised linear modelling, assume 
independence of the observations on which the regression is performed 
[105:3,5·116:116]. In health care-related research as well as in many other fields, this 
assumption is conceptually violated in a wide range of situations [83:1/1-2·99:1-2]. 
For example, there may be repeated measurements across time, nested within 
observed persons. Observed persons may be nested within families or geographical 
units, within physicians' offices, or within hospitals. Participants in multi-centre clinical 
trials are nested within study centres. More complex situations of multi-membership 
or cross-classification can, e.g., occur where persons are independently nested 
within physicians' offices and, at the same time, within insurance companies. 
 
Ignoring such hierarchical (multilevel) data structures was and probably still is the 
rule. Typically, analysis uses "conventional […] regression analysis with one 
dependent variable at the lowest (individual) level and a collection of explanatory 
variables from all available levels" [105:4], which involves disaggregation of higher 
level variables [58]. To what extent this approach influences research findings cannot 
be answered in general but will depend on the de facto degree of violation of the 
independence assumption. Potential consequences of ignoring hierarchical data 
structures include the following. 
• A decrease in statistical efficiency and inflated standard errors may occur, as no 
full use is made of the available information [83:1/2·169: 42-3]. On the other hand, 
violation of the independence assumption can lead to false low standard error 
estimates [9·58·83:1/2·105:3,5-6]. For both reasons, there is a risk of incorrect 
20 
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inferences regarding the existence of statistical associations and of incorrect 
decisions regarding the inclusion or exclusion of model parameters. 
• Effects on the response variable occurring at different hierarchical levels cannot 
be appropriately identified and explained [83:1/11·105:3-4,6-7]. Related difficulties 
to interpret regression results may lead to an arbitrary choice of models and 
impact negatively on predictive ability [220]. 
• Variation of the response variable of interest occurring at the higher level(s) 
cannot be quantified at the population level, i.e. any statements are at best 
possible for the higher level units directly observed [83:1/3].  
• Ultimately, wrong conclusions may occur [1·83:1/1-2]. 
 
Approaches to multilevel data structures 
The problem of multilevel data structures has been discussed for at least two and a 
half decades [83:1/2] and there are a variety of ways to address it (Table 1). 
However, most of the proposed techniques provide only partial solutions and suffer 
from sub-optimal use of the available information. Some of them are suitable if the 
researchers' interest is restricted to either the lowest or the highest level in the 
hierarchy of observation, and allow to estimate unbiased standard errors. However, a 
meaningful quantification of higher level variation in the total population of interest is 
only achieved by random effects analysis or multilevel modelling, and only the latter 
technique is suitable to satisfactorily assess effects occurring at different levels or 
involving several levels [9·52·54]. 
 
Multilevel modelling 
Multilevel modelling has been developed since the early 1980s [1·186:49]. It was first 
used in the educational sciences [83:1/1-3·105:8] but disseminated to other fields 
rapidly [54·105:8]. Recent advances in multilevel modelling software have further 
accelerated this development [91]. 
 
In health care-related research, the number of applications is still small if compared 
to the huge overall number of studies published [91], but growing exponentially 
(Figure 1). 
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Figure 1. Frequency of use of multilevel modelling in health care-related research 
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Multilevel modelling aims at combining and analysing information from different 
hierarchical levels within a single statistical model [105:7]. It can be regarded as a 
multilevel extension of multiple linear regression and other conventional multivariate 
regression techniques [105:8]. Fixed effects are estimated for all model covariates. In 
addition, random effects are estimated for the higher level covariates as needed, i.e. 
the variance-covariance structure of the data is analysed. Higher level effects are 
thus summarised by very few distribution parameters, instead of estimating separate, 
unrelated effects for each higher level unit [58]. In a second step, the higher level 
units are characterised by sets of higher level residuals derived using the empirical 
Bayes approach [33:57-8·52·91·99:7-9·161:27·186:221-35,245,247]. In other words, 
the values of the random effects (and the uncertainty around them) are estimated for 
each higher level unit, making use of the information directly available from this unit, 
but also of the information provided by all other units contributing to estimate the 
model (see chapter 3, pp. 36-7) [83:2/9-10·91·99:7-9·168·186:228]. This allows to 
compare the higher level units involved and may allow, for their corresponding lowest 
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level observations, to predict the response of interest with increased precision 
[82·83:2/9-10·161:27·168·186:245]. Influences on the response of interest occurring 
at different levels, or involving several levels, can be identified and characterised 
[9·54·58]. The key underlying assumption is that the observed higher level units are 
not distinct and unrelated, but a random sample drawn from a wider population of 
higher level units [58·83:2·99:3]. 
 
A well-structured, relatively non-technical introduction to multilevel modelling, 
although no longer reflecting today's technical possibilities, has been published by 
Duncan, Jones and Moon [58]. As a starting point, the authors use the concepts of 
contextual effects (i.e., higher level effects such as geographical area effects 
impacting on individual-level health outcomes of interest) and compositional effects 
(i.e., apparent higher level effects which are in fact caused by an unequal distribution 
of influential individual-level factors across higher level units.) 
 
Rationale to use multilevel modelling with the above-introduced studies 
The datasets underlying the above-introduced cost of asthma, gatekeeping, and 
neutropenia studies are all characterised by multilevel or multi-membership data 
structures. Primary analysis as reported in chapters 4-6 did not take this into account, 
with the partial exception of the neutropenia study where robust standard errors were 
estimated using the generalised estimating equations (GEE) approach. Obvious 
reasons not to use multilevel modelling, such as very small numbers of higher level 
units [163:95], did not apply. Some systematic reviews of the use of multilevel 
modelling in health care-related research were available [54·58·151·167·168], but did 
not help to decide if a benefit of using multilevel modelling with the datasets under 
study could be expected. 
 
This situation gave rise to the question if multilevel modelling would extend, confirm, 
or contradict the results of the conventional regression analyses performed on the 
cost of asthma, gatekeeping, and neutropenia datasets. Further, would multilevel 
modelling make a substantial contribution to the research questions under study, and 
would comparison of the multilevel and conventional-based results allow to draw 
more general conclusions regarding the use and usefulness of multilevel modelling? 
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Chapter 2 
 
Objectives 
 
The first objective of this thesis is to present the methodology and results of three 
observational studies conducted and/or analysed by the author, all addressing the 
impact of potential risk factors on clinical events of interest (neutropenia study), or on 
endpoints representing health care costs (cost of asthma study, gatekeeping study). 
This includes to describe and put into perspective any substantial contributions to the 
current body of knowledge in the fields of research addressed. (The objectives of the 
individual studies are detailed in chapters 4-6). 
 
All three underlying datasets are characterised by multilevel or multi-membership 
data structures. They were primarily analysed using conventional multivariate 
regression techniques, then re-analysed using multilevel modelling. In other words, 
the multilevel approach was used to perform a sensitivity analysis with a tool that was 
assumed to make more realistic assumptions on the nature of the data. The second 
objective of this thesis is to compare the findings established, and to assess if the 
results of the conventional approach are supplemented and refined, confirmed, or 
contradicted by the findings of the multilevel approach. 
 
Making use of the above, a third objective is to assess if multilevel modelling, by its 
application to the author's studies or to other studies, has influenced, or can be 
expected to influence, current knowledge in the fields addressed. 
 
The fourth, most general objective is to describe implications for the use of multilevel 
modelling in health care-related research: Under what circumstances is the multilevel 
approach promising or even a requirement, and what additional contributions can be 
expected? 
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Chapter 3 
 
Methods 
 
This chapter identifies the common statistical principles applied to the conventional 
analyses reported in chapters 4-6, and describes the approach to multilevel re-
analysis. The issue of predictive ability is addressed in this context and a framework 
for comparing the results of conventional regression analysis and multilevel analysis 
in a structured way is described. 
 
All statistical tests were carried out two-sided at a 5% significance level, and all 
confidence intervals (CIs) were two-sided 95% CIs, except where otherwise stated. 
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Approach to conventional analysis - descriptive and univariate 
statistics 
 
At the descriptive level, total numbers of observations were reported and the 
numbers, percentages and reasons of non-evaluable observations were assessed. 
The occurrence of missing values was assessed for the endpoints and covariates of 
major interest. Where appropriate, missing values were evaluated for any 
relationship with these endpoints and covariates. 
 
Endpoints and covariates were assessed based on the following descriptive 
statistics: number of observations, mean, standard deviation, median, quartiles and 
range for discrete numerical and continuous variables; number of observations, 
counts and percentages for categorical and ordered categorical variables. Graphical 
analyses (histograms, boxplots) were added as needed. Where appropriate, CIs 
were calculated for incidences, durations, etc. 
 
Univariate statistical tests comprised the chi-squared test or Fisher’s exact test for 
categorical data. Where one ordered categorical variable was involved, a chi squared 
test for trend was added [4:261]. Where two ordered categorical variables were 
involved, Spearman's correlation coefficient and its p value were added [4:265]. 
Where one discrete numerical or continuous variable was involved, parametric tests 
(e.g., T-test, ANOVA) or non-parametric tests (e.g., Mann-Whitney U test, Kruskal-
Wallis test) were performed as appropriate, depending on the underlying 
distributions. For two discrete numerical or continuous variables, Pearson's or 
Spearman's correlation coefficients and their p values were calculated, depending on 
the underlying distributions and shape of the corresponding scatter plots [4:279,286-
7]. 
 
Measures of effect and their CIs were calculated as appropriate. They comprised 
absolute and relative differences, relative risks (RRs), and odds ratios (ORs). 
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Approach to conventional analysis - regression analyses 
 
The choice of regression techniques was based on the scaling and distribution of the 
dependent variables of interest (responses). In the asthma study, multiple linear least 
squares regression (multiple regression) was used on logarithmically transformed 
health care cost data containing no zero values. In the gatekeeping study, two-part 
regression models were used to analyse heavily skewed health care cost data 
containing a substantial amount of zero values. These two-part models consisted of 
logistic models of any costs, and of generalized linear models (GLMs) of the amount 
of costs in the persons with non-zero costs. The GLMs assumed a gamma 
distribution of the response and used a logarithmic link function [20·51]. In the 
neutropenia study, logistic regression was used to model a binary response in a 
combined dataset composed of several retrospective audits of neutropenic event 
occurrence in breast cancer patients. As heterogeneity between these audits was 
found with respect to some variables [205], robust standard errors allowing for 
clustering of observations were estimated using the GEE approach [175·186:259-60]. 
In alternative model specifications, the individual audits were represented by dummy 
variables, or the clustering option was used at the level of study centres, for 
comparison purposes. 
 
Potential predictor variables qualified as candidate predictors if an association with 
the response variable (dependent variable) of interest seemed realistic on logical (i. 
e., biological, clinical, etc.) grounds or on statistical grounds (p ≤ 0.25 in univariate 
analysis) [15·104:95·142]. Potential direct correlates of the dependent variables of 
interest (such as resource use variables in the cost models) were not used to rule out 
circularity effects. In the model building process, main effects were identified by 
exploring all plausible combinations of covariates manually. Decisions to include or 
eliminate variables were based on the significance of the individual predictors (based 
on the T statistic in the case of multiple regression and on Wald tests in the cases of 
logistic regression and general linear modelling [105:45·116:141-3,647]), and on their 
ability to significantly improve the model (namely where groups of variables were 
addressed; based on multiple partial F tests in the case of multiple regression and on 
likelihood ratio tests in the other cases [104:12-6·116:143-5,649-53]). Formalised 
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variable selection procedures such as stepwise regression may yield implausible 
results and were used for control purposes only [90]. In a second step, statistically 
significant first order interaction terms were added. 
 
Additional relative fit criteria [186:262] taken into account when comparing competing 
models were the unadjusted and adjusted R squared statistic in the case of multiple 
regression [4:345-6], the pseudo R squared statistic in the case of logistic regression 
[104:164-7·143], and minimisation of the deviance and the Akaike Information 
Criterion (AIC) in generalised linear modelling [96:38,45]. 
 
In the assessment of model adequacy, Skrondal and Rabe-Hesketh distinguish 
global absolute fit criteria, which are indicators of any misspecification being present, 
and local absolute fit criteria, which are used to identify the sources of 
misspecification [186:267-8,272-3]. Local absolute fit criteria include, among others, 
graphical residuals diagnostics and the identification of overly influential 
observations. 
 
Global absolute fit was assessed using tests of model summary statistics in the case 
of multiple regression (using F tests [116:137-8]) and in the case of logistic 
regression (using likelihood ratio tests [104:12-6]). It was not specifically assessed in 
the GLM case. A number of model summary measures have been proposed for 
GLMs, but none of these could be assumed to have satisfactory properties [223]. 
Local absolute fit of the models was assessed and near-collinearity issues were 
addressed as shown in Table 1. The impact of any influential points identified was 
assessed by tentatively omitting them or absorbing them into dummy variables, and 
re-estimating the models. 
 
Apparent prediction error was assessed for the final multiple regression models and 
gamma generalised linear models using the root mean squared error (RMSE) and 
the mean absolute error (MAE) [51·127]. The RMSE was calculated by taking the 
absolute difference of each observation's predicted and observed outcome, squaring 
the difference, and taking the square root of the mean squared differences [51]. The 
mean absolute error was calculated by averaging the absolute difference of each 
observation's predicted and observed outcome [51]. In the case of logistic regression, 
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Table 1. Local absolute fit criteria (measures of goodness-of-fit and to identify 
influential data points) and techniques applied to assess near-collinearity problems, 
by type of regression 
Measures and 
techniques 
used 
Multiple regression Logistic regression Generalized linear 
modelling 
• to assess 
goodness-of-
fit 
Plots of residuals 
against predictor 
variables and predicted 
values, inverse normal 
plots of residuals 
[4:346-7] 
Hosmer-Lemeshow 
goodness-of-fit test 
[104:147-56], plots of 
mean observed against 
mean predicted event 
probabilities by deciles 
of the linear predictor 
Residual diagnostics 
using studentised 
Deviance residuals and 
Anscombe residuals 
[96:40-4·141:37-
40,396-9] 
• to identify 
influential 
data points 
Tentative exclusion of 
observations with high 
values of the 
dependent variable, of 
observations with large 
studentised residuals, 
and of data points with 
Cook's distance > 1 
[116:228-33] 
-- Tentative exclusion of 
observations with high 
values of the 
dependent variable, of 
observations with large 
studentised residuals, 
and of data points with 
Cook's distance > 1 
[141:406-7] 
• to assess 
near-
collinearity 
problems 
Check for high 
correlation coefficients 
between independent 
variables, inflated 
standardised 
regression coefficients, 
and high variance 
inflation factors (VIFs) 
[116:241-2] 
Check for high 
correlation coefficients 
between independent 
variables, and inflated 
standardised 
regression coefficients 
Check for high 
correlation coefficients 
between independent 
variables, check for 
inflated standardised 
regression coefficients, 
comparison of models 
using centred vs. non-
centred independent 
variables, assessment 
of collinearity in 
"parallel" multiple 
regression models 
 
classification tables indicating the proportion of correct predictions were used 
[104:156-60]. As addressed in the discussion (chapter 8), split-sample and cross-
validation methods were not primarily used in the conventional regression analyses. 
However, predictive ability was an important issue when comparing conventional and 
multilevel models. For reference purposes, cross-validation was performed, at a later 
stage, on those conventional models with multilevel counterparts. Details are 
described on pp. 39-40 below. 
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Approach to multilevel modelling 
 
Multilevel analyses were based on the same responses and distributional 
assumptions as the conventional regression analyses. In the asthma study, multilevel 
modelling of the continuous, normally distributed logarithm of direct medical asthma 
costs was used as the multilevel equivalent of multiple regression analysis. 
 
The binary endpoints of any health care costs being accrued (in the gatekeeping 
study) and of any neutropenic event occurrence (in the neutropenia study) were 
addressed by using multilevel GLMs of binomial responses and with a logit link 
function [83:7/1-3·163:101,127]. For the neutropenia dataset, the approach to 
estimate GEE-based robust standard errors was retained (see Appendices I and III). 
A possible impact on decisions regarding the inclusion or exclusion of model 
parameters was assessed by alternatively using conventional standard error 
estimates. Dummy variables representing the individual audits contributing to the 
neutropenia dataset were also tried (see Appendix I). 
 
In the gatekeeping study, multilevel modelling of health care costs in those with non-
zero costs, a heavily skewed cost response, was either based on multilevel GLMs 
with a logarithmic link function and assuming a gamma distribution, which is directly 
equivalent to the approach chosen in conventional analysis. Alternatively, the cost 
data were interpreted as discrete count data and a negative binomial distributional 
assumption was used in combination with a (canonical) logarithmic link function 
[83:7/10·141:373]. Under this assumption and conditionally on the fitted explanatory 
variables and higher level terms, the mean count for each level 1 unit has a gamma 
distribution. It was expected that this approach would allow to reproduce the original 
gamma GLM results fairly adequately, and perform subsequent multilevel analyses 
as applicable. (The adequacy of this approach was also supported by the fact that in 
the original analysis, tentative negative binomial regression and the gamma 
approach yielded very similar results.) 
 
The multilevel analyses used an analysis strategy similar to the one described by 
Hox [105:49-54]. They were based on the same candidate predictors as the 
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conventional regression analyses. In a first step, the hierarchical structure of each 
underlying dataset was analysed and hierarchical levels were assigned to the 
candidate predictors. In a second step, using the conventional regression models as 
a starting point, the intercept terms were allowed to vary at random at the higher 
levels, i.e. variance component models were estimated [105:52]. Variance partition 
coefficients indicating the proportion of the total variance which was due to higher 
level variance, were calculated [83:2/4-5·105:51]. For logistic multilevel models, the 
method proposed by Snijders and Bosker was used [164:114·192]. 
 
If substantial and significant higher level variation was found to be present in the 
dataset, the variance structure was analysed, i.e. potential higher level predictors in 
the strict sense as well as level 1 variables with a potential for higher level variation 
were tentatively allowed to vary at random, on a variable-by-variable basis at first 
[105:52-3]. Interactions between predictors from different levels which seemed 
plausible on logical grounds or based on the results of the conventional analyses, 
were assessed in the same way [105:53-4]. In order to achieve this, it was 
sometimes necessary to construct group level predictors by aggregating lower level 
variables (typically, level 1 variables) within their higher level units [52·105·163:63-
75]. In the resulting variance-covariance matrices, relevant and significant 
coefficients were retained, but near-zero or non-significant coefficients dropped, i.e. 
fixed to zero. 
 
The fixed parts of the models were modified where this was suggested by parameter 
or standard error changes occurring when the variance structure was taken into 
account [105:53-4]. In this context, all candidate predictors excluded from the original 
fixed effects models were tentatively re-assessed. In borderline situations, fixed 
effects parameters contained in the main conventional models were retained in the 
multilevel models, in order to facilitate comparison. For the same reason, covariates 
derived by aggregating lower level variables were not included in the final multilevel 
models if they did not show random variation, non-regarding their significance at the 
fixed effects level. 
 
In order to maintain comparability with the conventional regression analyses, against 
recommendations, predictor variables were not primarily centred. However, centring 
34 
  Chapter 3: Methods 
was used where estimation problems occurred and predictor variables with random 
slopes were tentatively centred to assess resulting changes in the estimated 
intercept variance [105:57-8,70-1]. 
 
Goodness-of-fit assessments and assessments of influential higher level units were 
performed on the resulting multilevel models. Subsequently, these models were 
modified and re-assessed as applicable [105:26]. The criteria and techniques used in 
this process were the same as for the conventional regression models where 
possible. Some particularities and additions are described in the subsequent 
sections. 
 
Following a widely used practice, the significance of the fixed parameter estimates, 
and the ability of groups of variables (i.e., sets of predictor variables or interaction 
terms) to significantly improve the model, was assessed using Wald tests [105:45]. 
(Wald tests have been reported to perform sub-optimally, particularly in the case of 
non-normal responses [186:261], but software-related issues restricted the use of 
likelihood ratio tests - see Appendix III for details.) 
 
The significance of the random effects (variance components) was primarily 
assessed by likelihood ratio tests and the resulting p-values were divided by two 
[16·105:45·186:261]. Wald tests were reported to be less appropriate in this case, 
because random effects estimators are not normally distributed (although 
approximately so in the case of normally distributed responses) and because the null 
value is at the left boundary of the parameter space of the expected distributions (as 
variances are expected to be ≥ 0) [161:18·164:32-3]. However, one-sided [105:43] 
Wald tests were additionally used where likelihood ratio tests were unavailable for 
technical reasons (see Appendix III) and in the logistic situation [164:113·169:39], 
where the appropriateness of likelihood ratio tests has been questioned [105:45]. 
Non-parametric bootstrap-based interval estimates for the variance parameters were 
also calculated to confirm the results obtained [164:113]. 
 
The main additional relative fit criterion taken into account in the modelling process 
was minimization of the AIC [105:45-6·186:262-7,352]. Global absolute fit and, 
consequently, internal validity was assumed for the multilevel models, based on the 
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corresponding assessments performed on the conventional regression models. 
Skrondal and Rabe-Hesketh mention several global absolute fit criteria for multilevel 
models, and Hox addresses efforts to derive R squared-like statistics, but all these 
are reported to be only partially satisfactory [105:63-71·186:268-71]. 
 
Assessments of local absolute fit were largely based on graphical residuals 
diagnostics. Multilevel modelling distinguishes level 1 residuals from higher level 
residuals. For example, in a two-level situation, the level 1 residuals describe how far 
the individual observations depart from the regression line representing the level 2 
unit they belong to. The level 2 residuals describe the variation which is present in 
the regression lines representing the level 2 units. In a random intercept random 
slope model, there would thus be two level 2 residuals, one describing the departure 
of the intercept of any given level 2 regression line from the intercept of the overall 
regression line, the other describing the departure of the slope. In a 3-level situation 
there would be additional level 3 residuals, etc. Higher level residuals are always 
shrunken residuals, i.e. their value is always lower than the mean of the raw 
residuals corresponding to the respective higher level unit [99:7-9]. (Raw residuals, in 
this context, are defined as the difference between the predicted and observed 
values of the response variable [186:228].) Following the principle of empirical Bayes 
estimation [33:57-8·52·91·161:27·186:221-35,247], the shrinkage occurs due to the 
fact that any given higher level unit is assumed to belong to a random distribution. 
Thus, the information available from the other units is taken into account [58·83:2/9-
10·168]. The fewer within-unit observations are available and the higher the within-
unit variance is, the smaller is the "credibility" of a given unit's deviation from the 
overall regression line, i.e. the more pronounced is the shrinkage effect towards the 
mean of all higher level units [83:2/9-10·99:7-9·164:35-7·186:228-9]. Expressed in 
more Bayesian terms, the estimated random effects parameters derived during the 
main stage of the multilevel modelling process are used as the prior distribution. The 
likelihood for each higher level unit is then derived from the covariate values and 
responses observed for this unit. Based on Bayes Theorem [33:17], posterior 
distributions and means are estimated, and the latter represent the unit-specific 
higher level residuals or empirical Bayes estimates [162]. The term empirical Bayes 
is used to denote situations where the prior distribution is estimated, using 
maximisation methods, from the same observed data that are to used to derive the 
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likelihood. In contrast, in full Bayesian estimation, establishing the prior distribution 
would involve the use of a hyperprior distribution and integration [33:57-8·186:225-6]. 
 
Residuals-based goodness-of-fit assessments were performed on the level 1 
residuals first, and on the higher level residuals thereafter [186:273]. 
• In the case of a continuous, normally distributed response, level 1 assessments 
were based on standard residual diagnostics similar to those applied in 
conventional multiple regression analysis. These included inverse normal plots of 
the studentised level 1 residuals and plots of studentised level 1 residuals against 
the fixed part predicted values [105:23·116:222-224]. (In the latter case, the 
residuals should be grouped around the x-axis in a parallel band.) 
• In the binary case, plots of mean predicted against mean observed event 
probabilities, by deciles of the linear predictor, were used, as in the non-multilevel 
case. The assumption of an underlying binomial distribution was assessed by 
tentatively allowing extra-binomial variation. Where the binomial assumption is 
part of the model specification itself, the level 1 residual variance component is 
set to one by definition [83:7/2]. Where extra-binomial variation is allowed, the 
level 1 variance is estimated, and it is expected to be very close to one 
[83:7/2·169:35-6]. If this criterion is not met, extra-binomial variation is observed, 
i.e. the data exhibit more or less variation than a binomial distribution. This may 
be due to true over- or underdispersion, or due to model misspecification (e.g., 
omission of levels, important observed or unobserved explanatory variables, or 
interaction terms), or it could be due to use of an incorrect link-function (i.e., the 
use of a logistic model would be inappropriate in this case). 
• In the GLMs using a logarithmic link function and assuming a gamma distribution 
of the conditional response, residual diagnostics taking into account GLM-specific 
particularities were planned to be used at level 1, using studentised Deviance 
residuals and Anscombe residuals (which are not expected to average to zero) 
[96:40-4·141:37-40,396-9·186:276]. 
 
With respect to the higher level residuals, in all cases, the assumption of a 
multivariate normal distribution was assessed graphically by inverse normal plots. 
[83:2/7-8·105:23·122]. In a binary response situation, this assumption may be 
violated when there are few lower level units per higher level unit, or when the 
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underlying probabilities are close to zero or close to one [163:127]. However, no 
practical impact of such a violation was assumed, if at all occurring, as it has been 
shown that parameter estimates in mixed (i.e., part fixed, part random) effects logistic 
regression are robust to misspecification of the distribution of the random effects 
[150]. 
 
The identification of influential observations followed a downwards approach, starting 
at the highest level [105:25-6·163:181-2]. Large higher level residuals were identified 
using caterpillar plots indicating statistically significant deviations from the average 
intercept, or average coefficient, at the 95% level [105:25]. Influence values 
combining residuals and leverage values to measure the impact of each unit or 
observation on the coefficients estimated at the respective level, were additionally 
used [121·163:168-72]. They are a multilevel equivalent of the difference in fit (DFIT) 
measure used in conventional regression [14], which describes the change in the 
predicted value of a data point which is induced by excluding this point before the 
model is estimated. The characteristics of any influential higher level units identified 
were explored further by tentatively absorbing into dummy variables either these 
units as a whole, or (groups of) observations with large lower level residuals nested 
within these units [105:27]. Model re-estimations were then performed and further 
steps were taken as appropriate [83:1/11·163:182]. 
 
Observations being influential at level 1 could have been identified and analysed 
using the same technique, non-regarding if they were nested in an influential level 2 
unit or not. However, this approach was not pursued further, as the issue of lowest 
level influential observations had already been addressed in the conventional 
analyses described in chapters 4-6. 
 
Collinearity issues were not explicitly re-addressed. The assessments performed 
when the conventional regression models were fitted were assumed to be sufficient, 
as the same sets of potential predictors were used. 
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Predictive power of multilevel vs. conventional models 
 
In order to judge predictive power, the final multilevel models were compared with the 
main conventional models, and with conventional models using same fixed effects 
predictors as the final multilevel models. The last-mentioned, additional comparison 
was introduced to distinguish gains in predictive power which were due to multilevel 
modelling-induced refinements at the fixed effects level, or due to the modelling of 
the higher level variation itself. 
 
As the indicator of prediction error, the MSE was used in multiple regression, and 
was intended to be used in generalised linear modelling. Logistic models were 
compared using the Brier score, an MSE-like measure derived by subtracting, for a 
given observation, the predicted probability from the binary endpoint value (i.e., from 
0 or 1), squaring it, and averaging it [97]. In addition, classification tables showing the 
percentage of incorrect predictions were used [104:156-60]. 
 
In a first step, the apparent prediction error of the above-mentioned models was 
calculated. For additional graphical illustration, overlaid plots of predicted vs. 
observed values and of raw residuals (observed minus predicted values) were drawn 
in the case of multiple regression. In the case of logistic regression, overlaid plots of 
predicted vs. observed event probabilities, by deciles of the linear predictor, were 
used. 
 
Apparent error-based assessments will typically overestimate predictive ability 
[116:401-3·170·186:271-2]. Apparent gains in predictive ability due to multilevel 
modelling might not be repeatable in cross-validation. Cross-validation techniques 
were therefore used for further assessment. These were modified to allow for 
differences in the predictive ability of multilevel models in observations whose 
corresponding higher level units did, or did not, contribute to model estimation. The 
empirical Bayes approach [33:57-8·52·91·161:27-8·186:221-35] only allows to 
produce meaningful random effects estimates for the former group of higher level 
units [162]. Here, the available information is used efficiently and gains in predictive 
ability are expected. In contrast, for the latter group of higher level units, informative 
39 
Chapter 3: Methods   
 
(i.e., non-zero) random effects estimates are unavailable, as estimating the likelihood 
function would require some knowledge not only of covariate values but also of the 
corresponding observed responses. This would contradict the notion of prediction for 
observations from additional higher level units with all responses unknown. 
Consequently, gains in predictive ability can only be expected in this situation if the 
multilevel modelling process leads to an improved modelling of the fixed effects also. 
 
Ten-fold cross-validation and bootstrapping were used to assess prediction error for 
the conventional regression models (see Appendix II for details) [29·60]. In order to 
allow for appropriate comparisons with the performance of the multilevel models, 
three situations were regarded. First, the hierarchical structure of the data was 
ignored and all observations were treated as independent. Second, the test set (the 
subset of observations used to assess predictive ability) was restricted to those 
observations which were not contained in the training set (the complementary subset 
of observations used for model estimation) but whose corresponding higher level 
units, through other observations, contributed to model estimation. Finally, the test 
set was restricted to those observations which were not contained in the training set 
and whose corresponding higher level units did neither contribute to model 
estimation, not even through other observations. 
 
Cross-validation of the multilevel models was restricted to ten-fold cross-validation, 
due to computation time requirements. It was performed for the second and third of 
the above-described situations. Consequently, the results were indicative of the 
predictive ability of the multilevel models "within" and "outside" the higher level units 
contributing to model estimation. The option of ignoring the hierarchical structure of 
the data was not used here, as the results would have been difficult to interpret. 
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Comparison of multilevel analyses and conventional regression 
analyses 
 
The main conventional regression models and the final multilevel models were 
compared on the basis of a set of predefined questions as listed hereafter. 
• Did the multilevel models reveal substantial and significant higher level variation? 
• If yes,  
- which proportion of the total variance was explained by between-higher level 
unit variation? 
- did the modelling of the variance structure provide substantial additional 
insights? 
- did the (fixed parts of the) final multilevel models comprise the same predictor 
variables as the main conventional models, or did the modelling of the 
variance structure necessitate modifications at level 1? 
- were the fixed parameter estimates similar to those found in the original 
regression analyses, or did they differ substantially? Were standard error 
changes observed? 
- was the relative fit of the multilevel models substantially improved according to 
the AIC criterion? 
- was the predictive power of the multilevel models increased? 
• As a summary, how do the key findings of the original analyses and of the 
multilevel analyses compare (brief qualitative description)? 
• Can the results of the multilevel analyses, compared to those of the original 
analyses, be described as 
- contradictory 
- making a major additional contribution 
- making an additional contribution 
- largely unchanged, confirmatory 
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Results 
 
The results section consists of four chapters. The first three report and discuss the 
designs, methodological details, and non multilevel-based results of the studies 
introduced in chapter 1. To recapitulate, the first study (chapter 4) addressed factors 
associated with the amount of direct medical asthma costs in an adult Swiss patient 
population. The second (chapter 5) focused on the question if gatekeeping plan 
membership, as opposed to fee-for-service plan membership, was associated with 
reduced health care costs in a general Swiss population. The third (chapter 6) used 
five retrospective European audits of breast cancer chemotherapy to identify risk 
factors of the occurrence of chemotherapy-induced neutropenic events. Multivariate 
regression methods were used to establish associations between these outcomes of 
interest and potential influences. The fourth results chapter (chapter 7) reports if and 
which additional insights were gained by replacing conventional multivariate 
regression methods with multilevel modelling, in order take the hierarchical structure 
of the underlying datasets into account. Findings from both approaches are 
compared. 
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ABSTRACT 
 
Background. A retrospective chart-based study examined the health economics of 
asthma in Switzerland in 1996/97. 
Objective. To address the effect of exacerbation status, disease severity (defined by 
medication required) and other variables on resource use and costs. 
Methods. A sample of 422 adults was analysed. Target variables were stratified by 
disease severity and exacerbation status. Bivariate associations were assessed. 
Multiple linear regression was performed on the logarithm of direct medical costs. 
Results. The probability of exacerbations was positively associated with disease 
severity. Resource use and costs were associated with both these variables. Multiple 
linear regression identified age, presence of asthma-related comorbidities, degree of 
severity, exacerbation status, quick reliever versus controller therapy, and diagnosis 
or treatment by a pulmonologist as independent influences on direct costs. An 
interaction between severity and exacerbation status was also noted. Regression 
identified direct costs in the highest severity group to be 2.5 times higher than in the 
lowest, if there were no exacerbations. If exacerbations were present, costs were 5.7 
times higher. 
Conclusions. Due to its high prevalence, asthma has a high impact on public health. 
This impact depends on disease severity and, according to these findings, may also 
depend on the extent to which exacerbations are avoided or at least controlled. 
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INTRODUCTION 
 
Asthma seriously affects both children and adults, and the prevalence of asthma has 
increased considerably during the last three decades [149·181]. The disease affects 
between 4% and 8% of the population in industrialised countries [87·98·187·210]. In 
Switzerland, prevalence has been reliably estimated by Leuenberger, at 6.7% in 
adults [124]. 
 
Diseases with such high prevalence require detailed knowledge not only of their 
clinical and medical aspects, but also of their economic implications. Information on 
the costs and cost structure of asthma is essential for sound health policy decisions 
in the field of respiratory diseases. Studies on the costs of asthma have therefore 
been performed in the U.S. as well as, more rarely, in European and other countries. 
An overview was given in a recent article by Weiss and Sullivan [216]. 
 
However, data from Switzerland on this topic are sparse. In 1996/97 Szucs and 
colleagues published an analysis of the resource use and cost structure of asthma in 
Switzerland [203·204]. They demonstrated that asthma has a large economic impact, 
with total costs of CHF 1'250 Million per year, and a structure of direct medical costs 
dominated by medication costs in children and by hospitalisation costs in adults. No 
further Swiss data have been published. 
 
The current analysis was based on the dataset collected by Szucs and colleagues. 
The goal was to identify independent determinants of asthma-related resource use 
and of direct medical asthma costs in adult Swiss patients. Particular importance was 
given to the impact of asthma severity and exacerbation status on direct medical 
costs. 
 
 
MATERIALS AND METHODS 
 
Patient sample and study design. The original dataset by Szucs and colleagues 
comprised 589 patients who were treated by 120 primary care physicians [203]. 
There were 472 adults and 117 children aged 14 years or younger. The latter were 
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excluded from this analysis as their clinical and economic characteristics differ 
considerably from those of the adult population. 
 
Szucs et al. collected data by retrospective chart review. There was a one year 
reference period in 1996/97. Assessment of asthma-specific resource use comprised 
physician visits, hospital care and medication. The decision if a particular resource 
use was asthma-specific or not was left to the physician's judgement. Data on 
community nursing were not collected, as this kind of service provision does not play 
a major role in Swiss asthma management. The possibility cannot be ruled out that 
some patients received unrecorded asthma-specific services from other physicians. 
These facts may have led to a modest underestimation of absolute direct medical 
costs. 
 
Loss of work due to personal illness or caring for relatives was recorded as a basis 
for calculating indirect costs, which are not considered in this analysis. Additional 
information was collected on disease duration, demographics and physiological 
variables, comprising height, weight, body mass index (BMI), one second forced 
expiratory volume (FEV1), and forced vital capacity (FVC). Asthma-related 
comorbidities were assessed by explicitly asking for the presence of chronic 
bronchitis, emphysema, cor pulmonale, reflux disease, and others. 
 
Reliable health-care related cost estimates are difficult to obtain in Switzerland, as 
there are no large administrative databases allowing for access to claims data. Most 
health insurance companies are reluctant to provide case-specific cost information. In 
this situation, Szucs and colleagues proceeded as follows to calculate direct medical 
costs in a health system perspective: Asthma-specific resource units were derived 
from the physician's medical charts as stated above. In the case of medication, 
prescriptions were used as a proxy of use. Unit costs were estimated as follows: (1) 
The average charge per inpatient day on the general ward of a public acute care 
hospital was calculated from a tariff list covering all Swiss hospitals [117]. Cantonal 
subsidies were added to this average charge, to obtain a proxy of hospitalization 
costs. (2) Costs of physician visits were calculated individually, based on the services 
performed. Mean charges per service were calculated from seven regional tariff lists 
(representing German and French speaking Switzerland) and used as proxy 
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measures for costs. (3) Medication unit costs were assumed to be represented by the 
Swiss public prescription prices as stated in the 1997 Swiss Drug Compendium [6]. 
 
All costs are indicated in Swiss Francs (CHF). In mid-1997, at the end of the 
reference period of the data collection, CHF 1 equaled US-$ 0.68. 
 
Assessment of disease severity was not an explicit goal of the original study. 
Therefore, degree-of-severity classification was based on the 1995 Global Initiative 
for Asthma (GINA) recommendations on medication use, which were in effect at the 
time of data collection [80]. This kind of procedure has been recommended if clinical 
information is insufficent [41]. Physicians' prescriptions and dosage instructions were 
used as a proxy of real medication use. Patients who, according to this information, 
regularly used short-acting β2-agonists only were classified as 'mild intermittent'. 
Patients regularly using inhaled corticosteroids, alone or in combination, were 
classified as 'mild persistent'. Patients regularly using long-acting β2-agonists or 
systemic corticosteroids, alone or in combination, were classified as 'moderate 
persistent' or 'severe persistent', respectively. Complementary information was 
available on treatment type (quick reliever versus controller therapy as defined by the 
treating physician, without any pre-given reference to guidelines) and on the 
presence or absence of asthma attacks/exacerbations (as defined by the treating 
physician) during the reference period. The remaining sample comprised 422 
patients; 50 patients were excluded due to lack of data for one or more of these 
variables. Exacerbations were not necessarily associated with a resource use 
episode. They could be self-reported to the treating physician at a later point in time. 
 
Statistical methods. Demographic and disease characteristics are presented in 
comparison with the complete adult study sample. 
 
Exacerbation frequencies were stratified by degree of severity. A Chi-squared trend 
test was used to evaluate the differences observed. Main resource use and cost 
variables were stratified by degree of severity and exacerbation status. 
 
Bivariate associations were assessed between direct medical costs, degree of 
severity, exacerbation status and other possible influences. Costs were heavily right-
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skewed, but logarithmic transformation achieved an approximately normal 
distribution. Non-parametric tests of the untransformed and T-tests of the 
transformed cost variable were used. In general, Chi-squared tests were used to 
compare two categorical variables. If one variable was continuous, Mann-Whitney U 
tests/Kruskall-Wallis tests or T-tests/ANOVA were used as appropriate [4]. If both 
variables were continuous, Spearman's or Pearson's correlation coefficients were 
calculated. 
 
Least-squares regression was used to evaluate interaction between degree of 
severity and exacerbation status in their effect on the number of physician visits, 
specialist referrals and hospitalisations. 
 
Finally, multiple least squares regression was performed on the logarithm of direct 
medical costs. Independent variables qualified as possible influence factors if an 
association with direct medical costs could reasonably be assumed (p ≤ 0.2 in 
bivariate analysis). Resource use variables that were direct contributors to costs 
(e.g., emergency room visits, days spent in hospital) were excluded. Nevertheless 
there may be a problem of circularity, particularly because disease severity, in the 
absence of other options, was defined by medication use and thus directly linked to 
(medication) costs. Similar correlations may affect the treatment type variable and 
other parameters, albeit to a much lesser extent. To assess the scope of this 
problem, an additional regression was performed on the logarithm of direct medical 
costs excluding medication costs, and the proportion of the variance of medication 
costs explained by the degree-of-severity and treatment type variables was 
calculated. 
 
In all cases p = 0.05 was used as the level of statistical significance and p-values 
were two-tailed. 
 
All calculations were performed using STATA 6.0® and SPSS 10.0®. 
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RESULTS 
 
Patient characteristics. The demographic and disease-specific characteristics of the 
remaining patient sample are shown in Table 1. In comparison with the complete 
adult study population, there were no unexpected differences. The percentage of 
patients with exacerbations was slightly higher, but the mean number of 
exacerbations was lower in the analysed sample. Fewer French speaking patients 
were included due to a higher number of missing degree-of-severity or exacerbation 
status data. Over 50% of the FEV1, FVC and absence-from-work data were missing. 
 
Table 1. Demographic and disease-specific characteristics of study population 
 Adults, information on 
severity and exacerbation 
status available (N = 422)a 
Complete adult study 
sample 
(N = 472)a 
 Value (mean ± standard deviation or %) 
Age (years) 53.4 ± 20.6 52.5 ± 20.8 
German / French speaking (%) 78.0 / 22.0 75.4 / 24.6 
Height (cm) 167.0 ± 8.9 (N = 219) 167.3 ± 9.3 (N = 246) 
Weight (kg) 72.0 ± 15.0 (N = 240) 72.0 ± 15.7 (N = 268) 
BMI (kg/m2) 25.8 ± 5.4 (N = 204) 25.6 ± 5.3 (N = 231) 
FEV1 (liters/second) 2.4 ± 1.0 (N = 193) 2.5 ± 1.1 (N = 216) 
FVC (liters) 3.3 ± 1.3 (N = 173) 3.3 ± 1.3 (N = 192) 
Duration of asthma (years) 12.4 ± 12.8 (N = 268) 11.3 ± 12.5 (N = 301) 
Employed (%) 44.2 (N = 410) 45.6 (N = 458) 
Absences from work (% of employed) 25.8 (N = 163 of 181) 23.9 (N = 188 of 209) 
Type of treatment: 
 Quick reliever therapy (%)b 
 Controller therapy (%)b 
 
23.7 
76.3 
 (N = 461) 
24.9 
75.1 
Degree of severity (GINA): 
 Mild intermittent (%) 
 Mild persistent (%) 
 Moderate persistent (%) 
 Severe persistent (%) 
 
10.4 
26.0 
32.0 
31.5 
 (N = 432) 
10.7 
26.2 
31.9 
31.3 
Presence of exacerbation(s) 
during observation period (%) 
37.7 36.4 
Number of exacerbationsc 1.6 ± 1.3 1.8 ± 2.5 
a Differing sample sizes due to missing values are indicated separately. 
b Quick reliever therapy: treatment only when symptoms occur. Controller therapy: prophylactic 
treatment. 
c Base: patients with exacerbations. 
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Degree of severity and exacerbation status. The distributions of the medication-
derived degree of severity groups and the occurrence and number of exacerbations 
are shown in Table 1. Spearman's correlation between FEV1 and medication-based 
degree of severity was –0.22 (p = 0.002). 
 
The proportion of patients who experienced at least one exacerbation during the 
reference period was almost constant in the mild intermittent (31.8%) to moderate 
persistent (31.1%) groups, with a minimum in the patients classified as mild 
persistent (28.2%). This percentage was distinctly higher in the severe persistent 
group (54.1%), leading to a highly significant Chi squared trend test (p < 0.0005). 
 
Resource use. The presence of exacerbations during the reference period was 
significantly associated with more physician visits (7.2 versus 4.9, p < 0.005), 
specialist referrals (0.33 versus 0.17, p = 0.048), and hospitalisations (0.19 versus 
0.015, p < 0.005) per year. Similar associations with degree of severity were 
observed; there were 7.9 versus 3.8 physician visits (p for trend < 0.005), 0.3 versus 
0.02 specialist referrals (p for trend = 0.13), and 0.16 versus 0.02 hospitalisations (p 
for trend = 0.05) per year in the highest versus lowest severity groups. Stratification 
by both exacerbation status and severity is shown in Table 2. Again, the number of 
resource units consumed increased with severity, and higher levels were reached in 
the presence of exacerbations. These tendencies were evident in all subgroups, 
albeit somewhat less unambiguously in the specialist referrals. Regression analysis 
demonstrated interaction between degree of severity and exacerbation status in their 
effect on the number of physician visits (p = 0.03 for a set of three dummy variables 
representing interaction) and hospitalisations (p = 0.04), but not the number of 
specialist referrals (p = 0.53). 
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Table 2. Resource omitted use by degree of severity and exacerbation status in units 
per patient-year 
Group N Physician 
visits 
Specialist 
referrals 
No. of hospita-
lisations 
  Mean ± standard deviation 
Total sample 422 5.8 ± 5.0 0.23 ± 0.80 0.083 ± 0.34 
Exacerbations absent 263 4.9 ± 4.5 0.17 ± 0.68 0.015 ± 0.12 
By degree of severity: 
 Mild intermittent 
 Mild persistent 
 Moderate persist. 
 Severe persistent 
 
30 
79 
39 
61 
 
3.7 ± 4.5 
4.1 ± 4.7 
5.2 ± 4.0 
6.3 ± 4.7 
 
0.03 ± 0.18 
0.18 ± 0.53 
0.16 ± 0.52 
0.25 ± 1.10 
 
0.033 ± 0.18 
0.013 ± 0.11 
0.011 ± 0.10 
0.016 ± 0.13 
Exacerbations present 159 7.2 ± 5.4 0.33 ± 0.96 0.19 ± 0.51 
By degree of severity: 
 Mild intermittent 
 Mild persistent 
 Moderate persist. 
 Severe persistent 
 
14 
31 
42 
72 
 
4.0 ± 2.7 
4.0 ± 3.4 
7.1 ± 5.3 
9.3 ± 5.7 
 
0 ± 0 
0.29 ± 0.78 
0.45 ± 1.30 
0.35 ± 0.86 
 
0 ± 0 
0.10 ± 0.30 
0.19 ± 0.40 
0.27 ± 0.65 
 
Costs. The presence of exacerbations during the reference period was associated 
with higher direct medical costs (CHF 3'202 versus CHF 1'029, p = 0.0001), 
physician costs (CHF 269 versus CHF 207, p < 0.00005), medication costs (CHF 724 
versus CHF 901, p = 0.056), and hospitalisation costs (CHF 2'031 versus CHF 99, p 
< 0.00005) per year. There also was a steady increase with degree of severity. In the 
highest versus lowest severity groups, direct medical costs amounted to CHF 3'075 
versus CHF 627, physician costs to CHF 284 versus CHF 109, medication costs to 
CHF 1'122 versus CHF 336, and hospital costs to CHF 1'669 versus CHF 182 (p for 
trend < 0.005 in all cases). Stratification by exacerbation status as well as severity 
revealed further details (Table 3). In the patients with no exacerbations, there was a 
clear positive association of severity with direct medical costs and medication costs, 
but less of an association with physician costs and no association with hospitalisation 
costs. In absolute terms, hospitalisation costs were minimal here. In the patients who 
experienced exacerbations, a positive association with severity was seen in all cost 
categories. Absolute hospitalisation costs were important here. In the moderate and 
severe patients with hospitalisations, mean hospitalisation costs were CHF 10'333 
(SD 7'018) and CHF 13'875 (SD 11'039) respectively. 
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Table 3. Costs by degree of severity and exacerbation status in CHF per patient-year 
Group N Direct 
medical costs
Physician 
costs 
Medication 
costs 
Hospitali-
sation costs
  Mean ± standard deviation 
Total sample 422 1'848 ± 4'134 230 ± 257 791 ± 746 827 ± 3'887 
Exacerbations absent 263 1'029 ± 1'274 207 ± 266 724 ± 654 99 ± 1'010 
By degree of severity: 
 Mild intermittent 
 Mild persistent 
 Moderate persist. 
 Severe persistent 
 
30 
79 
93 
61 
 
708 ± 1'509 
804 ± 676 
1'187 ± 1'617 
1'238 ± 1'089 
 
99 ± 101 
225 ± 362 
211 ± 217 
229 ± 230 
 
342 ± 481 
541 ± 380 
826 ± 516 
992 ± 978 
 
267 ± 1'461 
38 ± 338 
151 ± 1'452 
16 ± 128 
Exacerbations present 159 3'202 ± 6'315 269 ± 237 901 ± 868 2031 ± 6'019 
By degree of severity: 
 Mild intermittent 
 Mild persistent 
 Moderate persist. 
 Severe persistent 
 
14 
31 
42 
72 
 
452 ± 476 
1'275 ± 3'249 
3'089 ± 4'947 
4'631 ± 8'058 
 
130 ± 75 
153 ± 134 
297 ± 224 
331 ± 272 
 
322 ± 433 
380 ± 329 
912 ± 789 
1'231 ± 969 
 
0 ± 0 
742 ± 3'151 
1'881 ± 4'964
3'069 ± 7'717
 
Consequently, the relative proportions of cost categories differed greatly between 
those with and without exacerbations: In the latter, physician costs accounted for 
20.1% of total direct medical costs, medication costs accounted for 70.4%, and 
hospitalisation costs for 9.6%. In those with exacerbations, physician costs 
contributed 8.4%, medication costs contributed 28.1%, but hospitalisation costs 
contributed 63.4%. The absolute levels of physician and medication costs in those 
with exacerbations were only slightly higher than in those without exacerbations. To a 
very large extent, hospitalisation costs accounted for the differences observed. 
 
Spearman's correlation coefficients of annual direct medical costs with the number of 
physician visits (0.69), the number of specialist referrals (0.14), and the number of 
hospitalisations (0.44) were significant at the 5% level (p < 0.005 in all three cases). 
However, Spearman's correlation coefficients with possible non-resource use 
influence factors were weak, except in the case of age (0.25, p < 0.005), FEV1 (-
0.19, p = 0.008) and disease duration (0.13, p = 0.033). Pearson's coefficients of the 
same variables with the logarithm of direct costs were almost identical. There 
appeared to be no relevant correlations between costs and BMI or FVC. 
 
Man Whitney-U or Kruskall-Wallis tests revealed significantly higher costs for the 
following influences: controller therapy compared to quick reliever therapy (p < 
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0.005); involvement of a pulmonologist in diagnosis or regular treatment (p < 0.005); 
non-employment at the beginning of the reference period in patients aged 65 or 
younger (p = 0.005); and presence of asthma-related comorbidities (p = 0.029). The 
use of T-tests or ANOVA with the logarithm of direct costs led to the same results. 
Absences from work in the employed, German language region, and rural versus 
urban dwelling were associated with higher costs and had non-significant p-values 
below 0.2, whereby these factors qualified as candidate predictors in multivariate 
analysis. Evaluation by insurance coverage did not reveal any existing associations. 
 
There were no unexpected associations between possible influence factors on direct 
costs. Degree of severity and treatment type correlated significantly (p < 0.00005), 
but Spearman's correlation coefficient was only 0.33. 
 
Multivariate analysis of direct medical costs. Multiple regression analysis on direct 
medical costs was based on the following possible influence factors derived from 
bivariate analysis: degree of severity; presence of exacerbations; quick reliever 
versus controller therapy; involvement of a pulmonologist (in diagnosis or regular 
treatment); age; duration of disease; FEV1; presence of asthma-related 
comorbidities; employment status; absences from work; language region; and urban 
or rural dwelling. Other potential influences such as height, weight, BMI and FVC 
were also explored. 
 
Resource use variables (e.g., number of physician visits, number of hospital days) 
were not taken into account, as they were direct contributors to costs. 
 
Models using the logarithm of direct medical costs identified degree of severity, 
exacerbation status, quick reliever versus controller therapy, age and age squared, 
presence of asthma-related comorbidities, and involvement of a pulmonologist (in 
diagnosis or regular treatment) as relevant and significant influence factors, allowing 
for an adjusted R squared of 0.34. Influences of language region and urban versus 
rural dwelling were not confirmed. 
 
A four-level ordinal variable, represented by three dummy variables, was introduced 
in the model to allow for interaction between medication-based degree of severity 
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and exacerbation status. Thus, the effect of exacerbations could be described 
separately for each degree of severity. This resulted in a partial F-test with p-value of 
0.0008 for the set of dummy variables and increased the adjusted R squared to 0.36, 
showing a greater effect of exacerbations on costs in the more severe asthma 
patients. 
 
Terms representing employment status in the patients aged 65 or younger, and 
absences from work in the employed, were not included in the final analysis albeit 
significant or near-significant, as they altered the model only slightly (adjusted R 
squared = 0.38). 
 
Age and age squared were centered to avoid a colinearity problem with these 
variables. After this procedure, variance inflation factors showed a mean of 3.91. The 
highest value was seen in the exacerbation status variable (VIF 10.60), with the 
dummy variables representing interaction between degree of severity and 
exacerbation status showing VIFs of 8.28, 5.26 and 4.40. Other criteria were clearly 
non-critical: There were no standardized regression coefficients larger than 1. After 
inclusion of the interaction terms, the parameter estimates and standard errors for 
the other variables changed very little, except of course for those terms which were 
bound to change because their meaning is different in the model with the interaction 
terms. 
 
Details of the main model (N = 420) are shown in Table 4. In larger models including 
other potential confounders, the degree of severity and exacerbation variables, and 
the respective interaction terms, had very similar coefficients. (Details not shown.) 
Relevant coefficient changes only occurred when FEV1 and body height or BMI were 
included. These models, though, had to rely on less than 100 observations. 
 
Residual analysis (based on scatterplots of residuals versus predicted values and 
age, boxplots of residuals grouped by non-continuous influence factors and normality 
plot of residuals) gave satisfactory results. Exclusion of influential points identified by 
Cook's distance and the covariance ratio (resulting N = 393) did not affect 
significance or greatly alter coefficients, but increased R squared to 0.43. Alternative 
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versions of the model, e.g. using the frequency of exacerbations rather than their 
presence or absence, gave very similar results. 
 
Table 4. Multiple linear regression on the logarithm of direct medical costs (N = 420) 
F(12,407) = 20.63        Prob > F = 0.0000        R-squared = 0.38        Adj R-squared = 0.36
Covariates Coefficient Std. Err. t p > |t| 95% Conf. 
Interval 
Degree of severity:       
 Mild persistent 0.82a 0.20 4.19 < 0.001 0.44 1.21 
 Moderate persistent 1.01a 0.19 5.25 < 0.001 0.63 1.39 
 Severe persistent 0.90a 0.21 4.36 < 0.001 0.49 1.30 
Exacerbations presentf 0.31d 0.30 1.04 0.299 -0.27 0.89 
Interaction variable, ordinal:       
 Level 1 -0.49b 0.35 -1.37 0.172e -1.18 0.21 
 Level 2 0.23b 0.34 0.68 0.496e -0.44 0.90 
 Level 3 0.53b 0.34 1.56 0.118e -0.14 1.19 
Age (centered) 0.00541 0.00240 2.26 0.025 0.00070 0.01013 
Age squared (centered) -0.00026 0.00011 -2.36 0.019 -0.00047 -0.00004
Asthma-related comorbid. 
presentf 
0.37 0.13 2.94 0.003 0.12 0.62 
Involvement of 
pulmonologistf 
0.28 0.09 3.00 0.003 0.10 0.46 
Controller therapyf 0.60c 0.12 5.17 < 0.001 0.37 0.83 
Intercept 5.15 0.18 27.84 < 0.001 4.79 5.51 
a Compared to mild intermittent. 
b Compared to level 0. 
c Compared to quick reliever therapy. 
d This coefficient indicates the effect of exacerbations being present in a patient with the lowest 
degree of severity. The effect of exacerbations at higher degrees of severity is the sum of this 
coefficient and that for the relevant interaction term. 
e Partial F test for this set of variables: p < 0.001. 
f Dichotomous variables, values coded '0' or '1'. Presence of exacerbations, presence of 
comorbidities, involvement of a pulmonologist in diagnosis or treatment, and controller therapy 
are coded '1'. 
 
Costs increased with age, but the effect was mild, non-linear and less pronounced in 
older age groups. Assuming constant other parameters, the presence of asthma-
related comorbidities was associated with a 50% increase in direct medical asthma 
costs, controller therapy versus quick reliever therapy with an 80% increase and 
involvement of a pulmonologist in diagnosis or treatment with a 30% increase. 
Greater degrees of severity and the presence of exacerbations during the reference 
period were also associated with higher costs (Table 5). As the effect of these 
variables is greater than multiplicative, patients with a greater degree of asthma 
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severity who experienced exacerbations were particularly expensive. Patients 
classed as severe persistent who experienced exacerbations cost more than 5 times 
as much as mild intermittent patients who did not. 
 
Table 5. Effect of degree of severity and exacerbation status on direct medical costs 
according to the estimated regression model 
Degree of severity: Exacerbations absent Exacerbations present 
 Multiplication factor (95% Confidence Interval)a 
Mild intermittent  1 (reference) 1.4 (0.8 - 2.4) 
Mild persistent 2.3 (1.5 - 3.3) 1.9 (1.2 - 3.0) 
Moderate persistent 2.8 (1.9 - 4.0) 4.7 (3.1 - 7.3) 
Severe persistent 2.5 (1.6 - 3.7) 5.7 (3.8 - 8.4) 
a Calculations performed using Stata's lincom command. 
 
Regression analysis on the logarithm of direct medical costs excluding medication 
costs resulted in a model comprising the same influence factors as described above, 
except for age and the interaction term between degree of severity and exacerbation 
status (N = 420, R squared = 0.22). These variables themselves remained highly 
significant. Degree of severity and treatment type accounted for 19% of the variance 
seen in the medication costs. 
 
 
DISCUSSION 
 
This analysis is concerned with the determinants of the direct medical costs of adult 
asthma, which are most relevant from a third party payer perspective. An inclusion of 
indirect costs, whose analysis may require a different set of predictors, was not 
undertaken. 
 
Stratification by exacerbation status and degree of severity reveals these variables to 
be positively associated with all subcategories of direct medical costs. However, 
there is no association between severity and hospitalisation costs in the patients 
without exacerbations. In those with exacerbations, such an association is clearly 
present. In absolute terms, the cost difference observed between those with and 
without exacerbations mainly stems from dramatically increased hospitalization costs, 
while the levels of physician and medication costs are only slightly higher. 
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The multiple regression model presented identifies a set of factors which, while easy 
to measure, explain a considerable percentage of the variance seen in the direct 
medical costs of asthma. Age, comorbidity status, and several factors linked to the 
concept of disease severity (primarily degree of severity defined by medication, and 
exacerbation status) influence the direct medical costs of asthma. Treatment type 
(quick reliever versus controller therapy, as judged by the treating physician) reflects 
treatment habits, but also comprises aspects of disease severity. The same is 
probably true for the involvement of a pulmonologist, which can be assumed to be 
more frequent in cases that are more difficult to treat. If so, the higher cost 
associated with such an involvement can be expected to be partly due to patient or 
disease characteristics not covered by our degree-of-severity variable. Different 
treatment patterns in similar patients would be an additional or alternative 
explanation. However, there is some evidence that these patterns, albeit more costly 
at the outpatient level, are cost-saving overall by reducing complication costs [204]. 
 
It may seem improper to include several explanatory variables linked to the concept 
of disease severity that directly impact on cost, which is the outcome variable. In 
particular, the use of medication as a proxy measure of severity may overestimate 
the impact of this factor on costs and introduces circularity which may exaggerate 
statistical significance. It also assumes that empirical treatment follows guidelines, at 
least to a certain extent. On the other hand, the results obtained demonstrate that the 
economic impact of the degree-of-severity and treatment type variables was not 
restricted to medication costs (representing 43% of direct medical costs), and that the 
latter were not to a very large extent explained by these variables. In clinical terms, a 
higher degree of severity, defined by medication use, is probably associated with 
higher baseline medication costs (drug costs per usual daily dose), but also with 
considerably greater amounts of medication needed and, as confirmed by resource 
use analysis, other health care resources consumed. Restriction of regression 
analysis to the non-medication costs would exclude the first of these two aspects and 
therefore lead to an incomplete picture. 
 
The finding that greater degrees of asthma severity lead to higher medical costs 
confirms the results of other studies [11·86·135·182·209·216]. The findings of our 
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multivariate analysis are in accordance with data obtained by Hoskins and 
colleagues [103] on the influence of disease severity on the frequency of asthma 
exacerbations, and the influence of exacerbations on costs. However, detailed 
comparisons are hindered by the different health systems and methodologies used. 
 
The modest impact of age on direct medical costs in this analysis does not contradict 
other studies [159·209]. Plaza et al. reported the costs of asthma patients aged 65 or 
older to be twice as high as those of adults under 65, but the investigators did not 
correct for disease severity or apply multivariate methods [159]. The current analysis 
could not demonstrate a significant effect of insurance status. Such an effect was 
described in other studies, but insurance systems may induce greater cost 
differences in the U.S. and in Canada than in Switzerland [135·209]. In the U.S., 
health plans differ greatly in terms of coverage, and situations of underinsurance 
have been reported [7·144]. In Canada, drug plan participation is an issue [209]. In 
Switzerland, participation in the statutory health insurance, which is obligatory, 
guarantees a high level of medical care to everybody. 
 
Possible effects of BMI or FEV1 were difficult to assess due to missing values. 
Inclusion of these variables led to models based on less than 100 observations. 
Relevant coefficient changes of the medication-based degree of severity and 
exacerbation variables occurred, which supports the idea that these variables and 
FEV1 contain competing information on disease severity. 
 
The current analysis was based on a data collection primarily targeted at resource 
use structures and costs, not at identifying influence factors on costs. For this reason 
it was not possible to take into account some potentially important variables such as 
patient compliance, inhaler technique, or smoking status [11·103·177·209]. Future 
studies addressing associations between costs and medical correlates of asthma 
should assess these. Severity classification should be based on clinical parameters. 
A clear definition of exacerbations would allow a distinction between different kinds of 
events with different economic impacts, thus leading to more precise results. 
 
Despite the limitations discussed, the findings of this multivariate analysis show that 
severity and the presence of exacerbations have considerable and interacting effects 
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on direct medical costs of asthma. Due to its high prevalence, asthma has a high 
impact on public health. This impact depends on disease severity and may also 
depend on the extent to which exacerbations are avoided or at least controlled. A 
prospective study would be needed to finally clarify this issue. If the findings 
presented here are confirmed, further efforts at preventing exacerbations may well be 
repaid in reduced treatment costs, as well as reduced patient suffering. 
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ABSTRACT 
 
Study objective. The impact of isolated gatekeeping on health care costs remains 
unclear. We aimed to assess to what extent lower costs in a gatekeeping plan 
compared to a fee-for-service plan were due to more efficient resource management, 
or explained by risk selection. 
Design. Year 2000 costs to the Swiss statutory sick funds and potentially relevant 
covariates were assessed retrospectively from beneficiaries participating in an 
observational study, their primary care physicians and insurance companies. To 
adjust for casemix, two-part regression models of health care costs were fitted, 
consisting of logistic models of any costs occurring, and of generalized linear models 
of the amount of costs in persons with non-zero costs. Complementary data sources 
were used to identify selection effects. 
Setting. A gatekeeping plan introduced in 1997 and a fee-for-service plan, in Aarau, 
Switzerland. 
Participants. Of each plan, 905 randomly selected adult beneficiaries were invited. 
The overall participation rate was 39%, but was unevenly distributed between plans. 
Main results: The characteristics of gatekeeping and fee-for-service beneficiaries 
were largely similar. Unadjusted total costs per person were CHF 231 (8%) lower in 
the gatekeeping group. After multivariate adjustment, the estimated cost savings 
achieved by replacing fee-for-service based health insurance with gatekeeping in the 
source population amounted to CHF 403-517 (15-19%) per person. Some selection 
effects were detected but did not substantially influence this result. An impact of non-
detected selection effects cannot be ruled out. 
Conclusions: This study hints at substantial cost savings through gatekeeping which 
are not due to mere risk selection. 
 
 
KEYWORDS 
 
Economics, health care costs, managed care programs, gatekeeping, Europe 
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INTRODUCTION 
 
In the early 1990s Switzerland was among the first European countries to introduce 
managed care solutions [21]. Health insurance is mandatory in Switzerland and 
these solutions were offered to the population as an alternative to traditional fee-for-
service plans. In 2001, managed care organizations had a market share of 5% [8]. 
Unlike in the US, Swiss managed care lacks strong incentives to restrict the 
consumption of medical services [13:126-32·118]. 
 
Early efforts to evaluate the medical and financial impact of managed care in 
Switzerland indicated reduced costs, but casemix adjustment was incomplete 
[31:11,136-41·67·160:39-58]. 
 
Swiss gatekeeping plans report cost savings of 10-25% compared to fee-for-service 
based health insurance [13:136-7]. It remains unclear to what extent these savings 
are independent of risk selection mechanisms. Various studies have tried to answer 
similar questions for the US and Europe, but findings were ambiguous 
[24·49·77·110·137·178·212]. 
 
This study compares two local health plans, a gatekeeping and a fee-for-service plan, 
offered by the same group of health insurance companies in Aarau, Switzerland. 
These companies report costs to be about 10% lower in the gatekeeping plan, after 
adjusting for age and gender. We sought to assess to what extent this difference is 
due to more efficient resource management, or can be explained by risk selection. 
 
 
METHODS 
 
Health plans 
In the region of Aarau, a group of four companies provides health insurance to about 
31'250 fee-for-service beneficiaries and 12'500 gatekeeping beneficiaries. The terms 
of fee-for-service insurance are uniformly defined by Swiss law. Free access to 
primary care physicians and medical specialists is guaranteed. The gatekeeping plan 
is managed by a single intermediary company. Its beneficiaries pay reduced 
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insurance premiums. They are required to choose a primary care physician who will 
also act as a care coordinator and help avoiding unnecessary use of medical 
resources such as duplicate diagnostic tests. Specialist visits, except in emergencies, 
require referral by that coordinating physician. However, there is direct access to 
ophthalmologic and gynaecological care. General coverage of medical services does 
not differ between plans. Gatekeeping physicians have no financial incentives to limit 
the use of medical services. They receive a minor administrative fee of CHF 12 per 
inscribed patient per year. Any additional time spent on their coordinating function is 
reimbursed at normal rates, i.e. it is reflected in the gatekeeping beneficiaries' cost to 
the Swiss statutory sick funds. Gatekeeping physicians have varying proportions of 
fee-for-service patients. 
 
Study population 
The population studied were 18 years or older in 1996 and either fee-for-service or 
gatekeeping beneficiaries throughout 2000, whether they consumed medical services 
or not. (According to the intermediary company managing the gatekeeping plan, 
there were hardly any beneficiaries who switched between health plans during the 
year, except for persons who moved into or out of the area.) Cohorts of 905 
beneficiaries of each plan were randomly selected from the enrolment files. In early 
2001, they were mailed an informed consent form including a self-administered 
questionnaire. Only beneficiaries returning the questionnaire became known to the 
investigators. Further data were provided on consenting participants by their 
insurance companies and physicians. Three weeks after the first letter was sent, non-
responders were mailed a reminder. Data collection was completed in June 2001. 
Elaborate procedures were applied to ensure a maximum of data protection. 
 
Study outcome and covariates 
The primary outcome was gross cost to the Swiss statutory sick funds in 2000. 
Collection of covariates aimed to allow comprehensive casemix adjustment [179]. It 
included cost and morbidity data between January and December 1996, the year 
before the gatekeeping plan was first offered to the population. Cost data and health 
insurance contract details were provided by the insurance companies, the latter 
reflecting the beneficiaries' decisions taken in 1999 and defining their status in 2000. 
The physicians provided morbidity scores for 1996 and 2000 (Index of Co-Existent 
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Diseases - ICED) [89], physiologic data, and their own practice characteristics. Data 
collection from the study participants comprised demographic and socio-economic 
covariates; subjective health status (self-administered SF-36); health behaviour; 
inclination to over- or under-use medical services; and medical resource use. As 
discussed later, some of these covariates were time-dependent and documented the 
situation at the time of data collection, i.e. in the first half of 2001. Analyses were 
performed including and excluding these covariates. 
 
In addition to the main dataset, anonymous age and gender data for all randomly 
selected potential participants and year 2000 cost data for the total source 
population, aggregated by age, gender and health plan, were available. These were 
used to identify selection effects.  
 
All costs are in Swiss Francs (CHF). On Dec 31, 2000, CHF 1 equalled EUR 0.66. 
 
Statistical methods 
Multiple logistic regression was used to model plan membership as a function of 
beneficiary characteristics identified in univariate analysis. 
 
Expectedly, health care costs included a substantial proportion of zero values and 
were heavily left-skewed and heteroskedastic (their variance increasing with 
increasing cost). Two-part regression models of total and outpatient costs were fitted. 
In the first part we modelled whether any costs were accrued using logistic 
regression and in the second, generalized linear models (GLMs) were used to 
analyse the amount of costs in the persons with non-zero costs [57·145]. The GLMs 
used a logarithmic link function and assumed a gamma distribution of errors [20·51]. 
Potential covariates were assessed if an association with costs seemed plausible on 
logical or on statistical grounds (p ≤ 0.25 in univariate analysis). First, all time-
dependent covariates primarily describing the situation in 2000 or 2001 were 
excluded (reduced models). In a second step (extended models), such covariates 
were allowed. Resource use variables were not used as covariates. As detailed in 
Tables 4 and 5, some few observations with costs over CHF 20'000 in 2000 were 
excluded from the main analysis, in order to reduce the impact of chance effects in 
this small sample. Complementary analyses included all available observations. 
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Total predicted values were calculated by multiplying the predicted values of both 
sub-models [20]. To estimate the marginal (population-level) cost impact of 
gatekeeping, all participants were assumed to be gatekeeping beneficiaries, or fee-
for-service beneficiaries. Both sets of predicted values were calculated and their 
difference was taken. The result estimates the cost impact of replacing fee-for-
service based health insurance with gatekeeping in the source population. 
 
Two-sided p values of 0.05 were used to determine statistical significance. 
Confidence intervals (CIs) shown are at the 95% level. CIs for the marginal effects 
were calculated by bias-corrected bootstrapping using 1'000 repetitions. 
 
 
RESULTS 
 
Participation and data availability 
In total, 700 (39%) of the randomly selected persons returned the mailed 
questionnaire, 433 (48%) of the gatekeeping beneficiaries and 267 (30%) of the fee-
for-service beneficiaries. In both groups, 86% of these consented to have additional 
data collected from their insurance companies and physicians. Full data inclusive of 
year 2000 cost data and year 1996 cost and morbidity data were finally available 
from 466 (26%) of the randomly selected persons, 317 (35%) of the gatekeeping 
beneficiaries and 149 (16%) of the fee-for-service beneficiaries. 
 
Data completeness among respondents was at least 90%. Data provided by a total of 
82 participating physicians were near complete, but some physicians who only 
treated fee-for-service beneficiaries refused to participate, which reduced the number 
of fee-for-service beneficiaries with full data available. Data provided by the 
insurance companies were complete. 
 
Beneficiary characteristics and health status 
Demographic characteristics, health insurance contract details and indicators of 
socio-economic status were similar between plans (Table 1). The age range was 23-
92 years in the gatekeeping group and 23-96 years in the fee-for-service group. 
However, the gatekeeping beneficiaries were on average 3.2 years older than the 
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fee-for-service beneficiaries and the proportion of women was lower by 7%. The 
gatekeeping beneficiaries appeared to be slightly less mobile, less professionally 
active and had a lower household income. 
 
Table 1. Selected beneficiary characteristics by plan 
Characteristic Gate-
keeping 
(N = 433)a 
Fee-for-
service 
(N = 267)a 
p value
Age (mean years ± SD) 56.8 ± 17.1 53.6 ±16.3 0.014e 
Female gender (%) 53.2 60.3 0.068f 
Duration of health insurance with the same company 
(mean years ± SD) 
29.7 ± 18.2 28.8 ± 18.0 0.555e 
Complementary insurance contracts (mean number ± SD) 0.94 ± 0.75 1.0 ± 0.70 0.088g 
Importance assigned to low insurance premiums  
(mean score ± SD)b 
2.8 ± 1.1 2.5 ± 1.2 0.003g 
Professional status (%)c professionally active 
    housework and childcare 
    unemployed 
    retired 
48.7 
47.1 
1.9 
41.6 
60.1 
52.4 
2.6 
32.2 
0.004f 
0.171f 
0.492f 
0.013f 
Marital status (%)  unmarried 
    married 
    widowed 
    divorced 
10.0 
71.6 
11.2 
7.2 
16.7 
64.0 
10.6 
8.7 
0.055f 
Household size   adults 
(mean number ± SD)  children ≤ 18 years 
2.0 ± 0.7 
0.40 ± 0.82 
1.9 ± 0.8 
0.35 ± 0.73 
0.208g 
0.631g 
Nursing home residency (%) 1.9 1.9 0.988f 
Residency in the Aarau area in 1996 (%) 97.2 90.6 < 0.001f
BMI (mean kg/m2 ± SD) 25.2 ± 4.4 24.9 ± 4.4 0.498e 
Physically active or doing sports (%) 38.2 44.3 0.113f 
Current smoking (%) 22.2 30.0 0.022f 
Current alcohol consumption 87.0 87.2 0.801f 
Importance assigned to healthy nutrition (mean score ± SD)d 3.09 ± 0.67 3.04 ± 0.62 0.267g 
Subjective health status  SF-36 General health scale 
(mean score ± SD)   SF-36 Physical health summary scale 
     SF-36 Mental health summary scale 
70.6 ± 18.5 
49.6 ± 9.9 
52.1 ± 8.9 
71.3 ± 19.9 
50.0 ± 10.2 
51.2 ± 9.4 
0.648e 
0.648e 
0.247e 
ICED (mean score ± SD) in 2000 
    in 1996 
2.2 ± 3.1 
1.8 ± 2.7 
2.0 ± 2.9 
1.5 ± 2.4 
0.470g 
0.378g 
History of mental illness (%) 17.1 18.8 0.635f 
a N is slightly smaller at the individual variable level due to missing values. 
b Score on a 5-point Likert scale. 
c Several answers could be ticked. 
d Score on a 4-point Likert scale. 
e Unpaired t test. 
f Chi squared test. 
g Man-Whitney U test. 
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Both groups were similar with respect to health behaviour and health status (Table 
1). However, the gatekeeping group had a lower proportion of current smokers, 
especially in the younger age groups. The proportion of physically active persons 
was higher in the fee-for-service group (non-significant). 
 
Medical resource use and cost 
Medical resource use and cost to the Swiss statutory sick funds are detailed in Table 
2. Fewer consultations with medical specialists and fewer hospitalisations were 
reported in the gatekeeping group and their year 2000 total costs per person were 
CHF 231 lower. Outpatient costs were CHF 377 lower (consultation costs, CHF 7 
lower; medication costs, CHF 130 lower; other outpatient costs CHF 239 lower). 
Inpatient costs were CHF 145 higher in the gatekeeping group, but this difference 
was annulled when 9 observations with costs over CHF 20'000 were excluded. Year 
1996 costs were CHF 762 lower in the gatekeeping group, but this difference was 
reduced to CHF 199 when 6 observations with costs over CHF 20'000 were 
excluded. None of the differences observed were statistically significant. 
 
Table 2. Resource use and cost to the Swiss statutory sick funds by plan 
Characteristic Gatekeeping 
(N = 433)a 
Fee-for-service 
(N = 267)a 
p valueb
Primary care physician consultations in 
2000c  
3.2 ± 4.4; 2 3.2 ± 4.2; 2 0.440 
Medical specialist consultations in 2000c 1.0 ± 2.2; 0 1.6 ± 4.0; 0 0.083 
Hospitalisations in 2000c 0.16 ± 0.44; 0 0.21 ± 0.58; 0 0.664 
Total costs > CHF 0 in 2000 (%)  83.6 83.6 0.984 
Total costs in 2000d 2'496 ± 4'870; 1'120 2'727 ± 4'311; 1'344 0.407 
Outpatient costs in 2000d 1'815 ± 2'287; 1'102 2'192 ± 3'113; 1'261 0.382 
Inpatient costs in 2000d 680 ± 3'821; 0 535 ± 1'948; 0 0.994 
Total costs > CHF 0 in 1996 (%)  80.7 79.1 0.634 
Total costs in 1996d 1'674 ± 2'991; 731 2'436 ± 5'466; 824 0.646 
Outpatient costs in 1996d 1'284 ± 1'702; 670 1'648 ± 2'726; 811 0.469 
Inpatient costs in 1996d 390 ± 1'934; 0 789 ± 3'849; 0 0.375 
a N is smaller at the individual variable level due to missing values. 
b Man-Whitney U test. 
c Mean number ± SD; median. Self reported values, in good accordance with physician-reported 
values. 
d Mean CHF ± SD; median. Observations with zero values included. 
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Complementary data sources 
Comparison with complementary data sources was undertaken to identify selection 
effects. Among all randomly selected persons, the observation of a higher mean age 
and a lower proportion of women on the gatekeeping side was confirmed, but less 
distinct. Participation rates by age and gender group revealed moderate deviations 
(1-17%) from mean plan-specific participation rates. 
 
After adjusting for resulting differences in the age and gender distribution and after 
excluding all cases with costs over CHF 20'000, year 2000 study-level costs and the 
corresponding aggregated costs for the source population were similar. In the 
gatekeeping plan, study-level total costs per person were CHF 86 lower than 
population-level costs, and in the fee-for-service plan, they were CHF 69 lower. 
Within the strata defined by an age cut-off of 65 years and gender, some of the 
differences seen were more distinct, but still moderate. The female fee-for-service 
beneficiaries above 65 years of age were the only exception. Their study-level total 
costs were CHF 740 lower than in the source population, compared to CHF 18 lower 
in the corresponding gatekeeping beneficiaries. 
 
Predictors of plan membership 
Logistic regression indicated that gatekeeping plan membership in 2000 was 
positively associated with lower 1996 total health care costs; higher 1996 ICED 
score; having complementary dental insurance; having a higher importance assigned 
to healthy nutrition; having a lower household income; having more children in the 
household; living in the Aarau area in 1996; and having a primary care physician with 
a higher number of consultations per year. The explanatory power of the model 
remained low (pseudo R squared 0.10, 71% correct predictions). 
 
Predictors of cost 
In the reduced model, non-zero total costs in 2000 were associated with higher 1996 
outpatient costs; higher 1996 ICED score; lower age (note: after correction for 
morbidity). The effect of plan membership was modified by age, hinting at a reduced 
probability of non-zero costs in younger gatekeeping beneficiaries and vice versa. 
The extended model is shown in Table 3. 
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Table 3. Logistic regression model of non-zero total health care costs in 2000  
(part 1 of two-part model) 
N = 418a          Log likelihood -99.05b                 Pseudo R squared of the model = 0.43c
Independent variable Coefficient (95% CI) p value
Fee-for-service plan membership -3.43 (-5.76- -1.12) 0.004 
Fee-for-service plan membership divided by age (females)d 138.51 (35.37-241.65) 0.008 
Fee-for-service plan membership divided by age (males)d 143.83 (41.24-246.42) 0.006 
Age (females) 0.01 (-0.08-0.11) 0.762 
Age squared (females) -0.001 (-0.002- -0.000) 0.020 
Age (males) -0.06 (-0.12- -0.01) 0.021 
1996 outpatient costs (log scale) 0.31 (0.18-0.43) < 0.001
ICED score in 1996 0.67 (0.12-1.22) 0.017 
ICED score increase between 1996 and 2000 0.73 (0.14-1.31) 0.016 
SF-36 General Health Scale score -0.03 (-0.06- -0.01) 0.018 
Fixed beneficiary co-paymente CHF 400 -0.85 (-1.76-0.06 0.067 
     CHF 600 -0.92 (-2.23-0.39) 0.171 
             ≥ CHF 1'200 -1.92 (-3.04- -0.79) 0.001 
Importance assigned to low insurance premiumsf 0.41 (0.07-0.75) 0.019 
Self-reported low aversion of consulting a doctorf -0.43 (-0.81- -0.06) 0.024 
Being retired 1.75 (0.35-3.14) 0.014 
Constant 5.42 (1.96-8.89) 0.002 
a N < 466 due to missing values. 
b Uncritical Hosmer-Lemeshow goodness-of-fit test (p = 0.54). 
c Predictions correct in 89%. 
d Term representing effect modification. 
e Compared to lawful minimum of CHF 230. 
f Per increase by 1 on a 5-point Likert scale. 
 
In the study participants with non-zero costs, the reduced GLM showed higher total 
costs to be significantly associated with fee-for-service plan membership (likelihood 
ratio test, borderline p = 0.066); higher 1996 outpatient costs; higher 1996 ICED 
score; higher age; choice of lower self-payments but higher insurance premiums; 
having complementary semi-private insurance; living in the Aarau area in 1996 
(modified by age in females). The effect of 1996 ICED score was modified by age 
and 1996 outpatient costs. The extended model is shown in Table 4. 
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Table 4. Generalized linear model of total health care costs in 2000, per person with 
non-zero costsa (part 2 of two-part model) 
N = 347   Log likelihood -2988.97              Deviance 249.15 
Independent variable Coefficients (95% CI) p value 
Fee-for-service plan membership 0.24 (0.04-0.44) 0.021 
Age (females) -0.03 (-0.09-0.02) 0.246 
Age squared (females) 0.001 (0.000-0.001) 0.007 
Age (males) -0.13 (-0.21- -0.04) 0.003 
Age squared (males) 0.003 (0.001-0.005) 0.002 
Age ^ 3 (males) -0.000 (-0.000- -0.000) 0.007 
1996 outpatient costs (log scale) 0.06 (0.01-0.10) 0.010 
ICED score in 1996 0.61 (0.28-0.94) < 0.001 
ICED score in 1996 * age (female)b -0.01 (-0.01- -0.00) < 0.001 
ICED score in 1996 * age (male)b -0.01 (-0.01- -0.00) < 0.001 
ICED score in 1996 * SF-36 Item 2b -0.07 (-0.12- -0.01) 0.025 
ICED score in 1996 * 1996 outpatient costs (log scale)b 0.02 (0.00-0.05) 0.040 
ICED score increase between 1996 and 2000 0.13 (0.06-0.20) 0.001 
SF-36 Item 2 -0.13 (-0.29-0.03) 0.121 
SF-36 General Health Scale score -0.01 (-0.02- -0.01) < 0.001 
Complementary semi-private insurance -0.29 (-0.50- -0.09) 0.005 
Importance assigned to low insurance premiumsc 0.10 (0.02-0.19) 0.017 
Living in a partnership 0.60 (0.19-1.01) 0.004 
Marital status  marriedd 0.27 (-0.15-0.68) 0.208 
   widowedd 0.00 (-0.48-0.49) 0.989 
   divorcedd -0.63 (-1.16- -0.10) 0.19 
Household size 2 adultse -1.25 (-1.67- -0.82) < 0.001 
           ≥ 2 adultse -1.39 (-1.88- -0.90) <0.001 
Integration  Swiss born or Swiss citizenf -0.39 (-0.88-0.11) 0.127 
              Swiss born and Swiss citizenf 0.11 (-0.33-0.54) 0.624 
Aarau area residency in 1996 2.04 (1.14-2.95) < 0.001 
Aarau area residency in 1996 * age (female)b -0.02 (-0.05-0.00) 0.069 
Constant 7.36 (5.69-9.03) < 0.001 
a Three gatekeeping observations and 4 fee-for-service observations with health care costs over 
CHF 20'000 in 2000 not used. 
b Term representing effect modification. 
c Per increase by 1 on a 5-point Likert scale. 
d Compared to unmarried. Combined likelihood ratio test, p = 0.054. 
e Compared to 1 adult. 
f Compared to neither Swiss born nor Swiss citizen. Combined likelihood ratio test, p = 0.034. 
 
Comparison of predicted vs. observed costs per person revealed an overestimation 
in the fee-for-service group (difference CHF 283 when regarding the extended total 
cost model), but not in the gatekeeping group (difference CHF -5). When the female 
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fee-for-service beneficiaries above 65 years of age (17 observations) were excluded, 
the difference seen in the fee-for-service group was reduced to CHF -86. 
 
Association of gatekeeping and cost 
Direct parameter estimates derived from the conditional cost models as well as the 
estimated marginal (population) effects, comparing exclusive gatekeeping plan 
membership to exclusive fee-for-service plan membership, indicated costs savings 
through gatekeeping at the total and outpatient levels (Table 5). Estimated savings 
per person were in the range of CHF 403-517 (15-25% of the costs incurred by the 
fee-for-service source population). Some of the bootstrap-based confidence intervals 
for the marginal effects overlapped the null, but there was a strong and uniform 
tendency towards savings by gatekeeping. The reduced and extended models 
yielded consistent results at the total costs level, but the effect estimate derived from 
the reduced outpatient cost model appeared high. 
 
Table 5. Estimated cost impact of gatekeeping plan membership compared to fee-for-
service plan membership (based on two-part models) 
 Na Cost difference  
(fee-for-service - gate-
keeping) in persons 
with non-zero costsc 
Nb Cost difference 
(fee-for-service - 
gatekeeping) in 
all personsd 
Cost difference 
(fee-for-service - 
gatekeeping) in 
all persons (%)d,e
Total costs 
Reduced model 372 498 (-77-1'072) 439 403 (-120-1027) 14.5 
Extended model 347 513 (53-973) 395 517 (-11-1254) 18.9 
Outpatient costs 
Reduced model 377 544 (76-1'014) 444 453 (28-973) 24.6 
Extended model 354 394 (23-765) 402 372 (-4-813) 17.9 
a N available for GLM fitting. Reduced and extended total cost models, 3 gatekeeping 
observations and 4 fee-for-service observations with health care costs over CHF 20'000 in 
2000 not used. Reduced outpatient cost model, 1 fee-for-service observation with outpatient 
costs over CHF 20'000 in 2000 not used. In the extended outpatient cost model, this 
observation was not contained due to a missing value in one of the additional predictor 
variables. 
b N available for estimation of marginal (population) effects. 
c Conditional effect in persons with non-zero costs as derived from GLM coefficients. Mean CHF 
per person (CI). 
d Marginal (population) effect (combined effect estimate of two-part regression, comparing the 
assumptions of exclusive gatekeeping plan membership vs. exclusive fee-for-service plan 
membership). Mean CHF per person (bootstrapped CI). 
e Expressed as a percentage of the costs incurred by the fee-for-service source population in 
the year of reference. 
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Re-fitting the models and recalculating the marginal effects after inclusion of up to 7 
observations with costs over CHF 20'000 led to higher effect estimates (e.g. CHF 773 
instead of CHF 517 when using the extended total cost model). In contrast, 
decreasing the cut-off point further to CHF 15'000 changed the effect estimates only 
marginally (CHF 486 instead of CHF 517). Exclusion of the female fee-for-service 
beneficiaries above 65 years of age yielded higher effect estimates (CHF 645 instead 
of CHF 517). Exclusion of the persons who joined the gatekeeping plan later than in 
1997 yielded results in the range of the main results (CHF 481 instead of CHF 517). 
 
 
DISCUSSION 
 
This study of a gatekeeping and a fee-for-service plan in Aarau, Switzerland, hints at 
relevant cost savings through gatekeeping which are not due to mere risk selection. 
Adjustment for casemix was achieved by performing two-part multivariate analyses of 
year 2000 costs to the Swiss statutory sick funds, taking into account a wide variety 
of beneficiary and physician characteristics. The characteristics of gatekeeping 
beneficiaries and fee-for-service beneficiaries were largely similar. A considerable 
difference in the proportion of current smokers was concentrated on the younger 
study participants where a substantial impact on health care costs would not yet be 
expected. Whether physicians treated fee-for-service beneficiaries only, or 
beneficiaries from both plans, was not a significant predictor of cost on the fee-for-
service side. 
 
The result of casemix-adjusted gatekeeping-associated savings of around 20% 
confirms earlier Swiss reports and earlier, mostly trial-based findings from the US that 
gatekeeping may be an efficient technique of utilisation management 
[74·77·107·136·137·178]. However, non-randomised US studies found no or only 
marginal costs savings associated with gatekeeping [24·92·109·128·212]. A 
European study using country-level aggregate data found no gatekeeping effect on 
total costs, but significant savings in the outpatient setting [49]. 
 
In this study, constraints on planned sample size in conjunction with a low response 
rate and incomplete information from some participants led to a small number of 
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observations usable. Thus, the power to detect differential plan member 
characteristics may have been limited. Furthermore, response rates differed 
considerably between plans, hinting at the possibility of selection bias. 
 
Accounting for a wide range of potential confounders reduced the probability of 
strong selection bias. Moreover, external data allowed to assess in part to what 
extent selection effects were present in the study dataset. Essentially, comparison 
with aggregated cost data for the source population revealed that this study observed 
very low costs in the female fee-for-service beneficiaries from age 65 onwards. 
 
Comparison of predicted vs. observed costs at the GLM level revealed an isolated 
over-estimation of costs in the fee-for-service group, implying a possible 
exaggeration of the gatekeeping effect. Exclusion of the observations representing 
female fee-for-service beneficiaries from age 65 onwards diluted this over-estimation. 
Re-estimation of the two-part cost models after exclusion of this same group of 
observations did not reduce the combined estimates of the gatekeeping effect. This 
latter finding may suggest that the identified deviation of observed costs from 
population-level costs at the subgroup level induced no strong distortion of the main 
study results. However, additional influences of non-detected selection effects 
alongside unmeasured covariates cannot be ruled out. 
 
Cost and morbidity data for 1996, the year before the gatekeeping plan was first 
offered to the population, defined a baseline that could not be influenced by plan-
specific mechanisms. 
 
The finding of cost savings through gatekeeping is not invalidated by the observation 
that the unadjusted increase in total health care costs between 1996 and 2000 was 
more pronounced on the gatekeeping side. As confirmed by logistic regression 
modelling of plan membership, persons with higher health care costs in 1996 but not 
persons with a higher 1996 ICED score were reluctant to join the gatekeeping plan. 
This must have led to a regression-to-the-mean effect as it has been described 
before for similar settings [67]. A higher mean age in the gatekeeping group and the 
fact that more persons in this group reached the age threshold of 65 years between 
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1996 and 2000 may also have contributed to the more pronounced increase seen 
here. 
 
Data collection from the study participants occurred in the first half of 2001 and some 
time-dependent covariates (describing subjective health status, health behaviour and 
resource use preferences) documented the situation at this point in time, but were 
nevertheless used in the regression models on year 2000 costs. The intention was 
not to assess cause-effect relationships between these covariates and the target 
variable, but merely to reduce the amount of unexplained variance and thus to 
achieve more precise estimates of the gatekeeping effect. Moreover, most of the 
covariates in question tend to change slowly over time. The differences between the 
health plans under study are fairly limited and unlikely to cause differential changes 
of attitudes, behaviours or even health status in the mid-term. Thus, the 2001 values 
of these covariates can be assumed to represent the situation directly before and in 
2000 fairly adequately, except for random changes of health status. 
 
All regression analyses on cost were performed excluding as well as including these 
covariates and the resulting estimates of the gatekeeping effect were similar. 
However, the reduced model on outpatient costs yielded effect estimates which were 
higher than those seen in the total costs. This was due to insufficient adjustment and 
it turned out that the difference in explanatory power between the reduced and 
extended models occurred mainly because no subjective health status variable was 
available for the former. The level of self-payments chosen (an insurance contract 
detail) tended to be higher in healthier persons and could be used as an, albeit 
unsatisfactory, proxy. Variables indicating a high importance assigned to low 
insurance premiums, or a low household income, behaved near-identical in all cost 
models, but the former was less affected by missing values and therefore preferred. 
 
The gatekeeping plan under study does not incorporate additional utilisation 
management practices such as prospective utilisation review [219]. It focuses on the 
avoidance of duplicate diagnostic tests and unnecessary specialist consultations. 
Some case management occurs informally. The exact mechanisms behind the cost 
savings observed could not be identified, as cost and resource use data were not 
detailed enough for a refined analysis of the medical services provided. Therefore, 
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we cannot contribute to ongoing discussions whether the gatekeeping approach 
could be optimised, e.g. by allowing direct specialist access for particular subgroups 
of persons or under special circumstances [65·69]. In our case, most savings were 
realized in the outpatient setting. The number of consultations was less important for 
the overall result than the amount of services performed per consultation and the 
amount of medications prescribed. 
 
This study supports that utilisation management through gatekeeping may be 
associated with relevant savings in health care costs. 
 
 
COMMENT: What this paper adds 
 
• The aim of gatekeeping is to reduce the cost of health care without affecting its 
quality, primarily by avoiding duplicate diagnostic tests and unnecessary 
consultations with specialists. 
 
• Studies of the impact of gatekeeping in mixed settings, where other techniques of 
utilisation management were also in place, have been inconclusive. According to 
this study, isolated gatekeeping may be an efficient technique of utilisation 
management. 
 
 
COMMENT: Policy implications 
 
• Policy decisions that have an impact on national reimbursement systems, or on 
the type of products offered by health insurers, should consider gatekeeping as 
an option which avoids strong incentives to restrict the use of medical services 
and which may, therefore, be largely uncontroversial for a public concerned with 
quality. 
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ABSTRACT 
 
Goals of work. The aims of this study were to assess chemotherapy treatment 
characteristics, neutropenic event (NE) occurrence and related risk factors in breast 
cancer patients in Western Europe. 
Patients and methods. Six retrospective audits of breast cancer chemotherapy were 
combined into a dataset of 2'860 individuals. NEs were defined as neutropenia-
related hospitalisation, dose reduction ≥ 15%, or dose delay ≥ 7 days. Summation 
dose intensity (SDI) was calculated to compare different types of chemotherapy 
regimens on a single scale. Risk factors of NE occurrence and of low relative dose 
intensity (RDI) ≤ 85% were identified by multiple logistic regression. 
Main results. Patient populations were comparable between audits. Until 1998 CMF 
regimens were most frequently used, but thereafter anthracycline-based regimens 
were most common. NEs occurred in 20% of patients and low RDI in 16%. NE 
occurrence predicted low RDI and was associated with higher age; bigger body 
surface area; lower body mass index; regimen type; more chemotherapy cycles 
planned; normal to high SDI; concomitant radiotherapy; and year of treatment. First 
cycle NE occurrence predicted NEs from cycle two onwards. A risk score; using age, 
SDI, number of planned chemotherapy cycles, and concomitant radiotherapy; 
differentiated patients with increasing NE risk (9-37%). An alternative score version 
not using concomitant radiotherapy performed moderately less well. 
Conclusions. NEs occurred frequently in this combined dataset and they affected 
treatment delivery. Identifying patients at high NE risk enables targeted prophylaxis 
and may avoid dose limitations. 
 
 
KEYWORDS 
 
Breast cancer; adjuvant chemotherapy; adverse effects; neutropenia; Europe 
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INTRODUCTION 
 
Myelosuppression is a major side-effect of anticancer chemotherapy. Consequences 
include potentially life-threatening febrile neutropenic episodes, intravenous antibiotic 
treatment and prolonged hospitalisation [153]. Chemotherapy dose reductions and 
delays are common sequelae and may affect treatment outcomes adversely [10·126]. 
In early-stage breast cancer, adjuvant chemotherapy has become an element of 
standard therapy and reduces the hazard rate of death by about 15% [59]. However, 
this benefit may be reduced or lost when relative chemotherapy dose intensity (RDI) 
is reduced [23·30·36·158]. 
 
Trial-based reports of chemotherapy-induced neutropenia (CIN) and febrile 
neutropenia (FN) incidence in breast cancer patients vary widely. During the last 
decade, cyclophosphamide; methotrexate; fluorouracil (CMF) regimens and 
fluorouracil; doxorubicin or epirubicin; cyclophosphamide (FAC or FEC) regimens 
have been most widely used. A systematic review of randomised clinical trials with at 
least 50 patients per treatment arm published between 1990 and 2000 found grade 
III-IV CIN rates of 1-78% in CMF chemotherapy and of 3-100% in FAC or FEC 
chemotherapy [45]. These differences are partially explained by protocol-specific 
assessment rules and differences in the timing of absolute neutrophil counts (ANC) 
or white blood cell counts (WBC) [66]. Thus, current evidence does not always 
enable a specific neutropenia risk to be assigned to commonly used regimens. 
Detailed information on the impact of neutropenia on chemotherapy delivery in 
routine practice is also limited. 
 
Prophylactic measures such as colony-stimulating factor (CSF) and anti-infectives 
administration can be used to avoid neutropenic event (NE) occurrence and maintain 
RDI. Current US and European guidelines, as well as economic constraints, 
recommend a limited use of such prophylaxis, and this is reflected in practice 
[46·66·147·153]. Furthermore, new NCCN myeloid growth factor guidelines 
recommend that the overall risk of neutropenia should be calculated, taking into 
account both patient and treatment risk factors, before deciding whether to provide 
growth factor support [147]. Thus the development of clinically applicable risk models 
allowing prophylaxis to be targeted at high risk patients is important. Various studies 
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published during the last decade have addressed this and research is currently 
ongoing [129]. Results are awaited from ongoing American and European 
prospective observational studies. 
 
We have combined data from six retrospective European audits of breast cancer 
chemotherapy, enabling us to assess the incidence and extent of chemotherapy 
dose limitations, the incidence of NEs, and the associations of both with potential risk 
factors with greater statistical power than the individual audits. From these analyses 
we propose preliminary NE risk scores. 
 
 
PATIENTS AND METHODS 
 
Datasets combined 
Data on NE occurrence and impaired chemotherapy delivery were obtained from six 
audits in which patient identification information had been removed. Details of the 
Chemodose 99 audit conducted in 37 centres in Belgium and Luxembourg; the 
Optimización del Standard de Quimioterapia Administrada en diferentes Regímenes 
(OSQAR) audit conducted in 34 Spanish centres; the Audit of Primary Breast Cancer 
Patients conducted in 15 UK district general and teaching hospitals; and an audit 
conducted in six German centres were reported earlier [42·111·114·123]. 
Unpublished data came from two academic centres in Vienna, Austria (principal 
investigator L. Auerbach), and in Ghent, Belgium (principal investigator S. Van Belle). 
 
In the UK audit, data were collected prospectively in 60% of patients. All other data 
were collected retrospectively. Patient selection rules were designed to recruit a 
patient mix as seen in routine practice, but rules regarding the inclusion of stage IV 
patients differed between audits and the Belgian (Ghent) study only included patients 
receiving adjuvant CMF regimens. 
 
Variables available from all six audits comprised demographic details; diagnosis and 
disease stage; prognostic factors and hormone receptor status (except UK audit); 
planned and administered chemotherapy; toxicities; NEs and related hospitalisations; 
concomitant radiotherapy and CSF use. Some ANC and WBC values were missing in 
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all audits. Comorbidity and performance status data were not available, although the 
latter were unlikely to be important in a mostly adjuvant setting. Limited information 
on long-term outcome was available from the Austrian, German and Spanish audits, 
but not from the rest. 
 
Coding and grouping criteria were unified. Variable definitions were compared and in 
discrepant or unclear cases, recalculations were performed from the cycle-specific 
details available. With respect to chemotherapy dose limitations, cut-off points used 
were ≥ 15% for reductions and ≥ 7 days for delays. RDI was calculated as 
administered dose per unit time divided by planned dose per unit time. In the case of 
combination regimens, the RDIs for each drug were averaged. Low RDI was defined 
as RDI ≤ 85% [23]. NEs were defined as neutropenia-related dose delay; dose 
reduction; or hospitalisation. The decision whether events were neutropenia-related 
was made by the original investigators. Due to a lack of uniform assessment rules, 
ANC or WBC data were frequently missing and thus could not be used to verify NEs 
for the combined dataset. 
 
Summation dose intensity (SDI), measuring the planned dose intensity of 
combination regimens on a single summary scale, was calculated as proposed by 
Hryniuk et al. [106]. From first-line single-agent trials in metastatic breast cancer, 
these authors determined the unit dose intensity (UDI) required for each drug to 
produce a 30% complete plus partial response rate. For each regimen, the dose 
intensities of the individual agents used were expressed as fractions of their UDIs, 
and summed. Here, the resulting SDI values were standardised to a recognised 
‘standard’ of chemotherapy, namely intravenous CMF with drug administrations on 
days 1 and 8 of a 28-day cycle, at the following doses: cyclophosphamide, 600 mg 
m-2; methotrexate, 40 mg m-2; 5-fluorouracil 600 mg m-2 (CMF 600-40-600 d1,8 4w). 
An RDI adjusted to CMF 600-40-600 d1,8 4w was then calculated by multiplication 
with the standardised SDI values (adjusted RDI). 
 
Statistical methods 
Descriptive analysis used standard statistical methods. Univariate relationships 
between categorical variables were assessed by Chi-squared tests. Where one 
variable was continuous, t-tests and ANOVA or Mann-Whitney U tests and Kruskal-
86 
  Chapter 6: Results - Neutropenic event risk 
Wallis tests were used, depending on the distributions observed. Where both 
variables were continuous, Spearman's correlation coefficients were employed 
because of non-normality. 
 
Multiple logistic regression allowing for clustering by audit was used to calculate 
adjusted odds ratios (OR) with robust standard errors for the following outcomes: any 
NE occurrence; NE occurrence from cycle two onwards; and low RDI [175].  
 
Chemotherapy delays and dose reductions directly impacted on RDI and they were 
also part of the NE definition used. As a consequence of this circularity, the 
coefficient of the NE covariate may have been overestimated in the regression 
models on low RDI occurrence. Therefore, this was checked by using an alternative 
NE definition based on the limited ANC and WBC data available. 
 
The independent influences on NE occurrence identified in regression analysis were 
used as candidate items for the development of tentative NE risk scores. Selection of 
score items followed the principle of achieving a maximum of predictive and 
discriminatory power with a minimum of complexity. Cut-off points for continuous 
variables were chosen empirically to optimise score performance. 
 
Two-tailed p = 0.05 was used to determine statistical significance. Confidence 
intervals (CIs) shown are at the 95% level. 
 
 
RESULTS 
 
Patient and treatment characteristics 
The Austrian, Belgian and Luxembourg, Belgian (Ghent), German, Spanish, and UK 
audits contributed 375, 660, 82, 154, 1'167, and 422 patients (total 2'860). Of these, 
79% received their chemotherapy treatments during 1995-2001. 
 
Patient and disease characteristics were acceptably similar across audits (Table 1). 
However, the diagnostic spread in the Belgian (Ghent) audit was unusual with an 
increased proportion of stage I patients (32% vs. 18% across all audits) and a 
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reduced proportion at stage III (4% vs. 16% across all audits). Post-menopausal 
patients were under-represented in this dataset, although other patient 
characteristics were comparable to other audits. 
 
Table 1. Patient, disease and treatment characteristics 
Variable N total All audits Inter-audit range 
Age at diagnosis (years; mean ± SD) 2'745a 51.5 ± 11.3 48.0 ± 10.9 - 53.1 ± 11.8
Age at diagnosis 60 years or higher (%) 2'745a 24.4 13.6 - 30.7 
Menopausal status (% postmenopausal)c 2'365b 51.5 44.0 - 56.8 
Hormone receptor status (% positive) 2'179b 63.7 56.3 - 70.9 
Disease stagec    stage I (%) 2'743a 18.1 14.6 - 21.6 
     stage II (%)  62.5 54.9 - 69.0 
    stage III (%)  15.5 10.4 - 28.9 
              stage IV (%)  4.0 0.0 - 8.9 
Chemotherapy regimend   CMF-based (%) 2'834 a 55.7 47.0 - 72.3 
       anthracycline-based (%)  40.8 27.3 - 47.2 
                 taxane-based (%)  1.3 0.0 - 3.0 
         other (%)  2.2 0.3 - 7.3 
Concomitant radiotherapy (%) 2'606 a 30.9 23.7 - 61.6 
Colony-stimulating factor use (%) 2'832 a 12.9 1.4 - 18.3 
a N total < 2'860 due to missing values spread over various datasets. 
b N total < 2'860 due to inavailability of UK data and additional missing values spread over 
various datasets. 
c Inter-audit ranges of menopausal status and disease stage do not take into account the 
Belgian (Ghent) dataset, see text. 
d Inter-audit ranges of chemotherapy regimens used do not take into account the Belgian 
(Ghent) audit reporting data on patients receiving CMF chemotherapy only. 
Abbreviations: C, cyclophosphamide; F, 5-fluorouracil; M, methotrexate. 
 
In total, 240 different chemotherapy regimens were planned. A comparison of these 
regimens was facilitated by use of summation dose intensity (SDI) [106], using CMF 
600-40-600 d1,8 4w as a standard. Table 2 details the distribution of the most 
common regimen subtypes and their standardised SDI values, and Figure 1 shows a 
histogram of standardised SDI. Mean SDI was highest in CMF chemotherapy, 
followed by anthracycline-based, taxane-based, and other chemotherapy. Older 
patients generally received lower SDI regimens (correlation coefficient -0.10, p < 
0.001); more so in CMF (-0.13, p < 0.001) than in anthracycline-based chemotherapy 
(-0.07, p < 0.001). 
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Table 2. Frequency of use and standardiseda summation dose intensity (SDI) of 
subtypes of planned chemotherapy regimens 
Regimen subtype N 
totalb 
Frequency 
within regimen 
type (%) 
SDI  
(mean ± SD) 
SDI inter-audit range 
(mean ± SD) 
All regimens 2'832 -- 0.92 ± 0.19 0.84 ± 0.19 - 1.00 ± 0.00
CMF-based regimens 
All CMF-based 1'578 -- 0.94 ± 0.17 0.85 ± 0.21 - 1.02 ± 0.10
CMF, 28 day cycle 1'012 64.1 0.99 ± 0.11 0.86 ± 0.20 - 1.07 ± 0.00
CMF, 21 day cycle 375 23.8 0.76 ± 0.21 0.69 ± 0.00 - 1.03 ± 0.32
CMF, oral 187 11.9 1.04 ± 0.04 1.03 ± 0.08 - 1.04 ± 0.06
CMF-based sequential 4 0.3 0.66 ± 0.23 0.55 ± 0.07 - 1.00 ± -- 
Anthracycline-based regimens 
All anthracycline-based 1'155 -- 0.89 ± 0.20 0.76 ± 0.28 - 0.95 ± 0.22
FAC 194 16.8 1.05 ± 0.12 0.97 ± 0.00 - 1.05 ± 0.07
FEC 420 36.4 0.82 ± 0.92 0.61 ± 0.00 - 0.84 ± 0.13
AC 138 12.0 1.00 ± 0.07 0.90 ± 0.20 - 1.02 ± 0.06
EC 154 13.3 0.77 ± 0.29 0.69 ± 0.22 - 1.00 ± 0.46
A→CMF 63 5.5 0.83 ± 0.09 0.79 ± 0.04 - 1.00 ± 0.05
Anthracycline- and 
taxane-containing 
38 3.3 1.21 ± 0.43 0.98 ± 0.03 - 1.25 ± 0.45
Other anthracycline 148 12.8 0.88 ± 0.22 0.79 ± 0.10 - 1.00 ± 0.56
Taxane-based 37 -- 0.86 ± 0.34 0.82 ± 0.27 - 1.89 ± -- 
Other 62 -- 0.70 ± 0.08 0.63 ± 0.21 - 0.70 ± 0.07
a Standardised to intravenous CMF 600-40-600 d1,8 4w. 
b N total < 2'860 due to missing values spread over various datasets. 
Abbreviations: A, doxorubicin; C, cyclophosphamide; E, epirubicin; F, 5-fluorouracil; M, methotrexate. 
A→CMF refers to sequential regimens where several courses of A, then several courses of CMF are 
administered. 
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Figure 1. Histogram of standardised summation dose intensity (SDI) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concomitant radiotherapy was administered to 40% of patients receiving CMF-based 
chemotherapy and to 22%, 14%, and 16% of those receiving anthracycline-based, 
taxane-based, and other regimens respectively. CSFs were used in 12% of patients 
receiving CMF-based chemotherapy and in 14%, 30%, and 17% of those receiving 
anthracycline-based, taxane-based, and other regimens respectively. 
 
Since 1996, use of CMF regimens and concomitant radiotherapy have decreased, 
while use of anthracycline-based regimens has increased, becoming the most 
frequent regimen type after 1998. Use of CSFs increased in the early 1990s and 
remained relatively constant after 1995. 
 
Chemotherapy dose limitations 
Dose delays in at least one cycle occurred in 34% of patients (inter-audit range 16-
48%), of which 8% had delays that appeared to be directly related to concomitant 
radiotherapy administration; whether they were pre-planned chemotherapy 
interruptions could not be assessed. Dose reductions in at least one cycle occurred 
in 33% of patients (inter-audit range 14-49%). Forty-seven percent had either dose 
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delays or dose reductions (inter audit range 26-58%). Mean RDI ± SD was 94 ± 11% 
(inter-audit range 90 ± 16%-96 ± 8%). Figure 2 shows details by regimen type. 
 
Figure 2. Chemotherapy dose limitations by regimen type 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RDI ≤ 85% occurred in 16% of patients (inter-audit range 7-25%). It occurred more 
frequently in CMF-based than anthracycline-based chemotherapy (16% vs. 14%; p = 
0.052). However, anthracycline-based regimens tended to have a lower SDI than 
CMF-based regimens and when RDI was adjusted to CMF 600-40-600 d1,8 4w 
chemotherapy, 45% of patients fell short of the 85% threshold (inter-audit range 10-
56%). 
 
RDI was slightly lower in older patients (correlation coefficient -0.07, p = 0.001). 
However, the proportion of patients over age 60 who received RDI ≤ 85% was not 
significantly higher than for patients below 60 years (17% vs. 15%, p = 0.270). In 
contrast, the proportion of patients above 60 years who received adjusted RDI ≤ 85% 
was higher than for younger patients (51% vs. 43% below 60 years; p < 0.001). 
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Neutropenic event occurrence 
NEs (neutropenia-related dose delays, dose reductions or hospitalisations) were 
observed in 20% of patients (inter-audit range 15-25%), and repeated NEs in 8% 
(inter-audit range 6-11%). Neutropenia-related dose delays were seen in 13% (inter-
audit range 6-22%), dose reductions in 6% (inter-audit range 1-11%), and 
hospitalisations in 5% (inter-audit range 4-13%). Figure 3 shows details by regimen 
type. 
 
Figure 3. Neutropenic events by regimen type 
 
 
 
 
 
 
 
 
 
 
 
 
 
Neutropenic event occurrence (regression results) 
In logistic regression, NE occurrence was associated with higher age; higher BSA; 
lower BMI; regimen type; more planned chemotherapy cycles; normal to high SDI 
(2nd to 4th quartiles); concomitant radiotherapy administration; and year of treatment. 
Concomitant radiotherapy administration interacted with BSA, number of planned 
chemotherapy cycles, regimen type, and SDI. The change in NE risk over time was 
regimen-dependent. Table 3 details the model. 
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Table 3. Influences on any neutropenic event occurrence (logistic regression allowing 
for clustering by audit) 
N = 2'358          Pseudo R squared of the model = 
0.070 
Independent variable Odds ratio  
(95% CI) 
p valuea
Ageb 1.02 (1.01-1.03) < 0.001 
Body surface areab  if concomitant radiotherapy no 3.85 (1.84-8.07) < 0.001 
    if concomitant radiotherapy yes 0.95 (0.47-1.95) 0.895 
    if concomitant radiotherapy unknown 13.19 (2.38-73.11) 0.003 
Body mass indexb 0.97 (0.94-0.99) 0.013 
Chemotherapy regimenc three weekly CMF 2.75 (2.05-3.67) < 0.001 
    anthracycline-based 1.50 (0.98-2.30) 0.061 
    taxane-based 1.68 (1.44-1.97) < 0.001 
    other 0.87 (0.34-2.21) 0.764 
Normal to high SDId 1.70 (1.43-2.02) < 0.001 
Planned chemotherapy cyclesb if concomitant radiotherapy no 1.43 (1.18-1.74) < 0.001 
    if concomitant radiotherapy yes 1.18 (1.13-1.22) < 0.001 
    if concomitant radiotherapy unknown 0.92 (0.81-1.03) 0.153 
Year of treatmentb  linear, if 4 weekly CMF 0.94 (0.88-1.00) 0.068 
    linear, if 3 weekly CMF 1.02 (0.93-1.13) 0.626 
    linear, if anthracycline use 0.85 (0.75-0.95) 0.007 
    linear, if taxane-based regimen 1.91 (1.69-2.14) < 0.001 
    linear, if other regimen 1.50 (1.44-1.56) < 0.001 
    squared 0.99 (0.98-1.00) 0.075 
Concomitant radiotherapye yes, if 4 weekly CMF 0.65 (0.42-1.00) 0.049 
    yes, if 3 weekly CMF 0.37 (0.20-0.70) 0.002 
    yes, if anthracycline-based 0.26 (0.21-0.33) < 0.001 
    yes, if taxane-based -- -- 
    yes, if other regimen -- -- 
    unknown, if 4 weekly CMF 1.01 (0.01-97.00) 0.995 
    unknown, if 3 weekly CMF 1.25 (0.01-123.96) 0.925 
    unknown, if anthracycline-based 2.27 (0.04-116.86) 0.683 
    unknown, if taxane-based -- -- 
    unknown, if other regimenf 76.27 (2.20-2644.20) 0.017 
    yes, if low SDI 41.27 (5.37-316.85) < 0.001 
    yes, if normal to high SDI 128.50 (15.99-1032.9) < 0.001 
    unknown, if low SDI -- -- 
    unknown, if normal to high SDI 1.19 (0.14-10.14) 0.876 
a Combined Wald tests, for all sets of categorical or ordinal variables and for all sets of 
interaction terms, p < 0.05. Interaction effects are presented as simple effects, not as main 
effects plus interaction terms, for ease of interpretation. 
b Per one unit increase. 
c Compared to four weekly CMF. 
d Second to 4th quartiles compared to 1st quartile. 
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e Compared to no concomitant radiotherapy administration. 
f Parameter estimate based on 4 observations, assumed to be an artefact 
Abbreviations: C, cyclophosphamide; F, 5-fluorouracil; M, methotrexate; SDI, summation dose 
intensity. 
 
NE risk over time decreased for four-weekly CMF and anthracycline-based regimens, 
increased for taxane-based and other regimens, and increased then decreased for 
three-weekly CMF. Three-weekly CMF had a distinctly higher NE risk compared to 
four-weekly CMF. Taxane-based regimens also posed a greater NE risk than four-
weekly CMF, although the sample was rather small (N = 37). For anthracycline-
based regimens, the NE risk was only slightly greater than for four-weekly CMF when 
time trends were taken into account.  
 
A positive association of concomitant radiotherapy and NE occurrence was 
confirmed for patients receiving four-weekly CMF regimens with normal to high SDI 
(41% of our sample), with an OR of 2.5 (CI 1.4-4.5; calculated form the linear 
predictors underlying the ORs shown in Table 3, using mean values for body surface 
area and number of planned chemotherapy cycles). Use of radiotherapy weakened 
both the association of NE risk with higher BSA and with the number of planned 
chemotherapy cycles. 
 
First cycle NE occurrence was a strong predictor of NE occurrence from cycle two 
onwards, with an OR of 7.7 (CI 4.3-13.9). Otherwise, influence variables and 
observed interactions were as described for NE occurrence in any cycle, and 
coefficients were remarkably similar. 
 
When the observations used for model estimation were restricted to patients 
receiving CMF- or anthracycline-based chemotherapy, the associations and 
coefficients seen remained largely stable. 
 
Neutropenic event risk scores 
A drug-independent risk score based on age (≥ 50 years vs. < 50 years), SDI (2nd to 
4th quartiles vs. lowest quartile, corresponding to a standardised SDI cut-off of 0.80), 
number of planned chemotherapy cycles (≥ 6 vs. < 6), and concomitant radiotherapy 
administration performed best. The score value was derived by counting the number 
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of risk factors present, and by adding 1 if there were more than 6 chemotherapy 
cycles planned. Patient groups with an increasing risk of NE occurrence in any cycle 
of 9-37% were differentiated (Figure 4, upper half). The area under the receiver 
operating characteristic (ROC) curve was 0.60 (CI 0.58-0.63). When the suggested 
cut-off point of more than two risk factors being present was used, sensitivity was 
69% and specificity 47%. Omitting concomitant radiotherapy administration as a 
score item reduced the area under the ROC curve to 0.57 (Figure 4, lower half). 
Sensitivity was reduced to 51% and specificity increased to 61%. 
 
Figure 4. Neutropenic events in any cycle by risk score 
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When first cycle NE occurrence was included as an additional score item, patient 
groups with an increasing risk of NE occurrence from cycle two onwards (8-43%) 
were differentiated with sensitivity 71% and specificity 46%. Omitting concomitant 
radiotherapy administration from this score led to a similar degradation of 
performance as described above for any NE occurrence. 
 
Low RDI occurrence (regression results) 
Logistic regression showed low RDI occurrence to be significantly associated with NE 
occurrence; higher stage of disease; regimen type; concomitant radiotherapy 
administration; and year of treatment. When the alternative NE definition, based on 
the available blood cell count data, was used, the OR of low RDI for NE occurrence 
was reduced from 5.1 (CI 4.2-6.2) to 2.5 (CI 2.1-3.1). All other coefficients remained 
stable. 
 
 
DISCUSSION 
 
This is the first multi-country study to address the incidence, risk factors, and 
consequences of neutropenic events induced by adjuvant breast cancer 
chemotherapy. Six retrospective European audits of breast cancer chemotherapy, 
with comparable patients (similar to those seen in routine practice) were combined to 
generate the first transnational European database.  
 
The most commonly followed regimens were CMF- and anthracycline-based, with 
administration of taxane-based and other regimens being too rare to allow reliable 
results. CSF use was low and followed no coordinated approach, which, from an 
analytical perspective, may have been advantageous, because physiological 
relationships were not hidden by effective prophylaxis. 
 
NEs and low RDI were confirmed to be frequent events and several independent 
predictors of NE occurrence were identified. SDI was demonstrated to be such a 
predictor, for the first time according to our knowledge. Using a cut-off point between 
the 1st and the 2nd quartile of the SDI distribution was optimal for prediction purposes, 
but treating SDI as a continuous variable also produced significant results. Using SDI 
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was crucial in separating the effects of regimen type from those of planned dose 
intensity. 
 
A higher NE risk in three-weekly compared to four-weekly CMF was observed in the 
Spanish and UK audits; i.e. all audits with a substantial proportion of three-weekly 
CMF patients. This association has been previously reported [64·123], and different 
centre characteristics have been proposed as a partial explanation [123]. The NE risk 
of anthracycline-based regimens was only moderately increased compared to four-
weekly CMF, but an element of incomplete adjustment may be present in this result, 
as we corrected for SDI but not for anthracycline dosage directly. Changes in NE risk 
over time and dependent upon regimen type, may have been due to increasing 
experience and changes in medical practice. 
 
NE risk was shown to increase linearly with age; an observation supported by earlier 
studies [10·206]. Correcting for SDI was important for detecting this relationship, 
which was partially hidden by a tendency to use lower planned dose intensity in older 
patients. While the association of age and NE risk appears marginal when expressed 
per year of age (OR 1.02; see Table 3), this corresponds to an OR of around 1.5 for 
an age difference of 25 years. An increased NE risk in patients with higher BSA and 
a protective effect of higher BMI were also demonstrated. This seems biologically 
plausible, particularly if it is acknowledged that BSA-based chemotherapy dosing 
may not be an optimal solution. The BSA effect was diluted in patients receiving 
concomitant radiotherapy, which might be because radiotherapy adds a BSA-
independent risk component. Concomitant radiotherapy administration itself 
appeared to be associated with a higher NE risk in univariate analysis; in multivariate 
analysis this finding was only unequivocal for four-weekly CMF regimens with normal 
to high SDI. 
 
Of the variables analysed, a combination of age, SDI, number of planned 
chemotherapy cycles, concomitant radiotherapy administration and first cycle NE (in 
the case of NEs occurring from cycle two onwards) provided the best indicator of risk. 
Tentative addition of score items representing BSA, BMI, or chemotherapy regimen 
type did not improve performance. The observed wide variety of regimen 
specifications, which is in part reflected in the SDI variable, and differences in 
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practice patterns may have obscured the differences between the main types of 
chemotherapy regimens involved. In support of our conclusions, age, radiotherapy 
administration and first cycle NE have previously been used in clinical prediction 
models [44·185·206]. However, the cut-off found for age, at 50 years, may have been 
influenced by practice patterns and may not be universally applicable. Compared to 
scores derived from datasets with more baseline and first cycle haematology 
parameters available, our tentative scores performed only slightly less well [206]. 
Omitting concomitant radiotherapy, which is becoming rare, affected the performance 
moderately. The other parameters used, including SDI, can be expected to become 
important components of future risk models combining patient-related and treatment-
related factors. 
 
An association of NE and low RDI was confirmed even when NE were assessed from 
the limited ANC and WBC values available. Low adjusted RDI was found to occur 
more frequently in anthracycline-based compared to CMF-based chemotherapy due 
to lower SDI values in the former. In contrast, Lyman et al. reported lower SDI values 
in CMF- than in anthracycline-based chemotherapy in the US [130]. 
 
Our findings underline the importance of early prophylaxis. NEs are frequent and 
they often impact on chemotherapy delivery, with the likely effect of diminished 
efficacy. The importance of maintaining full chemotherapy dose intensity, in younger 
and older patients, has been described by several authors [23·30·36·158]. A current 
tendency toward dose-dense regimens may further exacerbate this problem 
[40·62·207]. 
 
In order to further our current findings on the risk of NE, a prospective study 
measuring all potential risk factors including first cycle ANC has commenced in 
Europe. This will allow our findings to be validated against an external dataset, and 
should allow our risk score to be developed and refined to a model with increased 
discriminatory power. Such a risk model is becoming fundamentally important as 
economic constraints and current guidelines require expensive prophylactic 
treatments to be targeted to those at greatest risk [147]. 
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Chapter 7 
 
Multilevel re-analysis 
 
Hierarchical structure of datasets 
All three datasets analysed were characterised by hierarchical (multilevel) data 
structures. In the asthma dataset, patients were nested within physicians [203], which 
corresponds to a simple two-level situation. The gatekeeping dataset showed a 
cross-classification structure, i.e. health plan beneficiaries were independently nested 
within physicians and within insurance companies. However, in the original analysis, 
no influence of insurance company on cost to the Swiss statutory sick funds was 
identified and a brief multilevel re-assessment confirmed this finding. Therefore, the 
gatekeeping dataset was also analysed as a two-level dataset, with health plan bene-
ficiaries at level 1 and physicians at level 2. In the neutropenia dataset, three levels 
were present: patients were nested within study centres which were nested within 
audits conducted in different countries. Sample size details are shown in Table 1. 
 
Table 1. Hierarchical structure of datasets 
 Asthma 
dataset 
Gatekeeping 
dataset 
Neutropenia 
dataset 
Level 3 description 
  N 
-- -- audits 
6 
Level 2 description 
  N 
  N per level 3 unit (mean; min-max)
physicians 
107 
physicians 
59 
-- 
study centres 
95 
15.8; 1-38a 
Level 1 description 
 
  N 
  N per level 2 unit (mean; min-max)
patients 
 
422 
3.9; 1-5 
health plan 
beneficiaries 
466b 
7.9; 1-32 
patients 
 
2'860 
30.1; 1-375a 
a Two of the audits were single-centre studies with 82 and 375 observations, respectively. When 
these were excluded, the mean number of level 1 units per level 2 unit was 25.8 (range 1-89). 
b Maximum number of level 1 observations available for estimation of the logistic models of any 
health care costs being accrued. In some regression models, N was smaller due to missing 
values in some of the covariates used. The maximum number of level 1 units available for 
estimation of the GLMs of total health care costs in those with non-zero costs was N = 391. 
 
A number of potential level 2 predictors (e.g., specialty of treating physician) were 
available from the asthma and gatekeeping datasets. Moreover, in all three cases, 
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some level 1 predictors could be assumed to be influenced by or intertwined with 
higher level characteristics (e.g., chemotherapy regimen chosen). Details are shown 
in Appendix I. 
 
The presence of higher level variation was assessed for the main endpoints of the 
analyses reported in chapters 4-6. (In the original analysis of the gatekeeping study, 
a distinction between reduced and extended cost models was made, and multilevel 
re-analysis was based on the latter, more complete models.) 
 
Presence of higher level variation 
Random intercept variance components models were estimated by allowing the 
intercept terms of the conventional regression models described in chapters 4-6 to 
vary at random. Significant higher level variance was found to be present in the 
asthma dataset and in the neutropenia dataset at level 2, but not in the neutropenia 
dataset at level 3 and not in the gatekeeping dataset. Details are shown in Table 2. 
 
In the asthma dataset, 17.5% of the residual variance (i.e., of the variance not 
explained by the fixed part predictors) was between-physician variance occurring at 
level 2. Correspondingly, in the neutropenia dataset, 15.1% of the residual variance 
was found to be between-centre variance. 
 
Given these results, more in-depth multilevel analyses were restricted to the asthma 
dataset, and to the neutropenia dataset with a focus on levels 1 and 2. 
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Table 2. Presence of higher level variation according to random intercept variance 
components models 
Dataset / analysis (endpoint) Intercept Intercept variance 
(standard error) 
p valuea Intra-higher 
level 
correlation 
Level 2 
Asthma dataset (direct medical 
cost of asthma, log scale) 
4.249 0.140 (0.047) < 0.001 0.175 
Gatekeeping dataset, logistic 
model of any costs being 
accrued (total health care costs 
and outpatient costs) 
5.618 0.259 (0.389) 0.201 -- 
Gatekeeping dataset, GLM of 
costs in those with non-zero 
costs (outpatient costs) 
4.884 0.000 (0.000) 0.500 -- 
Gatekeeping dataset, GLM of 
costs in those with non-zero 
costs (total health care costs) 
7.361 0.000 (0.000) 0.500 -- 
Neutropenia dataset (any 
neutropenic event occurrence)b 
-6.734 0.585 (0.156) < 0.001 0.151c 
Level 3 
Neutropenia dataset (any 
neutropenic event occurrence)b 
-6.734 0.002 (0.029) 0.473 -- 
a Likelihood ratio test, p-value divided by 2 (see Methods, p. 35). 
b Based on three-level random intercept variance components model (clustering option not 
specified). 
c Based on two-level random intercept variance components model (clustering option not 
specified); calculated as proposed by Snijders and Bosker [164: 114·192]. 
 
Asthma dataset: result of multilevel analysis 
In the asthma dataset, significant level 2 variation was observed for the variable 
distinguishing quick reliever from controller therapy and for the variable describing 
employment status in those aged 65 years or younger. The random intercept term 
became non-significant when the first of the afore-mentioned covariates was allowed 
to vary at random. None of the primary level 2 variables available (representing 
urban or rural area and language region), or of the level 1 variables aggregated at 
level 2 and tentatively added to the model, were significant at the fixed effects level 
or showed significant random variation. 
 
The explanatory variable "involvement of a pulmonologist in diagnosis or treatment", 
which was used in the conventional regression model, could not be assigned to 
either level 1 or level 2. For further analysis, it was split up in its original components, 
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i.e. "diagnosis of asthma by a pulmonologist" and "specialty of treating physician" 
(comprising the categories of general practitioner, specialist in general internal 
medicine, pulmonologist, and pediatrician [203]). The latter covariate was non-
significant and eliminated from the model. Diagnosis of asthma by a pulmonologist 
was significant at level 1 (but not at level 2) and thus retained. 
 
In a subsequent step, one level 2 unit (physician) with outlying characteristics and 
three level 1 observations (patients) who turned their corresponding level 2 units into 
apparent outliers were identified and found to substantially influence the model. As a 
consequence of absorbing them into dummy variables, the covariate describing 
employment status in those aged 65 years or younger became non-significant at 
level 1 and level 2 and was thus removed. The coefficients for age and age squared 
were somewhat reduced and the latter became non-significant but was retained to 
facilitate comparison with the conventional regression model reported in chapter 4. 
 
The resulting final multilevel model (Table 3) differed in three respects from the 
conventional model shown in chapter 4, Table 4. (1) It contained a random term for 
the variable distinguishing quick reliever from controller therapy. (2) The covariate 
"involvement of a pulmonologist in diagnosis or treatment" was replaced by a related 
covariate, "diagnosis of asthma by a pulmonologist". (3) One level 2 unit and three 
level 1 observations were absorbed into dummy variables. 
 
The coefficient estimates for the fixed effects parameters contained in both the 
conventional model and the final multilevel model had the same direction. 
Differences in size were small to moderate. 
 
Concentration of level 2 random variation in the covariate indicating the use of 
controller therapy, as opposed to quick reliever therapy, indicated physician-specific 
differences in the cost impact of this choice (see comparison section below and 
chapter 8, p. 129). 
 
Residuals diagnostics for this final multilevel model of asthma costs showed 
acceptable properties (Figures 1-3). Some high predicted values with zero residuals, 
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as appearing in Figure 3, were a consequence of absorbing influential observations 
into dummy variables, as described. 
 
Table 3. Final two-level model of direct medical costs (log scale) induced by asthma, 
including a random effect for quick reliever versus controller therapya 
Number of level 1 units = 420 Log likelihood = -510.128
Number of level 2 units = 107 AIC 1060.26
Variable Esti-mates 
Std. 
Err. 
Test 
stat.b p value 
95% Confidence 
Interval 
Fixed part       
Degree of severity:       
 Mild persistentc 0.917 0.176 5.21 < 0.001 0.572 1.262 
 Moderate persistentc 1.136 0.174 6.53 < 0.001 0.795 1.476 
 Severe persistentc 1.045 0.189 5.52 < 0.001 0.674 1.416 
Exacerbations present 0.386 0.262 1.47 0.140 -0.127 0.898 
Interaction of degree of severity and 
presence of exacerbations, ordinal: 
      
 Level 1d -0.517 0.315 -1.65 0.100 -1.134 0.099 
 Level 2d 0.088 0.303 0.29 0.7773 -0.506 0.681 
 Level 3d 0.371 0.304 1.22 0.222 -0.224 0.966 
Age (centered) 0.007 0.002 3.22 0.001 0.003 0.012 
Age squared (centered) -0.00014 0.00010 -1.36 0.173 -0.00033 0.00006
Asthma-related comorb. present 0.304 0.116 2.62 0.009 0.076 0.531 
Diagnosis by a pulmonologist:       
 Noe -0.234 0.098 -2.37 0.018 -0.426 -0.041 
 Unknowne -0.342 0.132 -2.59 0.010 -0.601 -0.083 
Controller therapyf 0.589 0.108 5.45 < 0.001 0.377 0.801 
Dummy for influential observation 1 -2.849 0.872 -3.27 0.001 -4.557 -1.140 
Dummy for influential observation 2 3.527 0.857 4.12 < 0.001 1.848 5.206 
Dummy for influential observation 3 3.848 0.783 4.91 < 0.001 2.313 5.383 
Dummy for influential level 2 unit -1.279 0.499 -2.56 0.010 -2.257 -0.301 
Intercept 5.278 0.173 30.45 < 0.001 4.938 5.618 
Random part - level 1       
Residual variance 0.584 0.046   0.494 0.674 
Random part - level 2       
Controller therapy variance 0.145 0.052 13.46 < 0.001 0.052 0.252 
a Conventional regression model for comparison: chapter 4, Table 4. 
b Fixed parameters, Wald test based on z statistic; random variance, likelihood ratio test, p-
value divided by 2 (see Methods, p. 35). Standard errors and CIs based on the Wald statistic 
throughout. 
c Compared to mild intermittent. Wald test for this set of variables, p < 0.001. 
d Compared to level 0. Wald test for this set of variables, p = 0.002. 
e Compared to yes. Wald test  for this set of variables, p = 0.007. 
f Compared to quick reliever therapy. 
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Figure 1. Final multilevel cost of asthma model - inverse normal plot of studentised 
level 1 residuals 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Final multilevel cost of asthma model - plot of studentised level 1 residuals 
against fixed part predicted values 
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Figure 3. Final multilevel cost of asthma model - inverse normal plots of studentised 
level 2 residuals 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Neutropenia dataset: result of multilevel analysis 
In the neutropenia dataset, no significant level 3 variation was detected, but 
significant level 2 variation was observed for the intercept and for the variable 
indicating the use of an anthracycline-based chemotherapy regimen. The 
corresponding covariance term was also significant. In contrast, the fixed effects 
terms representing year of treatment, year of treatment squared, and interaction 
between year of treatment and chemotherapy regimen type became clearly non-
significant and were removed from the model. All other fixed effects coefficients and 
their standard errors remained essentially stable. 
 
Some aggregated variables tentatively added to the model were found to be 
significant at the fixed effects level, but did not show any significant random variation. 
They represented, at the centre level, the proportion of patients aged 65 or older, the 
proportion of patients with a BMI ≥ 30 kg/m2, the proportion of patients receiving an 
anthracycline-based chemotherapy regimen, and the proportion of patients receiving 
a three-weekly CMF regimen. As these covariates did not contribute to the analysis 
of higher level variation or increase predictive ability, and might have introduced 
over-modelling, it was decided not to include them in the final multilevel model. 
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However, an alternative model containing them was fully assessed as described in 
Appendix I. 
 
The resulting final multilevel model of any neutropenic event occurrence (Table 4) 
differed in two respects from the main conventional model shown in chapter 6, Table 
3 (rewritten in Appendix I, Table 6 to facilitate comparison). (1) It contained variance 
terms for the intercept and for the variable indicating use of an anthracycline-based 
chemotherapy regimen, plus the corresponding covariance term. (2) The fixed effects 
terms representing year of treatment, year of treatment squared, and interaction 
between year of treatment and chemotherapy regimen type were dropped. 
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Table 4. Final two-level model of any neutropenic event occurrence (logistic 
regression); including variance and covariance terms for the intercept and use of an 
anthracycline-based chemotherapy regimena 
Number of level 1 units = 2'358 
Number of level 2 units = 93 
Log likelihood -1115.315
Std. err. adjusted for 6 clusters (audits) AIC 2284.63
Variable Esti-mates 
Std. 
Err. 
Test 
stat.b 
p 
valueb 
95% Confidence 
Interval 
Fixed part       
Agec 0.022 0.006 3.52 < 0.001 0.010 0.034 
Body surface areac 1.357 0.284 4.78 < 0.001 0.800 1.914 
BMIc -0.046 0.012 -3.83 < 0.001 -0.069 -0.022 
Chemotherapy regimen:d       
 Three weekly CMF 0.845 0.074 11.38 < 0.001 0.699 0.990 
 Anthracycline-based 0.323 0.181 1.78 0.075 -0.033 0.680 
 Taxane-based 1.591 0.072 22.13 < 0.001 1.450 1.731 
 Other 0.944 0.417 2.26 0.024 0.126 1.762 
Normal to high SDIe 0.625 0.153 4.10 < 0.001 0.326 0.925 
Planned chemotherapy cyclesc 0.369 0.105 3.52 < 0.001 0.164 0.575 
Concomitant radiotherapy 
administration (Rx):f 
      
 Rx yes 2.94 0.936 3.14 0.002 1.105 4.775 
 Rx unknown -0.927 1.825 -0.51 0.612 -4.503 2.650 
Interaction of chemotherapy 
regimen and Rx: 
      
 Three weekly CMF, Rx yes -0.382 0.450 -0.85 0.396 -1.263 0.500 
 Anthracycline-based, Rx yes -0.872 0.134 -6.52 < 0.001 -1.134 -0.610 
 Taxane-based, Rx yes 1.362 0.210 6.48 < 0.001 0.950 1.774 
 Other, Rx yes -- -- -- -- -- -- 
 Three weekly CMF, Rx unkn. 0.660 0.505 1.31 0.192 -0.330 1.650 
 Anthracycline-based, Rx unkn. 0.687 0.494 1.39 0.164 -0.281 1.656 
 Taxane-based, Rx unknown -- -- -- -- -- -- 
 Other, Rx unknowng 2.047 1.104 1.85 0.064 -0.116 4.210 
Interaction of body surface area 
and Rx: 
      
 Rx yes -1.235 0.344 -3.59 < 0.001 -1.908 -0.562 
 Rx unknown 1.678 0.652 2.57 0.010 0.400 2.957 
Interaction of planned 
chemotherapy cycles and Rx: 
      
 Rx yes -0.194 0.089 -2.19 0.029 -0.368 -0.020 
 Rx unknown -0.401 0.083 -4.83 < 0.001 -0.563 -0.238 
Interaction of normal to high SDI 
and Rx: 
      
 Rx yes 1.135 0.327 3.47 0.001 0.493 1.777 
 Rx unknown -0.104 1.003 -0.10 0.917 -2.070 1.861 
Intercept -6.895 0.747 -9.22 < 0.001 -8.360 -5.429 
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Table 4 ctd. 
Random part - level 1       
Binomial variance 1h 0     
Random part - level 2       
Intercept variance 0.716 0.114 
60.01 
(2dgf)i 
< 0.001 0.493 0.939 
Anthracycline-based chemo-
therapy regimen variance 
0.802 0.284 
18.21 
(2dgf)i 
< 0.001 0.245 1.359 
Covariance -0.433 0.150 4.61 0.016 -0.727 -0.139 
a Conventional regression model for comparison: chapter 6, Table 3, re-written to facilitate 
comparison in Appendix I, Table 6. 
b Fixed parameters, Wald test based on z statistic; random parameters, likelihood ratio test, p-
value divided by 2 (see Methods, p. 35). Standard errors and CIs based on the Wald statistic 
throughout. Wald tests for all sets of categorical or ordinal variables and for all sets of 
interaction terms, p < 0.01. 
c Per one unit increase. 
d Compared to four weekly CMF. 
e Second to 4th quartiles compared to 1st quartile. 
f Compared to no concomitant radiotherapy administration. 
g Parameter estimate based on 4 observations, assumed to be an artefact. 
h Constrained to 1 [169:35]. 
i Removing any of the level 2 random variance terms also removes the covariance term. 
Abbreviations: C, cyclophosphamide; F, 5-fluorouracil; M, methotrexate; SDI, summation dose 
intensity. 
 
The coefficient estimates for the fixed effects parameters contained in both the 
conventional model and the final multilevel model had the same direction. 
Differences in size were small to moderate. Exceptions from these rules were limited 
to some coefficients which were based on very few observations and thus considered 
to be doubtful from the beginning (terms involving taxane-based and "other" 
chemotherapy regimens), or were clearly non-significant in both models but were 
retained as parts of sets of parameters which were significant as a whole ("unknown" 
concomitant radiotherapy administration and term representing interaction between 
normal to high SDI and "unknown" concomitant radiotherapy administration). 
 
The presence of substantial higher level variation in the variable indicating use of an 
anthracycline-based regimen indicated centre-specific differences in the neutropenia 
risk associated with this type of chemotherapy (see comparison section below and 
chapter 8, pp. 129-30). 
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Although no substantial variation was found at the audit level (level 3), GEE-based 
robust standard error estimates allowing for clustering by audit were used in order to 
ensure consistency with the main conventional model of any neutropenic event 
occurrence. Moreover, the power to correctly estimate variability at this level was 
presumably low, given a small number of 6 observational units only. Abandoning the 
approach to use robust standard errors led to increased standard error estimates, as 
in the corresponding conventional models. The differences were not such that they 
would have changed the conclusions or affected any decisions regarding the 
inclusion or exclusion of model parameters (see Appendix I). 
 
Graphical assessment indicated acceptable, albeit not ideal model fit (Figures 4 and 
5), and there was no indication of substantial extra-binomial variation. 
 
Figure 4. Main multilevel model of neutropenic event occurrence - mean observed 
against mean predicted event probabilities, by deciles of the linear predictor 
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Figure 5. Main multilevel model of neutropenic event occurrence - inverse normal 
plots of studentised level 2 residuals 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Predictive ability of conventional regression models and multilevel models 
Conventional regression-based and multilevel-based predictive ability was compared 
for the asthma and neutropenia studies. In both cases, the predictive ability of three 
models was regarded. These were the final multilevel models (Tables 3 and 4 
above), conventional models using the same fixed effects predictors as the final 
multilevel models, and the main conventional models reported in chapters 4 and 6. 
 
Predictive ability details for the asthma study are shown in Table 5. The final 
multilevel model of asthma costs showed a distinct reduction in apparent prediction 
error, by 34% compared to the main conventional model and by 24% compared to 
the conventional model using the same fixed effects predictors as the multilevel 
model. This gain in apparent predictive ability is graphically demonstrated in Figures 
6 and 7. The overlaid inverse normal plots of residuals shown in Figure 6 revealed a 
somewhat improved situation in the tail areas and lower residuals overall in the 
multilevel model. An overlaid plot of predicted against observed values (Figure 7) 
hinted at a somewhat better predictive ability of the multilevel model at both ends of 
the distribution. 
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Table 5. Apparent prediction error and cross-validation results for the cost of asthma 
models 
Criterion Main 
conventional 
model  
(chapter 4) 
Conventional model 
using same fixed 
effects predictors as 
the multilevel model 
Final multilevel 
model 
N 420 420 420 
AIC 1120.41 1072.24 1062.78 
Apparent prediction error 
MSE 0.793 0.690 0.524 
Cross-validation ignoring hierarchical structure 
MSE (e0 bootstrap) 0.880 0.863 -- 
MSE (.632 bootstrap) 0.848 0.799 -- 
MSE (10-fold cross-validation) 0.848 0.834 -- 
Cross-validation only taking into higher level units contributing to model estimation 
MSE (10-fold cross-validation) 0.839 0.825 0.789 
Cross-validation only taking into higher level units not contributing to  
model estimation 
MSE (10-fold cross-validation) 0.857 0.847 0.845 
 
Bootstrap-based and 10-fold cross-validation performed on the conventional models 
showed a moderate increase in prediction error, compared to the apparent situation. 
Conventional-based cross-validation results were consistent across methods and 
only slightly affected by either ignoring the hierarchical structure of the data or 
restricting the test set to observations whose corresponding higher level units had or 
had not contributed to model estimation. Ten-fold cross-validation of the final 
multilevel model revealed a more pronounced increase in prediction error compared 
to the apparent situation. A modest gain in efficiency was retained compared to the 
conventional models if the test set was restricted to observations whose 
corresponding level 2 units had contributed to model estimation. In this case, the 
multilevel-based prediction error was 6% lower than in the main conventional model 
and 4% lower than in the conventional model using the same fixed effects 
parameters as the multilevel model. If the test set was restricted to observations 
whose corresponding higher level units had not contributed to model estimation, the 
gain in predictive ability compared to the conventional models was minimal. 
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Figure 6. Cost of asthma models - overlaid inverse normal plots of level 1 residuals 
derived from the final multilevel model and of residuals derived from the main 
conventional model 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Cost of asthma models - predicted vs. observed log of direct medical costs, 
predicted values of final multilevel model overlaid with predicted values of main 
conventional model 
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In the neutropenia study, the prediction error of the main multilevel model was again 
distinctly reduced compared to the conventional models in the apparent situation. 
The MSE indicator was reduced by 13-14% and classification error by 11%. In 10-
fold cross-validation, if the test set was restricted to observations whose 
corresponding level 2 units had contributed to model estimation, the MSE indicator 
was reduced by 6-7% and classification error by 4-6%. If the test set was restricted to 
observations whose corresponding level 2 units had not contributed to model 
estimation, no substantial improvement compared to the conventional models 
remained. Details are shown in Table 6. 
 
Table 6. Apparent prediction error and cross-validation results for the models of 
neutropenic event occurrence 
Criterion Main 
conventional 
model  
(chapter 6) 
Conventional model 
using same fixed 
effects predictors as 
the multilevel model 
Main multilevel 
model 
N 2'358 2'358 2'358 
AIC 2355.94 2377.04 2284.63 
Apparent prediction error 
MSE / classification error 0.158 / 21.80% 0.160 / 21.80% 0.137 / 19.38% 
Cross-validation ignoring hierarchical structure 
MSE (e0 bootstrap) 0.164 / 22.42% 0.164 / 22.00% -- 
MSE (.632 bootstrap) 0.162 / 22.23% 0.163 / 21.93% -- 
MSE (10-fold cross-validation) 0.163 / 22.43% 0.164 / 22.02% -- 
Cross-validation only taking into higher level units contributing to model estimation 
MSE (10-fold cross-validation) 0.162 / 22.49% 0.163 / 21.87% 0.152 / 21.04% 
Cross-validation only taking into higher level units not contributing to  
model estimation 
MSE (10-fold cross-validation) 0.172 / 23.21% 0.169 / 22.65% 0.170 / 22.44% 
 
Comparison of conventional regression-based results and multilevel modelling 
results 
With respect to the response variables of interest, substantial and significant higher 
level variation was detected in the asthma dataset and in the neutropenia dataset, 
but not in the gatekeeping dataset. For the latter, the key findings of the original 
analyses were confirmed, but no additional insights were gained. 
 
In the asthma and neutropenia studies, 18% and 15% of the residual variance, 
respectively, was between-higher level unit variance. More detailed analysis of the 
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variance structure identified the predictors in which a substantial amount of this 
higher level variance occurred. In both cases, these predictors were not level 2 
predictors in the strict sense (i.e., direct higher level unit characteristics), but level 1 
predictors which were influenced by level 2 characteristics. 
 
In the asthma study, most of the higher level random variation occurred in the 
covariate indicating the use of controller therapy, as opposed to quick reliever 
therapy, showing physician-specific differences in the cost impact of this choice. In 
the neutropenia case, some of the higher level variation was concentrated in the 
covariate indicating use of an anthracycline-based regimen, thus showing centre-
specific differences in the neutropenia risk associated with this type of chemotherapy. 
In contrast, no higher level variation was seen in the other chemotherapy types 
represented in the dataset. Such additional information could not have been gained 
using conventional regression methods. 
 
The sets of fixed parameters used in the multilevel models differed slightly from those 
used in the conventional models, for three types of reasons. In the asthma case, one 
of the covariates used ("involvement of a pulmonologist in diagnosis or treatment") 
was composed of a level 1 characteristic ("diagnosis of asthma by a pulmonologist") 
and a level 2 characteristic ("specialty of treating physician"). In order to achieve 
clarity in multilevel analysis, this covariate was split up into its components and one 
of these components was eliminated due to non-significance. The second reason for 
modification of the set of fixed parameters used in the asthma analysis was the 
absorption of some influential level 2 units or their corresponding observations into 
dummy variables. Finally, in the neutropenia analysis, the terms representing year of 
treatment and year of treatment squared, and their corresponding interaction terms, 
lost their statistical significance when the variance structure was taken into account. 
This was not counterintuitive, as the level 2 units (centres) recruited their patients at 
different points in time, during a period of rapidly growing experience with the use of 
then novel chemotherapy regimens (involving anthracyclines and taxanes). The time 
effect may thus have been absorbed into the level 2 residuals. 
 
The coefficient estimates for the remaining fixed parameters had the same direction 
as their equivalents in the conventional regression models. Some of them differed in 
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size, but not to an extent that would have necessitated different interpretations. Most 
standard errors were slightly reduced in the multilevel models, confirming the 
theoretically expected gain in statistical efficiency. Exceptions from these rules were 
limited to some coefficients in the model of neutropenic event occurrence which were 
based on very few observations and thus considered to be doubtful from the 
beginning (terms involving taxane-based and "other" chemotherapy regimens), or 
were clearly non-significant in both models but were retained as parts of sets of 
parameters which were significant as a whole. 
 
The AIC, as a criterion of model fit, was reduced in the multilevel models, compared 
to the corresponding conventional models, in all cases (see Tables 5 and 6 above). 
 
In the asthma study as well as in the neutropenia study, the predictive ability of the 
multilevel models was improved in the apparent situation. In the asthma study, 
prediction error as measured using the MSE indicator was reduced by 24-34%. In the 
neutropenia study, the reduction was 13-14% for the MSE indicator and 11% for the 
classification error indicator. However, these gains were only partially confirmed 
under 10-fold cross-validation conditions. If the test set was restricted to observations 
whose corresponding higher level units had contributed to model estimation, the 
MSE indicator was reduced by 4-6% compared to conventional in the asthma study. 
In the neutropenia study, the MSE indicator was reduced by 6-7% and classification 
error was reduced by 4-6% compared to conventional. If prediction was restricted to 
those observations whose corresponding higher level units had not contributed to 
model estimation, the gain in predictive ability was essentially lost. 
 
In summary, multilevel modelling of direct medical asthma costs and of any 
neutropenic event occurrence made an additional contribution, compared to the 
conventional models, by providing new insights in the sources of the variance seen in 
the response variables, and by slightly increasing statistical precision. Moreover, 
there were modest gains in terms of predictive ability for out-of-sample observations 
whose corresponding higher level units had contributed to model estimation. The 
main findings of the conventional analyses remained fully valid. 
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Chapter 8 
 
Discussion and conclusions 
 
This work is based on three health care-related observational studies conducted 
and/or analysed by the author (chapters 4-6). All three were primarily analysed using 
conventional multivariate regression methods. In an additional step, re-analyses of all 
three datasets were performed using multilevel modelling, a statistical technique 
taking hierarchical data structures into account (chapter 7). Taking a more distant 
viewpoint then in the published discussion sections of chapters 4-6, this overall 
discussion tries to put into a broader perspective the contributions of the cost of 
asthma, gatekeeping, and neutropenia studies. In a second step, the contribution of 
multilevel modelling to these studies, and to other studies in the underlying fields of 
research, is reviewed. Based on this and other available information on the 
possibilities, disadvantages, and current spread of multilevel modelling, conclusions 
and recommendations regarding the use of this statistical technique are proposed 
and associated aspects of study design are briefly addressed. 
 
Cost of illness of asthma 
Cost of illness studies in the field of asthma uniformly show a considerable economic 
impact, with direct medical asthma costs accounting for 1-3% of total health care 
expenditures in most countries [138]. However, studies vary widely with respect to 
their choice of methodology, perspective of cost assessment, and patient population 
regarded. In adults, direct medical costs are typically reported to be responsible for 
30-70% of total asthma costs, with indirect costs due to asthma morbidity (i.e., lost 
working days and early retirement) accounting for the remainder [11·28·39·180·182]. 
If costs due to asthma mortality are additionally taken into account, the share of 
indirect costs may even be higher [199]. The key components of direct medical costs, 
jointly contributing about 70-80% of the total in most studies, are medication costs, 
followed by emergency room visits and hospitalisations 
[11·18·39·79·115·148·159·203·217·222]. In the paediatric setting, a substantial 
number of studies show essentially comparable results but a wider variation in the 
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proportion of emergency room and hospitalisation costs, and a lower importance of 
indirect costs [11·78·198·215]. 
 
Costs due to emergency room visits and hospitalisations are concentrated on a 
relatively small subgroup of asthma patients and are a major cost component in this 
group [25·27·146·188·216]. Consequently, correlates of asthma-related 
hospitalisations have been interpreted as correlates of asthma costs [79]. Higher 
disease severity has been firmly established as a cost driver [11·81·180·182·211]. 
The independent impact of asthma control, i.e. of the freedom from vs. occurrence of 
asthma exacerbations, has also been addressed [11·103·177·195]. The study 
reported in chapter 4 of this thesis has been the first one in adults to establish this 
link using multivariate regression methods, and to confirm an interaction between 
bad asthma control and a high degree of asthma severity. In the meantime, the cost 
impact of asthma exacerbations has been confirmed by several other studies 
[101·200]. More insights in the impact of bad asthma control are expected from the 
ongoing TENOR study, a large three-year multi-centre cohort study conducted in the 
US [55]. 
 
Recent publications also provided additional confirmation for the other patient-level 
factors the author found to be associated with higher asthma costs, i.e. higher age 
[199], asthma-related co-morbidity [94], and the use of controller vs. quick reliever 
therapy. Controller therapy has been strongly advocated in recent years and was 
often discussed in the context of guidelines adherence and patient as well as 
physician compliance [3·11·79·93]. Typically, substantial clinical benefits were 
observed at a moderately increased cost [75·93·189·201], which is consistent with 
the author's results. 
 
Apart from the author's analysis, no multivariate regression analyses directly 
addressing person-level asthma costs are available for adults, but some multivariate 
analyses of key correlates of cost have been published. Using logistic regression 
analysis, Hoskins et al. found the risk of asthma exacerbations to be associated with 
the time of day of symptom occurrence, and with exercise-induced symptoms [103]. 
Schatz et al. found lower median household income, previous emergency room visits 
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/ hospitalisations, indicators of increased medication use, and a higher number of 
drug prescribers to be associated with asthma-related hospitalisations. 
 
In children, multivariate analyses confirmed higher asthma severity, the use of peak 
expiratory flow rate meters, younger age, low-income status, non-white race, and 
longer duration of asthma to be associated with higher costs [78]. Ungar et al. 
reported influences of asthma control, age, and season [209]. Van Ganse et al. 
reported a link between disease severity and emergency rooms visits / 
hospitalisations [211]. Non-multivariate analyses highlighted the impact of tobacco 
smoke [140] and low economic status [5]. 
 
Although reports of multivariate-based research findings are rare overall, the 
association of disease severity / asthma control with direct medical asthma costs has 
been firmly established. In clinical terms, finding ways to improve asthma control may 
now be of major importance [11·22·79·195]. If it is felt, however, that additional 
studies are needed to achieve final clarity with respect to other potential influences, 
or for prediction purposes, the underlying data collections should ideally be 
prospective and measure all covariates of potential interest currently known, inclusive 
of provider-level characteristics. Other than in the author's study, disease severity 
should be assessed using physiologic measures, not medication characteristics, in 
order to avoid potential circularity. 
 
Gatekeeping vs. fee-for-service based health insurance 
The ability of the gatekeeping approach to contain or reduce health care costs in 
general populations is still under debate and the available evidence remains 
inconclusive, as briefly mentioned in chapter 5. Some trials and observational studies 
conducted in general populations in the US, as well as the author's study, hinted at 
such an ability [77·120·136·137·178], but other observational studies also conducted 
in general populations didn't [24·109·128·212]. Irrespective of the results, the vast 
majority of these studies compared gatekeeping with either fee-for-service based 
health insurance or with other settings lacking strong incentives to restrict the use of 
medical services. Some authors comparing gatekeeping plans to point-of-service 
plans, which allow self-referral to specialists but use other strong incentives such as 
substantial patient co-payments, did not find financial advantages of gatekeeping 
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[65·112·113]. To complete the picture, some analyses addressed specific health care 
resources whose use is usually expected to be influenced by gatekeeping (i.e., 
emergency room visits, re-hospitalisations), and did indeed demonstrate beneficial 
effects [72·190]. In contrast, a general reduction of specialist referrals by gatekeeping 
could not be firmly ascertained [70·71]. 
 
Among the most recently published studies, a US study using 1996 administrative 
and survey data from 8'195 adults showed modestly lower health care expenditures 
in gatekeeping arrangements as compared to fee-for-service based insurance [155]. 
However, this study was purely cross-sectional and no baseline cost data were 
available to the authors. A study by Bhat, looking at aggregate data from 24 OECD 
countries and using econometric methods, found an increased efficiency of health 
care delivery in countries widely using a gatekeeping approach to control the access 
to specialist and hospital care [17]. This result is essentially consistent with an earlier 
study by Delnoij et al., who also used aggregate data [49]. 
 
Negative aspects of the gatekeeping approach which may partially explain the overall 
unclear picture include a potential tendency to merely shift resource use from the 
higher levels of care to primary care [69]. Concerns about withholding care, and thus, 
reduced quality of care, have been raised but not demonstrated [174·184]. Moreover, 
such effects would be unlikely to influence the results of studies concentrating on 
expenditures, except if they had substantial health consequences in the short- to 
mid-term. 
 
Unequivocal are the challenges faced when gatekeeping plans are to be assessed. 
All studies tried to take into account issues of patient self-selection and varying case-
mix, usually by applying multivariate regression methods. However, the sets of 
covariates available were often limited. Some studies were purely cross-sectional 
and could not address issues of temporal sequence. The fact that in general 
populations, a substantial proportion of subjects has zero medical resource use, and 
thus, zero expenditures, was efficiently addressed by estimating two-part regression 
models [57·65·128·155]. Logistic regression was used to model if the response 
variable was non-zero, and multiple regression or (in the author's study) GLMs were 
used to model the response in those subjects with a non-zero response. In order to 
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meet the assumptions of multiple regression, response variables were sometimes 
transferred to the log scale, which involved a re-transformation problem when 
combined effect estimates were to be generated [56·155]. In contrast, the GLM 
approach avoids the re-transformation problem. Beyond these methodological and 
statistical challenges, a more general problem is the use of gatekeeping in a wide 
variety of situations, where other techniques of utilization management or incentives 
are also in place in different combinations. This includes the possibility of interaction 
and makes it very difficult to isolate effects. Moreover, diverse comparators are 
involved, which has a negative impact on generalisability. Most studies were 
conducted in settings where these issues could not be addressed satisfactorily. The 
author had a rare opportunity to study isolated gatekeeping, and he found cost-
savings compared to classical fee-for-service based health insurance. However, 
caveats remained, due to small sample size and because selection effects could not 
be ruled out entirely. 
 
Given rapidly changing health care environments, "the gatekeeping question" may 
not find a generalisable answer. Studies addressing specific applications of the 
gatekeeping approach remain nevertheless important. 
 
Neutropenic events in breast cancer chemotherapy 
In cancer patients, the risk of chemotherapy-induced neutropenia (CIN), febrile 
neutropenia (FN), and related events is influenced by treatment-related, patient-
related, and disease-related factors. Among these, the chemotherapy treatment 
regimens used are perceived as key factors "setting the stage" [132·153]. For 
example, in breast cancer, the neutropenic potential of the classical combination of 
cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) using a cycle length of 
four weeks was generally lower than that of anthracycline-containing regimens 
(although in the author's study, this became only visible in multivariate analysis). 
Modern anthracycline-taxane combinations were found to be even more aggressive 
[191]. Differences in dosage and schedule can have a very strong impact [191]. 
Accompanying anti-malignant treatments (e.g., concomitant radiotherapy 
administration) have been discussed as modifiers of risk [50·185], and the protective 
role of supportive treatments (i.e., myelopoietic growth factor administration) is 
generally recognised [40·191]. 
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Current opinion on patient-related and disease-related risk factors has been 
condensed into comprehensive reviews [48·132]. Proposed patient-related factors 
include higher age, performance status / functional impairment, presence of severe 
co-morbidity (including, but not limited to, heart disease, renal disease, and liver 
disease), and laboratory abnormalities. Laboratory abnormalities of interest may 
either occur pre-treatment (e.g., low pre-treatment white blood cell count, neutrophil 
count, or haemoglobin level) [131·132], or they may occur during the first cycle of 
chemotherapy treatment and predict neutropenic events in subsequent cycles (e.g., 
low nadir neutrophil count; day 5 lymphopenia; CD-4 lymphopenia) [19·26·132·185]. 
Laboratory abnormalities may be correlates of advanced disease, co-morbidity, or 
low chemotherapy tolerance. Proposed disease-related risk factors include tumour 
type and stage of disease [132]. However, it remains unclear if these factors have a 
stand-alone importance or if the observed increases in risk are merely due to more 
aggressive therapies being used in patients with, e.g., haematological malignancies 
or advanced disease. 
 
The available information has been used to develop and update guidelines of 
myelopoietic growth factor use [147·153·191]. However, to date, no comprehensive, 
clinically applicable risk models of neutropenic event occurrence have been 
presented or validated. There may be several partial explanations for this situation. 
• Much of our knowledge of the neutropenic potential of specific chemotherapy 
regimens stems from clinical trials of chemotherapy efficacy. Such trial-based 
reports have been shown to vary widely and their reliability and validity may be 
severely affected by study-specific differences in adverse event reporting [47]. 
• Various retrospective observational studies (including the author's study reported 
here) identified candidate risk factors and tentative risk models. However, many of 
these reports remained spurious and were not confirmed by other studies. No 
satisfactory, theory-guided integration of the available candidate risk factors into a 
comprehensive risk model has been proposed so far. 
• Cross-validation or external validation were rarely used [132]. Some few efforts 
were made, but the models assessed were rather limited in scope and 
concentrated on laboratory abnormalities such as first cycle neutropenia [172·185] 
or first cycle lymphopenia [26·38·166]. Both these indicators were shown to have 
an impact. There is a single example of a (non-randomised) clinical trial 
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conducted to confirm a neutropenic event risk factor, namely the prognostic value 
of first cycle neutropenia [171]. 
 
Future work should re-evaluate the risk factors that have been proposed to date and, 
on this basis, establish physiologically plausible risk models. These should then be 
cross-validated and externally validated against as many as possible suitable 
datasets. It would be an option to combine such datasets to increase statistical 
power, which would require to appropriately take into account the heterogeneity of 
the individual datasets. In this context, the multilevel approach to regression 
modelling might be a helpful technique. Another key requirement would be to 
adequately model the neutropenic potential of the chemotherapy treatments used. 
Given the primary importance of this factor, it would presumably be very difficult 
otherwise to correctly assess weaker influences. (In the past, grouping variables 
were sometimes used to represent identical or similar combinations of anti-malignant 
drugs, but with very different dosages and administration schedules. As a refinement, 
the approach by Hryniuk et al., to express the dose-intensity of a wide variety of 
breast cancer chemotherapy regimens on a single scale [106], was used to great 
advantage in the author's regression models reported here, but this can only be seen 
as a first step. It may prove necessary to move away from summary regimen 
descriptions altogether. Instead, covariates individually describing the planned dose 
intensities of the drugs with the highest neutropenic potential could be introduced, 
and be allowed to interact where physiologically plausible.) 
 
At a more mature stage of risk model development and validation, clinical trials could 
be used for final assessments. For example, patients could be randomised to receive 
either primary myelopoietic growth factor prophylaxis if the risk model under study 
indicated a risk above a certain threshold (treatment arm), or no primary myelopoietic 
growth factor prophylaxis (control). Such trials would typically be conducted in low- to 
medium-risk populations where primary growth factor prophylaxis is not 
recommended by current guidelines. It would be unethical to conduct them in 
patients receiving high-risk chemotherapy regimens where prophylaxis is indicated 
anyway. 
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Character of analyses performed 
The analyses reported in this thesis addressed either candidate risk factors for 
clinical events of interest, with a potential for serious medical and economic 
sequelae, or potential correlates of high health care costs. The statistical 
methodology used was structurally the same. 
 
All three underlying datasets had some weaknesses. In the asthma and neutropenia 
datasets, some known predictors of importance were either unavailable, affected by 
a substantial amount of missing values (e.g., baseline neutrophil counts in the 
neutropenia dataset), or of sub-optimal quality (degree of disease severity in the 
asthma dataset based on medication, not on physiologic measurements). In the 
gatekeeping dataset, limited sample size and the need to reduce statistical noise 
were major issues. At least in the asthma and gatekeeping studies, it was not the 
main goal, and it was clear from the beginning that it would not be possible, to 
establish comprehensive and final statistical models with a high predictive ability. The 
contribution of and coefficients for some specific covariates (asthma control; health 
plan membership) were of particular interest here [116:409]. In the neutropenia 
study, tentative risk scores were developed, but were not seen as complete solutions 
for immediate use in clinical practice. Elements of future, more complete models 
were to be ascertained and an impression of their possible contribution was to be 
gained. In all three cases, it was obvous that additional studies would be needed for 
more final results and consequently, the available statistical power was used without 
splitting the datasets, to identify or confirm influences on the outcomes of interest and 
to estimate effect sizes. No cross-validation efforts were made at this stage. 
(However, independently of this, cross-validation was used to assess the benefits of 
multilevel modelling.) External validation was not considered due to a lack of 
appropriate validation datasets. 
 
All three modelling processes were based on some concepts but, in essence, limited 
ascertained knowledge of the underlying processes and causal relationships. The 
models estimated can thus be viewed as empirical models in the sense of Cox, with 
some substantive components [43·186:252-4]. The "model generating approach" was 
used to make the best of the available information, i.e. tentative models were 
specified based on the available background information and then modified on an 
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empirical basis to achieve the best possible fit of the data [186:254-5]. This approach 
to modelling may be regarded as less theory-driven then desirable, but appeared to 
be the most suitable under the given circumstances. 
 
Apart from these issues, disregarding the multilevel (hierarchical) structure of the 
datasets used was perceived as the potentially most serious deficit of the primary 
analyses performed. Multilevel re-analyses were therefore performed and became 
the main focus of this thesis. 
 
Contribution of multilevel modelling to the fields of research addressed 
All three datasets analysed had multilevel or multi-membership data structures, but in 
the gatekeeping study, no higher level variation was detected. This can be 
interpreted as a confirmation of the appropriateness of the primary analysis 
performed. The finding of no significant higher level variation being present with 
respect to the binary response of accruing no or any health care costs, was less 
surprising than the finding of the amount of costs not being influenced by physician-
level characteristics. This is because decisions to consult or not to consult a 
physician are typically much less influenced by physician-level characteristics than 
the amount of medical resources used and, consequently, the cost induced once a 
consultation occurs. With respect to the amount of costs in those with any costs, the 
invisibility of any higher level variation may be explained by the fact that we studied a 
general population where inter-person (level 1) variation is huge and determined by a 
multitude of covariates. Moreover, physician-level treatment styles impacting on cost 
may differ, and be relatively uncorrelated, across diseases, depending on personal 
interest, perceived importance of different pathologies, etc. Therefore, physician-level 
random effects may be more easily visible where a single disease or group of 
diseases is addressed, as was the case in the asthma study. 
 
In the asthma and neutropenia datasets, substantial higher level variation was 
present. Multilevel analysis allowed  
• to slightly increase statistical precision; 
• to assess, for the outcomes of interest, the relative importance of patient-level 
and provider-level variation; 
• to identify the sources of higher level variation; 
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• to identify spurious findings "dictated" by the impact of few influential 
observations, by analysing influential higher level units [83:1/11]. In the asthma 
study, the employment status variable became non-significant at both levels when 
the impact of as few as seven individual-level observations, of which four were 
nested within an influential higher level unit, was "neutralised" by using dummy 
variables; 
• to modestly reduce prediction error (as assessed by cross-validation techniques) 
for out-of-sample observations whose corresponding higher level units contributed 
to model estimation; 
• Some changes in the model parameters used occurred (removal of year of 
treatment in the neutropenia study), but other than in some published studies [9], 
these changes were plausible consequences of the multilevel modelling process 
itself and did not necessitate substantial changes in interpretation. 
 
In both studies, although very different in detail, much or all of the higher level 
variation occurred in covariates representing clinical practice patterns, which is 
consistent with expectations from the literature [167·168]. In the asthma study, higher 
level variation occurred in the covariate indicating the use of controller therapy, as 
opposed to quick reliever therapy. This appeared plausible, as the value of this 
covariate was influenced by patient as well as physician characteristics. The random 
variation seen could be interpreted as being induced by a range of different 
(physician-specific) treatment intensities or strategies associated with the choice of 
controller therapy, from simple prescribing to using an enhanced level of diagnostic 
procedures and accompanying treatments. More specifically, it might reflect different 
degrees of adherence to treatment guidelines (see p. 121). As an additional aspect, 
the characteristics of the patients who received controller therapy may have differed 
across physicians. Therefore, it was not possible to decide if the higher level effect 
seen was purely contextual (i.e., confined to the provider-level), or if compositional 
effects (i.e., effects due to an uneven distribution of unmeasured patient-level 
characteristics) also played a role. 
 
In the neutropenia study, some of the higher level variation was concentrated in the 
covariate indicating use of an anthracycline-based regimen, thus hinting at centre-
specific differences in the neutropenia risk associated with this type of chemotherapy. 
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In contrast, no higher level variation was seen in the other chemotherapy types 
represented in the dataset. Generally spoken, it appeared plausible to find higher 
level variation in this group of covariates, as chemotherapy regimen choice was 
again patient-specific but higher level unit-dependent (i.e., centre-dependent), and as 
centres differed with respect to their frequency of use of, and experience with, 
different regimens. The fact that higher level variation was only confirmed for the 
anthracycline-based regimens, but not for other regimen types, found several partial 
explanations. At the time of data collection, clinicians were more experienced with 
CMF-type regimens then with anthracycline-based regimens, and the former had 
reached a higher level of standardisation. In contrast, the anthracycline-based group 
consisted of a wide range of different regimen specifications, which were clustered by 
centre. In the case of the taxane-based and "other" regimens, the amount of 
available information was small. 
 
Overall, the main findings of the original analyses were confirmed and some relevant 
additional information was gained. 
 
Literature searches did not identify any other studies applying multilevel modelling to 
the immediate research topics addressed by the author. In the wider field of 
managed care-related studies, one study used multilevel modelling to assess the 
impact of managed care penetration on patient-level health care costs [32]. A small 
impact of managed care on costs was visible in this cross-sectional study. Multilevel 
analysis allowed to identify some provider-level random effects which would not have 
been found by using conventional multiple regression. Two other studies used 
multilevel models to confirm provider-level influences on medical resource use 
[183·196]. In the neutropenia field, some random effects meta-analyses were 
conducted to address neutropenia-related prophylactic measures, or treatment 
strategies [12·63·76·156·197·202]. However, these studies are not directly 
comparable with the type of research reported here, although the models used are 
formally equivalent to random intercept multilevel models . 
 
Consequently, to date, a major contribution of multilevel modelling to the fields of 
research addressed by the author cannot be claimed. However, there were some 
contributions in detail. Moreover, it has been demonstrated that provider-level 
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characteristics may have a substantial influence and should be taken into account in 
future studies addressing similar topics.  
 
Criteria for the use of multilevel modelling 
Information on the current and potential contribution of multilevel modelling to health 
care-related research, in addition to the author's experience, stems from three types 
of sources. These are 
• theoretical texts describing the technique, its expected usefulness and problems; 
• review articles describing the use of multilevel modelling in different fields and 
listing promising areas of use, but typically without providing systematic 
assessments of the knowledge gains achieved [35·53·151·167·168]. Single case 
studies were often used to demonstrate such knowledge gains. Greenland refers 
to simulation studies which demonstrated advantages of multilevel modelling in a 
variety of situations including variable selection problems [91]); 
• original research articles using multilevel modelling. However, only in some 
instances, comparisons of conventional-based and multilevel modelling-based 
results were provided (see [9·32] for examples and [95] for an example where no 
benefit of multilevel modelling could be demonstrated). 
 
Following these sources, prerequisites of multilevel modelling are that the underlying 
data are characterised by a hierarchical (multilevel) or multi-membership structure 
and that regarding the higher level units as a sample drawn from a wider population 
of higher level units (as opposed to regarding them as totally unrelated) does not 
appear to be entirely unjustified [83:2·99:3]. Moreover, very small datasets will not 
allow to successfully use multilevel methods [91]. 
 
Beyond these most general criteria, the use of multilevel modelling is questionable in 
situations with very few higher level units [163:95]. In some cases, it will indeed be 
reasonable to view these units as distinct, independent entities (e.g., ethnic or 
religious groups) [9]. In other cases, the fundamental assumption of the higher level 
units being sampled from an underlying random distribution will be appropriate, but 
data on very few such units will not usually provide enough information to 
characterise this distribution. Thus, the power to estimate higher level variability and 
higher level effects becomes very low and it may be preferable to include the higher 
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level units as dummy variables in a single level model [54]. It would be inappropriate 
to conclude, though, that no higher level variation is present in these cases. 
 
If the sole interest is in effects occurring at the lowest level of a given hierarchy, 
alternative methods such as GEE-based estimation or sample survey techniques can 
be used to ensure unbiased standard errors [9·54·105:5-6]. In all other situations 
where the above-listed prerequisites are met, ignoring the hierarchical structure of 
the data may have a negative impact and multilevel modelling should be used at 
least tentatively, to assess if a substantial amount of higher level variation is present 
in the data. If this is confirmed, multilevel modelling is the analytic method of choice. 
Otherwise, it is unnecessary and simpler methods can again be used, or justified in 
hindsight, as was the case in the gatekeeping study [125]. 
 
Advantages and benefits of multilevel modelling 
Multilevel modelling is currently regarded as the most advanced technique to deal 
with multilevel and multi-membership data structures [91]. The technique can be 
used with all frequent types of responses, including survival data [84:178-81·221], 
although research is ongoing and some software implementations are still in a 
developmental stage (see Appendix III). Multilevel modelling is also combinable with 
two-part or multi-part modelling, as e.g. used to deal with health care cost data from 
general populations and other skewed data containing a substantial proportion of 
zero values. 
 
There is a broad consensus that the negative consequences of ignoring hierarchical 
data structures (loss of information and statistical efficiency, potentially incomplete or 
incorrect identification of effects, biased standard errors; see chapter 1) can be 
avoided by sensibly using multilevel modelling. Of the theoretically expected benefits, 
the analyses performed here confirmed the possibility to assess the presence of 
higher level variation, quantify its amount, and identify its sources; they confirmed a 
gain in statistical precision; they allowed to identify spurious findings by analysing 
influential higher level units [83:1/11]; and they achieved a modest reduction in 
prediction error. 
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The use of multilevel modelling may also yield substantially different or extended sets 
of significant predictor variables and, consequently, model parameters [9]. Erroneous 
conclusions may thus be avoided [1]. However, this was not the case in the author's 
studies, and neither in a substantial number of other studies where despite additional 
insights, the main conclusions of conventional analysis were essentially confirmed 
(see [32] for an example). 
 
Multilevel modelling allows to simultaneously test hypotheses at different levels of the 
hierarchy, and hypotheses involving several levels. This is of major importance where 
contextual and compositional effects are to be separated [58] and, more generally 
spoken, where substantive explanations involving several levels are to be tested. 
This would, e.g., be the case if based on prior knowledge, a risk model for a clinical 
event of interest had been developed, and if provider-level factors (e.g. clinical 
experience with a certain treatment) and specific relationships between patient-level 
and provider-level factors (e.g. different approaches to elderly patients) were part of 
such a model. 
 
The possibility to identify outlying observations at different levels of the hierarchy can 
contribute to improving overall model validity and performance, but in some 
situations, the main interest may be in the outlying higher level units themselves. 
Examples are assessments of the performance of health care providers aiming at 
direct intervention where quality of care is compromised, or studies of the success 
factors of newly introduced provider-level or community-level programmes. 
Distinguishing true outliers from apparent outliers (due to uneven distribution of 
lowest level characteristics, i.e. patient characteristics etc.) is of paramount 
importance in such situations. 
 
Multilevel modelling can be combined with the GEE approach to estimate unbiased 
standard errors in situations where the highest level units of the multilevel model are 
nested in even higher level clusters [161:26]. (Depending on software used; analysis 
of the neutropenia dataset made use of this option.) 
 
According to Greenland, multilevel modelling unifies the frequentist and Bayesian 
approaches to statistics [91]. Least squares-based algorithms to estimate multilevel 
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models should yield the same results as Bayesian estimation methods using non-
informative priors. Depending on the software used, use can be made of the "natural" 
Bayesian way to handle missing values (i.e., these can be estimated together with 
the other model parameters). 
 
Disadvantages and problems of multilevel modelling 
The most frequently mentioned disadvantage of multilevel modelling is its complexity 
[54·91·168]. This refers to the modelling process itself (where the approach 
described by Hox may provide some guidance [105:49-54]), but also to the difficulty 
of correctly interpreting effects occurring at different hierarchical levels or cross-level 
[58·83:1/11]. 
 
Constructing aggregate variables from lower level predictors may be important to 
make good use of the higher level information contained in a given dataset, but adds 
to this complexity. The approach taken should certainly be as theory-driven as 
possible, to ensure interpretability. According to the author's experience, demanding 
issues can arise here, e.g. if one allows for influences of the age distributions of 
patient populations nested within different providers, on the clinical practice patterns 
adopted by these providers. 
 
One of the additional problems of multilevel modelling described in the literature is 
the issue of sample size and power estimation [54·58]. No simple tools exist to 
perform such estimates for multilevel models, however some approximate formulae 
for standard error estimates are available and simulation-based approaches can be 
used [105:173·193:161-74]. From experience, sample size requirements are quite 
large at all levels. Paterson and Goldstein, for the two level situation, have suggested 
a minimum of 25 level 2 units with 25 level 1 units each [154]. Several other rules of 
thump have been proposed, depending on whether the main interest lies mainly in 
fixed parameters, in the random part, or in cross-level interactions [105:174-5]. Hox 
and Snijders give overviews of this topic [105:173-96·193:161-74]. 
 
Applying resampling techniques to multilevel situations requires the resampling 
process to take into account the hierarchical structure of the data [186:260]. The 
author found it relatively straightforward to modify standard cross-validation and 
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bootstrap techniques to assess the prediction error of a given multilevel model with a 
defined set of model parameters, but more complex problems arise if cross-validation 
or resampling techniques are to be used for parameter selection, or if the model 
estimation process itself should be resampling based [34·186:260]. (A solution for the 
latter problem using the resampling of residuals approach to bootstrapping is now 
implemented in one of more important software packages for multilevel modelling 
[34] - see Appendix III.) 
 
In this work, substantial reductions in apparent prediction error achieved by multilevel 
modelling were only partially confirmed under cross-validation conditions. When 
predictions were made for out-of-sample observations whose corresponding higher 
level units contributed to model estimation, only modest improvements were retained. 
It should be noted in this context that the number of level 1 observations per level 2 
unit was small and below multilevel modelling-specific sample size recommendations 
in the asthma dataset and in parts of the neutropenia dataset. This may have 
affected the precision of the level 2 unit-specific random effects estimates. More 
substantial gains in predictive ability might be achieved in situations with more lower 
level observations per higher level unit available. When predictions were made for 
observations whose corresponding higher level units did not contribute to model 
estimation, the gain in predictive ability was almost entirely lost. This is consistent 
with expectations, because no meaningful higher level residuals can be estimated for 
higher level units which did not contribute to model estimation [162]. Only "indirect" 
gains may occur in this situation, if the multilevel modelling process leads to 
substantial improvements of the fixed effects parts of the estimated models also. The 
importance of these limitations and the question if there is room for related 
methodological improvement may require further empirical study as well as more 
theoretical, mathematically oriented work beyond the ability of the author. 
 
Design aspects of multilevel studies 
This thesis is an example for the post hoc use of multilevel modelling, with datasets 
for which no such analysis was originally planned. However, more satisfactory results 
can certainly be expected from studies which are planned with the requirements of 
multilevel analysis in mind. 
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This requires, during the design and protocol development phase, to describe and 
define the multilevel structure of the data to be generated. The next step would then 
be to systematically identify, at all levels, which covariates might have an impact on 
the outcomes of interest and should therefore be collected. In current research, 
collecting higher level characteristics such as characteristics of health care providers 
is often neglected. Efforts should be made to define all covariates such that a level of 
the hierarchy can be unequivocally assigned to them (see pp. 105-6 for an example). 
The possibility of cross-level effects or interactions should also be taken into account 
when defining data collection requirements. For example, a patient characteristic 
(say, retirement) may have no direct relationship with an outcome of interest (say, 
direct medical cost induced by a given disease), but physicians (constituting the 
higher level units) may treat retired patients differently. Even more, the impact of 
retirement on treatment behaviour may vary across physicians. This cross-level effect 
could not be assessed if information on retirement was not collected. 
 
Where randomisation or random sampling processes are applied to balance the 
distribution of covariates, the techniques used should take the multilevel structure of 
the data into account. In a two-level situation, e.g., randomised sampling would 
typically be a two step process. Level 2 units would be sampled first, and then the 
level 1 units would be sampled from within these [193:159-60]. 
 
It should be taken into account that sample size requirements may be higher than in 
conventional analysis. Where simply increasing sample size to a level considered as 
safe is not an option, sample size and power estimates are a complex issue. As 
discussed above, no fully satisfactory solutions are currently available. 
 
Current and desirable use of multilevel modelling in health care-related 
research 
A Medline search on May 30, 2006 retrieved 1'202 entries indicating the use of 
multilevel modelling (and an exponential rise over time; see chapter 1). About 80% of 
these entries appeared to be true hits. 
 
Reviewing the topics addressed reveals that multilevel modelling was most frequently 
used where social or geographical units are of strong interest as explanatory factors 
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for the distribution of risk factors or health outcomes (see [53·108·139] for examples). 
Here, the advantages of multilevel modelling have long been recognised 
[52·54·58·167]. There is also a multitude of applications to other situations, but no 
clear pattern is visible. In most of health care-related research, personal interest of 
the researchers may still be the most important determinant of use of the technique. 
 
Review articles have reported and recommended the use of multilevel modelling 
• in social epidemiology [35]; 
• in public health research and research on health behaviours (where group-level 
factors may have an influence) [58·167·214]; 
• in health services research [54]; 
• in health economics, e.g. in studies addressing inequalities in resource allocation 
or the provision and utilisation of health services [58·168]; 
• in studies addressing variations in medical practice patterns, or, closely related, 
the performance of health care providers [58·167]; 
• in studies addressing unpaid caregiving by family members or partners [133]; 
• for longitudinal or repeated measurements data (where several observations 
spread over time are nested within persons) [54·134·151]; 
• for multivariate responses (multiple outcomes nested within persons) [54]; 
• in meta-analysis [105:8·165]. 
• in variable selection problems. Greenland has pointed out that the advantages of 
multilevel modelling are "especially great in studies that search for effects or 
interactions among many exposures (so-called ‘fishing expeditions’), in which 
standard methods of forcing in all variables or using mechanical variable-selection 
algorithms easily produce invalid inferences." [91]. 
 
While all these suggestions appear reasonable, the author would like to highlight the 
importance of using multilevel modelling where characteristics of health care 
providers, and clinical practice patterns in particular, may impact on health outcomes 
and health economic outcomes [168]. Such factors were shown to play a role in two 
out of the three analyses reported here, but they are often neglected in current 
research practice. It is only another facet of the same argument that multilevel 
modelling should also be used in multi-centre studies to take into account centre 
characteristics and behaviours. 
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As has been highlighted by Rice and Jones, this is not only true for observational 
studies, but also for multi-centre randomised clinical trials [168]. In such trials, a high 
degree of regulation and detailed research protocols are hoped to minimise centre-
specific effects, particularly in the pharmaceutical setting, but the success of these 
efforts cannot be taken as granted. "[…] even with randomization, it can be expected 
that the site of treatment may have an impact on the outcome regardless of treatment 
the patient receives. This may result from various sources and is likely to be due to 
differences in medical practice as administered by individual clinicians or clinical 
management and resources dictated by provider units. However, it may also be due 
to differences in subpopulations from which each site recruits and hence although 
patients may be randomised to treatments at each site, they may not be 
representative of the general population. Pooling data over sites without regard of 
such site-specific differences may lead to incorrect inference (for example, inefficient 
parameter estimates). The inclusion of site as a level in a multilevel analysis will 
ensure that the clustering effects within sites will be adequately controlled for." [168] 
Consequently, multilevel modelling should routinely be used in pharmaceutical 
development as well as other health care-related research to assess or rule out an 
impact of higher level variation on the results of national as well as international 
multi-centre trials. 
 
In conclusion, multilevel regression modelling is an important statistical technique, 
the only one to date which allows to comprehensively deal with nested (multilevel or 
multi-membership) data structures. Where such data structures are present, study 
design should explicitly take them into account and multilevel modelling should be 
used routinely, irrespective of the observational or experimental character of the 
research conducted. Advantages in terms of predictive ability may be limited and in 
many cases, use of the technique will remain tentative and prove unnecessary in 
hindsight. However, these caveats should not be used as arguments against 
applying multilevel modelling in the first instance, to cover all possibilities. 
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Appendix I 
 
Multilevel re-analysis details 
 
 
Asthma dataset 
 
Structure of dataset 
The asthma dataset by Szucs et al. is characterised by a two-level hierarchical data 
structure, with patients being the level 1 units und physicians being the level 2 units 
[203]. 
 
Table 1 shows potential predictor variables by level. Details regarding data collection 
and variable definitions are contained in chapter 4. 
 
Table 1. Potential predictors of direct medical costs (log scale) induced by asthma 
Predictor variable Remarks regarding level Used in main 
conventional model? 
Level 1 (patients) 
Age and age squared Impact on target variable may be 
influenced by unmeasured level 2 
characteristic 
Yes 
Duration of asthma Impact on target variable may be 
influenced by unmeasured level 2 
characteristic 
Noa 
Height  No due to missing values 
Weight  No due to missing values 
BMI  No due to missing values 
FEV1  No due to missing values 
FVC  No due to missing values 
Degree of asthma severity 
(based on 1995 Global 
Initiative for Asthma (GINA) 
recommendations on 
medication use) [80] 
Impact on target variable may be 
influenced by unmeasured level 2 
characteristic 
Yes 
Presence of asthma 
exacerbations 
Impact on target variable may be 
influenced by unmeasured level 2 
characteristic 
Yes 
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Table 1 ctd. 
Interaction of degree of 
severity and presence of 
asthma exacerbations 
Impact on target variable may be 
influenced by unmeasured level 2 
characteristic 
Yes 
Presence of asthma-related 
comorbidities 
Impact on target variable may be 
influenced by unmeasured level 2 
characteristic 
Yes 
Quick reliever vs controller 
therapy 
Impact on target variable may be 
influenced by unmeasured level 2 
characteristic 
Yes 
Involvement of a 
pulomonologist in diagnosis 
or treatment 
Level unclear, to be split up in 
"Diagnosis of asthma by a 
pulmologist" and "Specialty of 
treating physician" (see level 2) 
Yes 
Employment status in those 
aged 65 years or younger 
Impact on target variable may be 
influenced by unmeasured level 2 
characteristic 
Nob 
Absences from work Impact on target variable may be 
influenced by unmeasured level 2 
characteristic 
Nob 
Insurance status Impact on target variable may be 
influenced by unmeasured level 2 
characteristic 
Nob 
Level 2 (physicians) 
Specialty of treating physician  No, non-significant 
Location in a rural or urban 
area 
 No, non-significant 
Language region  No, non-significant 
a Reason for non-inclusion in main conventional model: Due to many missing values, the 
number of usable observations would have been reduced to N = 268. Also, there was no 
indication of a substantial contribution to the model, not even if duration was replaced by age 
at diagnosis to reduce the correlation with age. 
b Reason for non-inclusion in main conventional model: Regression coefficients for these 
predictors were (near) significant but their inclusion did not lead to a substantial improvement 
of the model. (Erroneously, insurance status is not mentioned in chapter 4.) 
 
The majority of potential predictors were level 1 variables. Height, weight, BMI, FEV1 
and FVC were excluded from the multilevel analyses due to a massive amount of 
missing values. (Tentative use of these variables in conventional models hinted at an 
impact of weight, BMI and FEV1, but this could not be pursued further due to data 
quality issues.) The impact of some other level 1 variables describing disease 
characteristics (e.g., degree of asthma control) and treatment characteristics (e.g., 
choice of quick reliever vs. controller therapy) on the target variable could be 
assumed to be influenced by the behaviour of the treating physician, an unmeasured 
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level 2 characteristic. Group level predictors were constructed by aggregating the 
values of these variables within their level 2 units (i.e., physicians), where they had 
an intuitive meaning. For example, the approach to the treatment of employed 
asthma patients and thus, the costs induced, might have differed between physicians 
with a low vs. high proportion of employed patients. Physicians frequently dealing 
with employed patients might be particularly aware of the specific requirements of 
this group, and behave accordingly. 
 
Multilevel modelling process and intermediate results 
Step 1. Random intercept model (variance components model). 
 
A random intercept model was estimated (Table 2) and showed a highly significant 
random intercept term (p < 0.001). The fixed parameter estimates remained 
essentially stable. 
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Table 2. Two-level random intercept model of direct medical costs (log scale) induced 
by asthmaa 
Number of level 1 units = 420 Log likelihood = -539.880
Number of level 2 units = 107 AIC 1109.76
Variable Esti-mates 
Std. 
Err. 
Test 
stat.b p value
95% Confidence 
Interval 
Fixed part       
Degree of severity:       
 Mild persistentc 0.747 0.187 3.99 < 0.001 0.379 1.114 
 Moderate persistentc 1.026 0.181 5.66 < 0.001 0.671 1.381 
 Severe persistentc 0.907 0.197 4.60 < 0.001 0.521 1.294 
Exacerbations present 0.326 0.289 1.13 0.260 -0.241 0.892 
Interaction of degree of severity and 
presence of exacerbations, ordinal: 
      
 Level 1d -0.422 0.346 -1.22 0.224 -1.100 0.257 
 Level 2d 0.111 0.331 0.34 0.737 -0.537 0.759 
 Level 3d 0.504 0.330 1.53 0.127 -0.142 1.149 
Age (centered) 0.006 0.002 2.66 0.008 0.002 0.011 
Age squared (centered) -0.0002 0.0001 -2.11 0.035 -0.0004 -0.0000
Asthma-related comorb. present 0.321 0.123 2.62 0.009 0.080 0.561 
Involvement of pulmonologist 0.524 0.115 4.56 < 0.001 0.299 0.750 
Controller therapye 0.249 0.094 2.65 0.008 0.065 0.433 
Intercept 4.249 0.310 13.71 < 0.001 3.641 4.856 
Random part - level 1       
Residual variance 0.685 0.053   0.554 0.762 
Random part - level 2       
Intercept variance 0.140 0.047 14.69 < 0.001 0.047 0.232 
a Conventional regression model for comparison: chapter 4, Table 4. 
b Fixed parameters, Wald test based on z statistic; random parameters, likelihood ratio test, p-
value divided by 2 (see Methods, p. 35). Standard errors and CIs based on the Wald statistic 
throughout. 
c Compared to mild intermittent. Wald test for this set of variables, p < 0.001. 
d Compared to level 0. Wald test for this set of variables, p = 0.002. 
e Compared to quick reliever therapy. 
 
Step 2. Analysis of the variance structure. 
 
Based on the covariates with a potential for level 2 variation, the variance structure 
was analysed as described in the methods section. The resulting model (Table 3) 
contained additional random effects for the variable distinguishing quick reliever from 
controller therapy and for the variable describing employment status in those aged 65 
years or younger. No significant covariance terms were found and all covariance 
terms were set to zero. The random intercept term turned non-significant. 
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Table 3. Two-level model of direct medical costs (log scale) induced by asthma, 
including random effects for the intercept, quick reliever versus controller therapy, 
and employment status in those aged 65 or youngera 
Number of level 1 units = 408 Log likelihood = -521.200
Number of level 2 units = 106 AIC 1080.40
Variable Esti-mates 
Std. 
Err. 
Test 
stat.b p value 
95% Confidence 
Interval 
Fixed part       
Degree of severity:       
 Mild persistentc 0.799 0.190 17.646 < 0.001 0.427 1.171 
 Moderate persistentc 1.085 0.186 34.172 < 0.001 0.720 1.450 
 Severe persistentc 0.879 0.202 18.934 < 0.001 0.483 1.275 
Exacerbations present 0.333 0.282 1.390 0.238 -0.220 0.886 
Interaction of degree of severity and 
presence of exacerbations, ordinal: 
      
 Level 1d -0.414 0.341 1.475 0.225 -1.082 0.254 
 Level 2d 0.072 0.326 0.049 0.825 -0.567 0.712 
 Level 3d 0.539 0.326 2.723 0.099 -0.010 1.118 
Age (centered) 0.009 0.003 11.269 0.001 0.004 0.013 
Age squared (centered) -0.0002 0.0001 4.948 0.026 -0.0004 -0.0000
Asthma-related comorb. present 0.293 0.124 5.539 0.019 0.050 0.536 
Diagnosis by a pulmonologist:       
 Noe -0.231 0.107 4.608 0.032 -0.441 -0.021 
 Unknowne -0.351 0.149 5.519 0.019 -0.643 -0.059 
Controller therapyf 0.512 0.119 18.595 < 0.001 0.279 0.745 
No employment despite under 
age 65 (employment status) 
0.219 0.127 2.966 0.085 -0.030 0.468 
Intercept 5.431 0.190 811.768 < 0.001 5.059 5.803 
Random part - level 1       
Residual variance 0.621 0.054   0.515 0.727 
Random part - level 2       
Intercept variance 0.049 0.054 0.823 0.182 -0.057 0.155 
Controller therapy variance 0.152 0.078 4.376 0.018 -0.001 0.305 
Employment status variance 0.226 0.143 3.605 0.029 -0.054 0.506 
a Conventional regression model for comparison: chapter 4, Table 4. 
b Fixed parameters, chi squared-based Wald test; random parameters, likelihood ratio test, p-
value divided by 2 (see Methods, p. 35). Standard errors and CIs based on the Wald statistic 
throughout. 
c Compared to mild intermittent. Wald test for this set of variables, p < 0.001. 
d Compared to level 0. Wald test for this set of variables, p = 0.002. 
e Compared to yes. Wald test for this set of variables, p = 0.016. 
f Compared to quick reliever therapy. 
 
NOTE: The AIC shown in Table 3 is not comparable with the AIC shown in Table 2, 
as the number of observations differed due to some missing values in the 
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employment status variable. The correct comparator AIC, based on the restricted set 
of 408 observations, was determined to be 1083.61. The AICs given in the text below 
were based on this same set of 408 observations, to allow for comparisons. 
 
Step 3. Goodness-of-fit. 
 
For the model shown in Table 3, the inverse normal plot of the studentised level 1 
residuals showed acceptable properties, with some deviation from the normal 
distribution in the tail areas (Figure 1). Plotting the studentised level 1 residuals 
against the fixed part predicted values (Figure 2) showed no particularities apart from 
a slight tendency towards heteroskedasticity, which was not unexpected in a 
regression model of health care costs. 
 
The three sets of studentised level 2 residuals, representing random deviations from 
the average intercept, the average coefficient of the variable distinguishing quick 
reliever from controller therapy, and the average coefficient of the working status 
variable, showed no serious deviations from the normal distribution (Figure 3). 
 
Step 4: Influential level 2 units. 
 
Caterpillar plots of the ranked level 2 residuals and diagnostics plots showing 
influence values [163:169-71] were used to identify influential level 2 units (marked in 
Figures 4, 5) and their corresponding observations at level 1 (marked in Figure 6). 
Four out of the seven observations marked had high residuals at level 1. Re-
estimating the model using dummy variables for these four observations led to a 
significantly improved model, the AIC being reduced from 1080.40 to 1040.30. Figure 
7 shows a repetition of the caterpillar plots, now based on the re-estimated model, 
with the residuals representing the "red" level 2 unit moved towards the middle of the 
distribution, but the residuals for the "green" level 2 unit still being located at its lower 
end. A possible interpretation would be that in the former case, the extreme position 
of the affected level 2 unit was mostly due to the level 1 characteristics of the outlying 
observations contained therein, while it was due to "true" level 2 characteristics (i.e., 
special characteristics of the affected physician) in the latter case. No such distinction 
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could be made for the "blue" level 2 unit as it contained only one observation at level 
1. 
 
Figure 1. Inverse normal plot of studentised level 1 residuals 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Plot of studentised level 1 residuals against fixed part predicted values 
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Figure 3. Inverse normal plots of studentised level 2 residuals 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Caterpillar plots of ranked level 2 residuals with 95% CIs 
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Figure 5. Diagnostics plots as available from MLwiN statistical package, example of 
level 2 intercept residuals 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Inverse normal plot of studentised level 1 residuals, observations 
representing influential level 2 units marked 
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Figure 7. Caterpillar plots of ranked level 2 residuals with 95% CIs, based on a re-
estimation of the multilevel model using dummy variables for four influential 
observations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The logical next step was to absorb all observations nested within the "green" level 2 
unit into a single dummy variable, while still representing the outlying "red" and "blue" 
observations by individual dummy variables. The explanatory value of the model 
would thus be optimised by neutralising, in its entirety, the impact of a level 2 unit 
confirmed to have abnormal and influential characteristics. The AIC of the resulting 
model was reduced further to 1038.63. 
 
Step 5: Final multilevel model. 
 
The last mentioned model was finalised by removing the working status variable, 
which became non-significant at both levels when the influential level 2 units 
identified were taken into account as described above (in the last mentioned model 
with AIC 1038.63, p = 0.500 for the variance term and p = 0.251 for the fixed term). 
The random intercept term was also removed as it remained non-significant in all 
models containing a random effect for the variable distinguishing quick reliever from 
controller therapy (in the last mentioned model with AIC 1038.63, p = 0.182). 
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Details of the final model are shown in chapter 4, Table 3. Residual-based re-
diagnosis showed acceptable properties for this model. Re-estimating the final model 
from a set from 408 instead of 420 observations, to allow for comparisons with the 
above shown AICs, led to an AIC of 1038.95. 
 
Step 6: Model re-calculation using alternative algorithms. 
 
Estimating the final model using Adaptive Quadrature (as implemented in Stata) or 
the Restricted Iterative Generalized Least Squares approach (RIGLS; as 
implemented in MLwiN) resulted in essentially identical parameter estimates. A final 
re-estimation used the non-parametric bootstrap method implemented in MLwiN. Five 
sets of 500 replicates were run, and the bias-corrected results were again fully 
confirmatory. 
 
Remark on centring the "quick reliever vs. controller therapy" covariate 
It has been recommended to use centred random slope covariates in multilevel 
modelling, in order to make the intercept and its variance interpretable (see Methods, 
pp. 34-5) [105:57-8,70-1]. Leaving numerical problems aside, all other model 
parameters are expected to remain unaffected by this procedure, and the resulting 
models are expected to be equivalent. 
 
However, in the multilevel analysis of the asthma dataset, using the non-centred 
"quick reliever vs. controller therapy" covariate turned the random intercept term 
small and non-significant, which led to its removal from the model. When the "quick 
reliever vs. controller therapy" covariate was subsequently centred, the model 
changed considerably and was no longer equivalent to the main model. (The log-
likelihood differed substantially.) In line with expectations, this problem was not 
observed when the random intercept term was re-added. It may be a point for further 
discussion if removing non-significant random intercept terms, as happened here, 
should be avoided to rule out such problems. 
 
Independently of this issue, the centring did not facilitate interpretation in this case 
where the random slope covariate was binary and coded 0/1. In the non-centred 
situation, and disregarding the impact of the scaling of the other covariates for a 
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moment, the intercept represented the patients receiving quick-reliever therapy, with 
no substantial random variation. After centring the random slope covariate, the 
intercept represented a difficult to conceive theoretical patient with a theoretical 
average treatment [105:56]. 
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Gatekeeping dataset 
 
Preliminary remark 
The gatekeeping dataset described in chapter 5 allowed to assess covariates of 
health plan membership as well as covariates of health care costs. Conventional 
analysis focused on health care costs, and this same response of interest was used 
in the multilevel re-analysis described here. A distinction between reduced and 
extended cost models was made in chapter 5, and multilevel assessments were 
based on the latter, more complete models. 
 
Structure of dataset 
The gatekeeping dataset formally has a cross-classification structure, with health 
plan beneficiaries being the level 1 units and belonging to two groupings each at 
level 2 (insurance companies and physicians). In the primary analysis of cost to the 
Swiss statutory sick funds, no significant influence of insurance company was 
identified and a brief multilevel re-assessment confirmed this finding. Therefore, 
multilevel re-analysis used a two-level model with beneficiaries at level 1 and 
physicians at level 2. 
 
List of potential predictor variables 
Collection of potential covariates in the gatekeeping study aimed at achieving an 
appropriate casemix adjustment in a general population and was thus very 
comprehensive. Table 4 lists the potential level 1 predictor variables which showed to 
be of importance in the primary analysis. In addition, all potential level 2 predictor 
variables are shown. 
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Table 4. Potential predictors of total and outpatient costs to the Swiss statutory sick 
funds in 2000 
Predictor variable Remarks regarding level Used in extended two-
part, non-multilevel 
cost models?a 
Level 1 (patients) 
Health plan membership 
(gatekeeping vs. fee-for-
service) 
Impact on target variable may be 
influenced by unmeasured level 2 
characteristic 
Yes 
Age (Impact on target variable unlikely 
to be strongly influenced by 
unmeasured level 2 characteristic) 
Yes 
Gender (Impact on target variable unlikely 
to be strongly influenced by 
unmeasured level 2 characteristic) 
Yes 
SF-36 scales (Impact on target variable unlikely 
to be strongly influenced by 
unmeasured level 2 characteristic) 
Yes (SF-2 scale and 
general health scale) 
Morbidity, measured by ICED 
[89], in the year before the 
gatekeeping plan started 
(Impact on target variable unlikely 
to be strongly influenced by 
unmeasured level 2 characteristic) 
Yes 
Increase in morbidity, 
measured by ICED [89], 
between the year before the 
gatekeeping plan started, and 
2000 
(Impact on target variable unlikely 
to be strongly influenced by 
unmeasured level 2 characteristic) 
Yes 
History of mental illness  No, non-significant 
Smoking behaviour  No, non-significant 
Alcohol consumption  No, non-significant 
BMI  No, non-significant 
Physical activity  No, non-significant 
Importance assigned to 
healthy nutrition 
 No, non-significant 
Self-reported avoidance of 
seeing a doctor 
 Yes 
Outpatient costs in the year 
before the gatekeeping plan 
started 
Impact on target variable may be 
influenced by unmeasured level 2 
characteristic 
Yes 
Educational level  No, non-significant due 
to presence of 
covariates with partially 
overlapping content 
Professional status  Yes (being retired) 
Living in a partnership  Yes 
Marital status  Yes 
Household size  Yes 
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Table 4 ctd. 
Household income  No, non-significant due to 
presence of a covariate 
with overlapping content 
Integration score (composite 
measure of being Swiss born 
and / or a Swiss citizen 
 Yes 
Residency in the Aarau area 
in 1996 
 Yes 
Nursing home residency Impact on target variable may be 
influenced by unmeasured level 2 
characteristic 
No, non-significant (after 
controlling for morbidity!) 
Importance assigned to low 
insurance premiums (highly 
correlated with household 
income) 
 Yes 
Duration of health insurance 
with the same company 
 No, non-significant 
Number and type of 
complementary insurance 
contracts 
Impact on target variable may be 
influenced by unmeasured level 2 
characteristic 
Yes (complementary 
semi-private insurance, 
complementary dental 
insurance) 
Level 2 (physicians) 
Year of medical degree of 
physician 
 No, non-significant 
Specialty of physician  No, non-significant 
Physician treating 
gatekeeping and fee-for-
service beneficiaries, or fee-
for-service beneficiaries only 
 No, non-significant 
Physician working in an 
individual or group practice 
 No, non-significant 
Time since entry in current 
practice 
 No, non-significant 
Number of consultations per 
year 
 No, non-significant 
a See chapter 5 for details of the total cost models, particularly Tables 3, 4. Details of outpatient 
cost models not shown. 
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Assessment of higher level variation 
 
Part 1 of two-part models: logistic models of any health care costs occurring 
The main logistic regression model of any costs to the Swiss statutory sick funds 
occurring (chapter 5, Table 3) was used as a basis and the intercept was allowed to 
vary at random. No significant level 2 variation was detected (intercept 5.62; level 2 
variance 0.26 with standard error 0.39; log likelihood -99.05 compared to -98.70 for 
the original fixed effects model; likelihood ratio statistic 0.70 (1dgf); p value 0.201). 
 
This Adaptive Quadrature-based result was re-evaluated using RIGLS in combination 
with Penalized Quasi Likelihood (PQL) estimation. The finding of no significant level 
2 variation being present was confirmed, although the results differed in detail 
(intercept 7.14; level 2 variance 0.48 with standard error 0.41). 
 
Tentatively allowing the covariates with a potential for higher level variation to vary at 
random did not produce any substantial or significant results. No further related 
assessments were performed. 
 
Part 2 of two-part models: GLMs of total and outpatient health care costs in 
those with non-zero costs  
The GLMs describing total costs and outpatient costs to the Swiss statutory sick 
funds in those beneficiaries with non-zero costs were used as a basis and their 
intercepts were allowed to vary at random. Virtually no level 2 variance was detected. 
For example, in the total cost model, the intercept was 7.36 and the level 2 variance 
was < 0.001 with standard error < 0.001. 
 
This Adaptive Quadrature-based result was fully confirmed by RIGLS and PQL-
based estimation. To match with the requirements of the software used for this, the 
cost variables were now treated as discrete count variables and the original GLMs 
(assuming a gamma distribution of errors) were reconstructed under a negative 
binomial distributional assumption [83: 7/10]. 
 
Tentatively allowing the covariates with a potential for higher level variation to vary at 
random did neither produce any substantial or significant results. 
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In order to rule out a situation where over-modelling at level 1 might hide any level 2 
variation, the number of covariates in the fixed part of the model was gradually 
reduced, but even after removal of all covariate terms apart from the intercept, the 
level 2 random variation of the intercept remained near-zero and non-significant. 
 
In order to make incorrect estimation results an even less likely explanation, an 
additional multilevel model assuming normality was tentatively fitted to the logarithm 
of the response variable. Again, no substantial or significant level 2 variation was 
found. This is supportive of the above-described findings, non-regarding that even on 
the log scale, the normality assumption was inadequate in this case, given a 
coefficient of variation of the untransformed response variable of around 0.73 [141: 
292-3, 296-297]. No further related assessments were performed. 
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Neutropenia dataset 
 
Structure of dataset 
The neutropenia dataset is a combination of six audits of breast cancer 
chemotherapy conducted in different European countries (see chapter 6). It is 
characterised by a three-level hierarchical data structure, with patients being the level 
1 units, study centres being the level 2 units, and audits conducted in different 
countries being the level 3 units. 
 
Table 5 shows potential predictor variables by level. For details regarding data 
collection and variable definitions, see chapter 6. 
 
There were no level 2 predictors in the strict sense, as type of centre (e.g., academic 
vs. non-academic) and centre size were unavailable, and no relevant level 3 
predictors in the strict sense. However, many of the level 1 predictors could be 
assumed to be "intertwined" with the higher levels of the hierarchy in different ways. 
In some cases, their impact on the target variable was potentially influenced by level 
2 characteristics (e.g., the aggressiveness of treatment of old cancer patients could 
be expected to vary across centres and treating physicians). The values of some 
other level 1 variables (e.g., chemotherapy regimen chosen) could be assumed to be 
directly influenced by their corresponding level 2 units, i.e. by centre-level differences 
in clinical practice and physician-level differences in treatment behaviours and clinical 
experience. The values of some level 1 variables could even have been influenced 
by their corresponding level 3 units (audits). For example, different national drug 
coverage policies could have influenced the chemotherapy regimens chosen. A 
strong impact of the audits (i.e., the study designs) themselves appeared unlikely, as 
they were very similar and purely observational in nature. 
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Table 5. Potential predictors of any neutropenic event occurrence 
Predictor variable Remarks regarding level Used in main con-
ventional model? 
Level 1 (patients) 
Age and age squared Impact on target variable may be 
influenced by level 2 characteristics 
(clinical practice) 
Yes 
Menopausal status Impact on target variable may be 
influenced by level 2 characteristics 
(clinical practice) 
No, highly 
correlated with age 
Body surface area Impact on target variable may be 
influenced by level 2 characteristics 
(clinical practice) 
Yes 
BMI Impact on target variable may be 
influenced by level 2 characteristics 
(clinical practice) 
Yes 
Oestrogen receptor status Impact on target variable may be 
influenced by level 2 characteristics 
(clinical practice) 
No, non-significant 
Disease stage Impact on target variable may be 
influenced by level 2 characteristics 
(clinical practice) 
No, non-significant 
Chemotherapy regimen Influenced by level 2 characteristics 
(clinical practice) 
Yes 
Summation dose intensity 
(SDI) 
Influenced by level 2 characteristics 
(clinical practice) 
Yes 
Planned chemotherapy 
cycles 
Influenced by level 2 characteristics 
(clinical practice) 
Yes 
Concomitant radiotherapy 
administration 
Influenced by level 2 characteristics 
(clinical practice) 
Yes 
Is treatment part of a clinical 
trial protocol? 
Influenced by level 2 characteristics 
(clinical practice) 
No, not available 
Level 2 (centres) 
Academic vs. non-academic 
centre 
 No, not available 
Centre size (patients with 
disease of interest treated per 
year 
 No, not available 
Level 3 (audit) 
Country  No, highly correla-
ted with audit itself 
Level difficult to assign 
Year of treatment and year of 
treatment squared 
If interpreted as level 1, impact on 
target variable influenced by level 2 
characteristics (clinical practice) and 
level 3 characteristics (timing of study) 
Yes 
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Alternative presentation of conventional model 
Presentation of the main conventional logistic regression model of any neutropenic 
event occurrence in chapter 6, Table 3 used simple effects to describe two-way 
interactions. However, the more familiar approach of showing main effects plus 
interaction terms was adopted to present the multilevel models. Moreover, linear 
coefficients are shown in the tables displaying multilevel models, instead of odds 
ratios. For reference purposes, Table 6 shows the main conventional logistic 
regression model of any neutropenic event occurrence re-written in this form. The 
model shown is fully mathematically equivalent to the model shown in chapter 6, 
Table 3. 
 
Table 6. Influences on any neutropenic event occurrence (logistic regression allowing 
for clustering by audit). Two-way interactions re-written as main effects plus 
interaction termsa 
N = 2'358 Pseudo R squared 0.070
Std. err. adjusted for 6 clusters (audits) Log pseudolikelihood -1147.969AIC 2355.94
Variable Esti-mates 
Std. 
Err. 
Test 
stat.b 
p 
valueb 
95% Confidence 
Interval 
Agec 0.017 0.005 3.53 < 0.001 0.008 0.026 
Body surface areac 1.349 0.377 3.57 < 0.001 0.609 2.088 
BMIc -0.035 0.014 -2.47 0.013 -0.062 -0.007 
Chemotherapy regimen:d       
 Three weekly CMF 1.010 0.149 6.79 < 0.001 0.719 1.301 
 Anthracycline-based 0.407 0.217 1.87 0.061 -0.019 0.833 
 Taxane-based 0.520 0.080 6.48 < 0.001 0.363 0.677 
 Other -0.144 0.477 -0.30 0.764 -1.080 0.793 
Normal to high SDIe 0.529 0.088 5.99 < 0.001 0.356 0.702 
Planned chemotherapy cyclesc 0.359 0.100 3.59 < 0.001 0.163 0.555 
Concomitant radiotherapy 
administration (Rx):f 
      
 Rx yes 3.288 1.205 2.73 0.006 0.927 5.649 
 Rx unknown 0.015 2.327 0.01 0.995 -4.545 4.575 
Year of treatment (centered)c -0.006 0.003 -1.82 0.068 -0.013 0.001 
Year of treatment squared 
(centered)c 
-0.0008 0.0004 -1.78 0.075 -0.0016 0.0001 
Interaction of chemotherapy 
regimen and year of treatment: 
      
 Three weekly CMF 0.085 0.047 1.81 0.071 -0.007 0.176 
 Anthracycline-based -0.106 0.045 -2.37 0.018 -0.194 -0.018 
 Taxane-based 0.707 0.078 9.11 < 0.001 0.555 0.859 
 Other 0.468 0.036 13.05 < 0.001 0.398 0.538 
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Table 6 ctd. 
Interaction of chemotherapy 
regimen and Rx: 
      
 Three weekly CMF, Rx yes -0.553 0.469 -1.18 0.238 -1.472 0.366 
 Anthracycline-based, Rx yes -0.902 0.212 -4.25 < 0.001 -1.319 -0.486 
 Taxane-based, Rx yes 0.432 0.219 1.97 0.049 0.002 0.862 
 Other, Rx yes -- -- -- -- -- -- 
 Three weekly CMF, Rx unkn. 0.206 0.393 0.52 0.601 -0.566 0.977 
 Anthracycline-based, Rx unkn. 0.805 0.399 2.02 0.044 0.023 1.587 
 Taxane-based, Rx unknown -- -- -- -- -- -- 
 Other, Rx unknowng 4.320 0.873 4.95 < 0.001 2.608 6.031 
Interaction of body surface area 
and Rx: 
      
 Rx yes -1.397 0.449 -3.11 0.002 -2.278 -0.516 
 Rx unknown 1.231 0.850 1.45 0.148 -0.435 2.897 
Interaction of planned 
chemotherapy cycles and Rx: 
      
 Rx yes -0.197 0.096 -2.06 0.039 -0.385 -0.010 
 Rx unknown -0.446 0.082 -5.46 < 0.001 -0.607 -0.286 
Interaction of normal to high SDI 
and Rx: 
      
 Rx yes 1.136 0.314 < 0.001 0.520 1.752 
 Rx unknown 0.171 1.095 0.16 0.876 -1.974 2.317 
Intercept -6.494 0.640 -10.15 < 0.001 -7.748 -5.240 
3.61 
a Mathematically equivalent to chapter 6, Table 3. 
b Combined Wald tests (z tests) for all sets of categorical or ordinal variables and for all sets of 
interaction terms, p < 0.05. 
c Per one unit increase. 
d Compared to four weekly CMF. 
e Second to 4th quartiles compared to 1st quartile. 
f Compared to no concomitant radiotherapy administration. 
g Parameter estimate based on 4 observations, assumed to be an artefact 
Abbreviations: C, cyclophosphamide; F, 5-fluorouracil; M, methotrexate; SDI, summation dose 
intensity. 
 
Multilevel modelling process and intermediate results 
Step 1. Random intercept model (variance components model). 
 
The intercept was allowed to vary at random at levels 2 (centres) and 3 (audits), 
revealing substantial and significant variation at level 2, but no significant variation at 
level 3. Dropping the level 3 random intercept term resulted in virtually identical 
parameter estimates otherwise. The resulting two-level random intercept model 
(Table 7) showed coefficient and standard error estimates which were mostly similar 
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to those seen in the main conventional model. However, the significance of the year 
of treatment and year of treatment squared terms was lost, and the same was true 
for the term representing interaction of year of treatment and use of a three weekly 
CMF regimen. The set of terms representing interaction of year of treatment and 
chemotherapy regimen type remained highly significant as a whole. Other substantial 
changes were limited to coefficients which were based on very few observations, and 
thus doubtful anyway (terms representing taxane-based and "other" chemotherapy 
regimens). 
 
Table 7. Two-level random intercept model of any neutropenic event occurrence 
(logistic regression allowing for clustering by audit)a 
Number of level 1 units = 2'358 
Number of level 2 units = 93 
Log likelihood -1114.342
Std. err. adjusted for 6 clusters (audits) AIC 2290.68 
Variable Esti-mates 
Std. 
Err. 
Test 
stat.b 
p 
valueb 
95% Confidence 
Interval 
Fixed part       
Agec 0.022 0.006 3.54 < 0.001 0.010 0.034 
Body surface areac 1.431 0.289 4.96 < 0.001 0.865 2.000 
BMIc -0.045 0.012 -3.85 < 0.001 -0.068 -0.022 
Chemotherapy regimen:d       
 Three weekly CMF 0.777 0.130 5.96 < 0.001 0.521 1.302 
 Anthracycline-based 0.609 0.232 2.62 0.009 0.154 1.064 
 Taxane-based 1.182 0.201 5.88 < 0.001 0.788 1.576 
 Other 0.264 0.449 0.59 0.557 -0.616 1.143 
Normal to high SDIe 0.478 0.176 2.72 0.007 0.133 0.822 
Planned chemotherapy cyclesc 0.351 0.110 3.21 0.001 0.137 0.566 
Concomitant radiotherapy 
administration (Rx):f 
      
 Rx yes 3.237 0.862 3.75 < 0.001 1.547 4.927 
 Rx unknown -0.504 2.338 -0.22 0.829 -5.086 4.077 
Year of treatment (centered)c -0.004 0.005 -0.81 0.418 -0.014 0.006 
Year of treatment squared 
(centered)c 
-0.0006 0.0004 -1.63 0.104 -0.0013 0.0001 
Interaction of chemotherapy 
regimen and year of treatment: 
      
 Three weekly CMF 0.021 0.031 0.66 0.506 -0.041 0.083 
 Anthracycline-based -0.095 0.047 -2.03 0.043 -0.186 -0.003 
 Taxane-based 0.679 0.097 7.01 < 0.001 0.489 0.869 
 Other 0.419 0.035 11.85 < 0.001 0.350 0.489 
180 
  Appendix I: Multilevel re-analysis details 
 
Table 7 ctd. 
Interaction of chemotherapy 
regimen and Rx: 
      
 Three weekly CMF, Rx yes -0.376 0.479 -0.79 0.432 -1.315 0.563 
 Anthracycline-based, Rx yes -0.915 0.186 -4.93 < 0.001 -1.279 -0.551 
 Taxane-based, Rx yes 0.645 0.170 3.97 < 0.001 0.311 0.979 
 Other, Rx yes -- -- -- -- -- -- 
 Three weekly CMF, Rx unkn. 0.845 0.478 1.77 0.077 -0.091 1.782 
 Anthracycline-based, Rx unkn. 0.872 0.459 1.90 0.057 -0.027 1.771 
 Taxane-based, Rx unknown -- -- -- -- -- -- 
 Other, Rx unknowng 4.644 0.982 4.73 < 0.001 2.719 6.570 
Interaction of body surface area 
and Rx: 
      
 Rx yes -1.409 0.294 -4.79 < 0.001 -1.985 -0.833 
 Rx unknown 1.358 0.797 1.70 0.089 -0.205 2.920 
Interaction of planned 
chemotherapy cycles and Rx: 
      
 Rx yes -0.211 0.089 -2.36 0.018 -0.386 -0.036 
 Rx unknown -0.425 0.083 -5.11 < 0.001 -0.588 -0.262 
Interaction of normal to high SDI 
and Rx: 
      
 Rx yes 1.186 0.352 3.37 0.001 0.497 1.876 
 Rx unknown 0.008 1.033 0.01 0.993 -2.015 2.032 
Intercept -6.733 0.727 -9.26 < 0.001 -8.158 -5.307 
Random part - level 1       
Binomial variance 1h 0     
Random part - level 2       
Intercept variance 0.587 0.065 67.25 < 0.001 0.460 0.714 
a Conventional regression model for comparison: chapter 6, Table 3, re-written to facilitate 
comparison in Appendix I, Table 6. 
b Fixed parameters, Wald test based on z statistic; random parameters, likelihood ratio test, p-
value divided by 2 (see Methods, p. 35). Standard errors and CIs based on the Wald statistic 
throughout. Wald tests for all sets of categorical or ordinal variables and for all sets of 
interaction terms, p < 0.03. 
c Per one unit increase. 
d Compared to four weekly CMF. 
e Second to 4th quartiles compared to 1st quartile. 
f Compared to no concomitant radiotherapy administration. 
g Parameter estimate based on 4 observations, assumed to be an artefact 
h Constrained to 1 [169: 35]. 
Abbreviations: C, cyclophosphamide; F, 5-fluorouracil; M, methotrexate; SDI, summation dose 
intensity. 
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Step 2. Analysis of the variance structure. 
 
Using the covariates with a potential for level 2 variation, the variance structure was 
analysed as described in the methods section. Significant level 2 variation was 
observed for the intercept and for the variable indicating the use of an anthracycline-
based chemotherapy regimen. The corresponding covariance term was also 
significant. In contrast, the fixed effects terms representing year of treatment, year of 
treatment squared, and interaction between year of treatment and chemotherapy 
regimen type became now clearly non-significant and were removed from the model. 
The resulting final multilevel model is shown in chapter 7, Table 4. 
 
Some level 1 predictors with a potential for level 2 variation were aggregated at the 
centre level, divided into quartiles and tentatively added to the model. None of them 
were significant at level 2 or interacted significantly with other covariates, but the 
following were significant at level 1. 
• Proportion of patients aged 65 or older: the centres representing the highest 
quartile of this variable showed a reduced neutropenic event risk for their patients. 
In order to limit the number of additional model terms, a binary variable was 
constructed on this basis. 
• Proportion of patients with a BMI ≥ 30 kg/m2: the centres representing the second 
to fourth quartiles of this variable showed an increased neutropenic event risk for 
their patients. In order to limit the number of additional model terms, a binary 
variable was constructed on this basis. 
• Proportion of anthracycline-based regimens used: the quartiles of this variable 
showed a continuously decreasing neutropenic event risk with increasing 
anthracyclines use. In order to limit the number of additional model terms, the 
continuous equivalent of this variable was used. 
• Proportion of three-weekly CMF regimens used: this variable showed a complex 
relationship with neutropenic event occurrence. The risk was highest in the 
centres which did not use any three weekly CMF regimens (first and second 
quartiles combined). It was lower in the centres which used three-weekly CMF 
rarely (third quartile; three-weekly CMF used in 6.5% of patients on average) than 
in those who used it frequently (fourth quartile; three-weekly CMF used in 47.0% 
of patients on average). 
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As these covariates did not contribute to the analysis of higher level variation and in 
order to reduce the risk of over-modelling, it was decided not to use them in the final 
multilevel model of any neutropenic event occurrence. However, the extended model 
containing these covariates is shown in Table 8 and was fully assessed. Including the 
above-described terms reduced the AIC from 2284.63 to 2267.05. There were no 
massive changes of the other fixed effects coefficients or their standard errors, but 
increased coefficients and smaller standard errors were observed in some cases. 
Predictive ability was not increased. The apparent prediction error was, MSE 0.138 
and classification error 19.55% in the extended model vs. MSE 0.137 and 
classification error 19.38% in the final model. Ten-fold cross-validation restricting the 
test set to observations from the level 2 units contributing to model estimation 
showed a similar result, with MSE 0.152 and classification error 21.17% in the 
extended model vs. MSE 0.152 and classification error 21.04% in the final model. If 
the test set was restricted to observations from the level 2 units not used for model 
estimation, the MSE was 0.167 and classification error 23.05% in the extended 
model vs. MSE 0.170 and classification error 22.44% in the final model. 
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Table 8. Two-level model of any neutropenic event occurrence (logistic regression); 
including variance and covariance terms for the intercept and use of an anthracycline-
based chemotherapy regimen, and additional predictors aggregated at the centre 
levela 
Number of level 1 units = 2'358 
Number of level 2 units = 93 
Log likelihood -1101.527
Std. err. adjusted for 6 clusters (audits) AIC 2267.05
Variable Esti-mates 
Std. 
Err. 
Test 
stat.b 
p 
valueb 
95% Confidence 
Interval 
Fixed part - level 1       
Agec 0.025 0.007 3.49 < 0.001 0.011 0.039 
Body surface areac 1.418 0.315 4.50 < 0.001 0.800 2.036 
BMIc -0.050 0.011 -4.63 < 0.001 -0.071 -0.029 
Chemotherapy regimen:d       
 Three weekly CMF 0.708 0.087 8.09 < 0.001 0.536 0.879 
 Anthracycline-based 0.570 0.177 3.22 0.001 0.223 0.918 
 Taxane-based 1.841 0.144 12.75 < 0.001 1.559 2.124 
 Other 1.036 0.395 2.62 0.009 0.261 1.810 
Normal to high SDIe 0.522 0.146 3.58 < 0.001 0.236 0.808 
Planned chemotherapy cyclesc 0.353 0.098 3.62 < 0.001 0.162 0.544 
Concomitant radiotherapy 
administration (Rx):f 
      
 Rx yes 3.042 0.665 4.58 < 0.001 1.739 4.346 
 Rx unknown -1.082 1.841 -0.59 0.557 -4.690 2.526 
Interaction of chemotherapy 
regimen and Rx: 
      
 Three weekly CMF, Rx yes -0.399 0.433 -0.92 0.357 -1.247 0.450 
 Anthracycline-based, Rx yes -0.950 0.114 -8.32 < 0.001 -1.174 -0.726 
 Taxane-based, Rx yes 1.524 0.246 6.18 < 0.001 1.041 2.007 
 Other, Rx yes -- -- -- -- -- -- 
 Three weekly CMF, Rx unkn. 0.830 0.440 1.89 0.059 -0.032 1.693 
 Anthracycline-based, Rx unkn. 0.789 0.400 1.97 0.048 0.005 1.572 
 Taxane-based, Rx unknown -- -- -- -- -- -- 
 Other, Rx unknowng 1.992 1.005 1.98 0.047 0.022 3.962 
Interaction of body surface area 
and Rx: 
      
 Rx yes -1.248 0.207 -6.03 < 0.001 -1.654 -0.842 
 Rx unknown 1.659 0.687 2.41 0.016 0.312 3.006 
Interaction of planned 
chemotherapy cycles and Rx: 
      
 Rx yes -0.196 0.089 -2.20 0.028 -0.371 -0.021 
 Rx unknown -0.386 0.075 -5.17 < 0.001 -0.532 -0.239 
Interaction of normal to high SDI 
and Rx: 
      
 Rx yes 1.037 0.367 2.83 0.005 0.318 1.756 
 Rx unknown -0.076 0.969 -0.08 0.938 -1.974 1.823 
Intercept -6.561 0.640 -10.25 < 0.001 -7.815 -5.307 
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Table 8 ctd. 
Fixed part - level 2       
High proportion of patients above 
65 years of ageh 
-0.598 0.195 -3.07 0.002 -0.980 -0.217 
Higher proportion of patients with 
BMI ≥ 30 kg/m2 (lowest quartile)e
0.519 0.186 2.80 0.005 0.155 0.882 
Proportion of patients receiving 
anthracycline-based 
chemotherapy regimens 
-1.173 0.176 -6.68 0.008 -1.517 -0.829 
Small proportion of patients 
receiving three weekly CMF 
regimensi 
-0.422 0.146 -2.89 0.004 -0.709 -0.136 
High proportion of patients 
receiving three weekly CMF 
regimensi 
0.244 0.176 1.11 0.267 -0.187 0.675 
Random part - level 1       
Binomial variance 1j 0     
Random part - level 2       
Intercept variance 0.647 0.139 
50.44 
(2dgf)k 
< 0.001 0.315 0.931 
Anthracycline-based chemo-
therapy regimen variance 
0.838 0.248 
20.35 
(2dgf)k 
< 0.001 0.134 1.252 
Covariance -0.627 0.120 13.28 < 0.001 -0.942 -0.206 
a Conventional regression model for comparison: chapter 6, Table 3, re-written to facilitate 
comparison in Appendix I, Table 6. 
b Fixed parameters, Wald test based on z statistic; random parameters, likelihood ratio test, p-
value divided by 2 (see Methods, p. 35). Standard errors and CIs based on the Wald statistic 
throughout. Wald tests for all sets of categorical or ordinal variables and for all sets of 
interaction terms, p < 0.05. 
i Third and 4th quartiles separately compared to 1st and 2nd quartiles combined. (Mean 
proportion of three-weekly CMF use by quartile: 1st and 2nd quartiles combined, 0.0%; 3rd 
quartile, 6.5%; 4th quartile, 47.0%.) 
c Per one unit increase. 
d Compared to four weekly CMF. 
e Second to 4th quartiles compared to 1st quartile. 
f Compared to no concomitant radiotherapy administration. 
g Parameter estimate based on 4 observations, assumed to be an artefact. 
h Fourth quartile compared to 1st to 3rd quartiles. 
j Constrained to 1 [169: 35]. 
k Removing any of the level 2 random variance terms also removes the covariance term. 
Abbreviations: C, cyclophosphamide; F, 5-fluorouracil; M, methotrexate; SDI, summation dose 
intensity. 
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Step 3. Goodness-of-fit. 
 
For the final multilevel model of any neutropenic event occurrence, the plot of mean 
observed against mean predicted event probabilities, by deciles of the linear 
predictor, showed acceptable albeit not ideal properties (chapter 7, Figure 4). The 
two sets of studentised level 2 residuals representing random deviations from the 
average intercept and from the average coefficient of the variable indicating use of an 
anthracycline-based chemotherapy regimen showed no serious deviations from the 
normal distribution (chapter 7, Figure 5). 
 
The corresponding plots for the extended model described in Table 8 are shown 
below in Figures 8 and 9. The plot of mean observed against mean predicted event 
probabilities might be interpreted as showing slightly superior properties for this 
model. 
 
Figure 8. Extended multilevel model of neutropenic event occurrence - mean observed 
against mean predicted event probabilities, by deciles of the linear predictor 
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Figure 9. Extended multilevel model of neutropenic event occurrence - inverse normal 
plots of studentised level 2 residuals 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lifting the constraint on the residual level 1 variance and allowing it to vary at random 
led to an estimate of 0.939 (standard error 0.028) for the final multilevel model and to 
an estimate of 0.960 (standard error 0.029) for the extended multilevel model. These 
minor deviations from the one did not indicate the presence of any substantial extra-
binomial variation. There was no hint of a misspecification of the link function or of an 
omission of relevant covariates or interaction terms according to this criterion [169: 
35]. 
 
Step 4: Influential level 2 units. 
 
Plots of ranked level 2 residuals and influence values hinted at two influential level 2 
units in both models. Tentatively absorbing these into dummy variables did not 
change the other model parameters substantially or decrease the AIC in a relevant 
way. No changes to the final and extended multilevel models of any neutropenic 
event occurrence were induced. (Details not shown.) 
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Step 5: Final multilevel model. 
 
 
 
The multilevel model shown in chapter 7, Table 4 is perceived as the final multilevel 
model of any neutropenic event occurrence resulting from this dataset. 
 
Step 6: Model re-calculation using alternative algorithms. 
Estimating the final model using Adaptive Quadrature (as implemented in Stata) or 
RIGLS followed 2nd order PQL (as implemented in MLwin) resulted in similar, but not 
identical parameter estimates. (In the tables, adaptive quadrature-based results are 
shown throughout.) A final re-estimation using the non-parametric bootstrap method 
implemented in MLwiN was planned but could not be performed due to numerical 
problems. 
 
Remark on the use of robust standard error estimates 
In the conventional analysis of any neutropenic event occurrence, the possibility of 
non-independence within the level 3 units (audits), or within the level 2 units 
(centres), was taken into account by estimating GEE-based robust standard errors 
allowing for clustering of observations. Alternatively, dummy variables were used to 
represent the level 3 units in the model. The changes induced by these different 
options were small. In most instances, using the robust method led to slightly 
reduced standard errors in this dataset. More substantial changes were only 
observed in some variables representing taxane-based or "other" chemotherapies, or 
interactions of these. These chemotherapy regimen types were represented by very 
few observations only and the validity of any related results was considered 
questionable from the beginning. Moreover, the dummy option did not decrease the 
AIC substantially. 
In the multilevel models, similar observations were made. Robust standard error 
estimates allowing for clustering by audit tended again to be smaller, but the 
differences were not such that they would have affected any decisions regarding the 
inclusion or exclusion of model parameters. (Decisions regarding the inclusion or 
exclusion of variance and covariance terms were based on likelihood ratio tests, 
which were not influenced by the choice to use or not to use robust standard errors.) 
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Appendix II 
 
Cross-validation details 
 
This appendix addresses the implementation of ten-fold and bootstrap-based cross-
validation to assess the prediction error of conventional and multilevel models. Three 
different situations were regarded: 
(A) The assessment of predictive ability used observations from any higher level 
units, irrespective of whether these did or did not contribute to model estimation. 
This was considered to be equivalent to ignoring the hierarchical structure of the 
data. 
(B) The assessment of predictive ability used observations whose corresponding 
higher level units did (through other observations) contribute to model 
estimation. 
(C) The assessment of predictive ability used observations whose corresponding 
higher level units did not contribute to model estimation. 
 
Conventional models 
 
(A) Hierarchical structure of data ignored 
In order to perform ten-fold cross-validation, the dataset was randomly split into ten 
equal subsets. 
 
The parameters of the given model of interest were then estimated ten times, from 
training sets consisting of 90% of the observations each (always leaving out one of 
the ten subsets). 
 
 
 
Each time, indicators of prediction error were calculated from the remaining 10% 
observations (tenth subset). The results were averaged. 
The bootstrap approach was implemented analogously. e0 and .632 bootstrap 
estimators were used [60·61]. 
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(B) Test set restricted to those observations whose corresponding higher level 
units, through other observations, contributed to model estimation 
The same approach as above was used, but observations whose corresponding 
higher level units did not contribute to model estimation were excluded from the test 
sets. 
Alternatively, in order to loose fewer observations from the test sets and make better 
use of the available information, the splitting or resampling (in the booststrap case) of 
the dataset was done within each higher level unit (stratified approach). (The results 
of this alternative approach turned out to be near-identical to those of the main 
approach and are not reported in detail.) 
Only the e0 bootstrap estimator was used, as the correct way of deriving an .632 
estimator in this situation was not clear. 
(C) Test set restricted to those observations whose corresponding higher level 
units did not contribute to model estimation 
 
 
Approach not used, as the interpretation of the results would have been unclear. 
(B) Test set restricted to those observations whose corresponding higher level 
units, through other observations, contributed to model estimation 
 
 
 
Here, the splitting or resampling was performed on the higher level units, not on the 
individual observations. The training sets consisted of all observations from the 
selected higher level units, and the test sets consisted of all other observations. 
Only the e0 bootstrap estimator was used, as the correct way of deriving an .632 
estimator in this situation was not clear. 
Multilevel models 
 
(A) Hierarchical structure of data ignored 
 
The same approach as for the conventional models was used, but only ten-fold 
cross-validation was performed. Due to computation time issues, no bootstrap-based 
cross-validation was performed on the multilevel models (see Appendix III). 
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Prediction on the test sets (out of sample prediction) was based on the covariate 
values of the test set observations and on the random effects estimates (empirical 
Bayes estimates) for their corresponding higher level units as generated by the 
training set-based multilevel modelling process (i.e. information from the test set 
observations was not used to update the random effects estimates; also see 
Appendix III). 
 
(C) Test set restricted to those observations whose corresponding higher level 
units did not contribute to model estimation 
The same approach as for the conventional models was used, but again, only ten-
fold cross-validation was performed. 
 
Prediction on the test sets (out of sample prediction) was based on the covariate 
values of the test set observations and on values of zero for the higher level unit-
specific random effects, as no informative empirical Bayes estimates were available 
for these higher level units not contributing to model estimation (also see Appendix 
III) [162]. 
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Appendix III 
 
Statistical software and estimation methods 
 
 
 
All descriptive and univariate analyses, and conventional regression analyses, were 
performed using standard methods and algorithms as implemented in Stata® and 
Stata/SE®, versions 6.0-9.0 (Stata Corporation, College Station, USA). Multilevel re-
analyses were performed in Stata/SE® version 9.0, and in MLwiN® version 2.02 
(Multilevel Models Project, Institute of Education, London, UK). 
Multilevel modelling is implemented in Stata by way of a user-written procedure 
named gllamm (abbreviating "Generalized Linear Latent and Mixed Models") and an 
accompanying prediction procedure named gllapred [161]. gllamm uses Gaussian 
Quadrature or Adaptive Quadrature and can be used with various types of response 
variables. (An additional Stata procedure, xtmixed, also allows to estimate multilevel 
linear regression models but cannot be used with non-continuous responses. In order 
to maintain consistency, only gllamm was used to estimate multilevel models in 
Stata.) 
MLwiN is a highly specialized multilevel modelling software and can be used with 
continuous, count, binary/binomial, and survival data. Parameter estimation is based 
on the Iterative Generalized Least Squares (IGLS) and Restricted Iterative 
Generalized Least Squares (RIGLS) methods. These are combined with first and 
second order Marginal Quasi Likelihood (MQL), or optionally with Penalized Quasi 
Likelihood (PQL), in the case of non-linear responses [164: 206]. Bayesian methods 
(Markov Chain Monte Carlo - MCMC simulation) and bootstrap-based methods are 
offered as alternatives. The bootstrap solution implemented in MLwiN uses the 
resampling of residuals approach and parametric as well as non-parametric versions 
are available [34]. 
 
Both Stata's gllamm procedure and MLwiN have some strenghts and weaknesses, 
which are listed below. 
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Stata (gllamm / gllapred procedure) 
Positives: 
• Extremely flexible with respect to types of response variables, related 
distributional assumptions (distributional families) and available link functions. 
• Allows to estimate GEE-based robust standard errors allowing for clustering  
(non-independence of observations) within higher level units. (For example, in a 
situation with many level 2 units and few level 3 units, it may make sense to 
estimate a two-level model allowing for clustering at level 3. This approach has 
been used in the neutropenia study.) 
• Provides the log likelihood statistic for all types of responses, i.e. allows to 
perform likelihood ratio tests on all model parameters and in all situations. 
 
Negatives: 
• Extremely slow, particularly in the case of non-normal responses. 
• No possibility to restrict individual covariance terms to zero (all or none approach). 
Therefore, not all MLwiN models can be re-estimated in Stata. 
 
Remark regarding out of sample prediction: 
• An "fsample" option for out of sample prediction is integrated in gllapred, the 
prediction procedure for gllamm [161:27-9]. However, if "fsample" is used as is, 
the likelihood, and subsequently the random effects estimates for the higher level 
units involved, are updated using the observed responses of the observations for 
which the prediction is to be made [162]. This behaviour makes it more difficult to 
assess the out of sample predictive ability of multilevel models, non-regarding if 
the prediction aims at observations whose corresponding higher level units did, or 
did not, contribute to estimating the multilevel model. For such assessments, the 
original random effects estimates as derived from the multilevel modelling process 
should be used, or values of zero for higher level units which did not contribute to 
model estimation [162]. The technical solution used by the author to achieve this 
involved use of the "us()" option with gllapred, which opens up a possibility to 
force predictions to be based on the original, or on zero, random effects 
estimates. 
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MLwiN 
Positives: 
• Very fast and flexible when using IGLS/RIGLS, reasonably fast when using 
resampling-based estimation methods (MCMC or bootstrap). 
• Very flexible and efficient graphical tools for residuals and outlier assessments. 
 
Negatives: 
• No possibility to directly make a gamma distributional assumption for continuous 
or quasi-continuous responses. (As an alternative, quasi-continuous responses 
can be interpreted as discrete counts and a negative binomial distributional 
assumption can be made [83:7/10·141:373]. 
• No possibility to estimate GEE-based robust standard errors allowing for 
clustering by higher level units. 
• No likelihood ratio tests can be performed for discrete response models (i.e., 
logistic and negative binomial models). The log likelihood statistic is unavailable in 
these cases, as the quasi-likelihood methods used for estimation are thought to 
produce unreliable likelihood estimates [164:113]. 
 
Taking these strengths and weaknesses into account, the following approach to 
multilevel modelling was chosen. For each study, the main conventional regression 
model(s) were reconstructed using Stata's gllamm procedure. The intercept terms 
were then allowed to vary at random, in order to assess the presence of substantial 
and significant higher level variation. Where such higher level variation was present, 
the corresponding random intercept model was reconstructed in MLwiN. The efficient 
IGLS/RIGLS algorithms (and, eventually, MQL/PQL algorithms) implemented in 
MLwiN were used to further analyse the variance structure and to perform goodness-
of-fit assessments. Influential higher level units were also identified in MLwiN and 
related action was taken as applicable. The final IGLS/RIGLS-based multilevel 
models were then re-estimated using the non-parametric bootstrap method 
implemented in MLwiN, and using Stata's gllamm procedure (switching back to GEE-
based standard error estimates in the case of the neutropenia study). This approach 
was chosen as a validity check, because the multilevel algorithms used have not yet 
reached the degree of maturity and reliability which one is now used to when 
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standard non-multilevel regression techniques are applied. The gllamm-based results 
were defined as the final multilevel models. 
 
The author used the estimation methods and settings recommended for the various 
types of multilevel models assessed, according to the documentations provided with 
the statistical packages. All gllamm models used Adaptive Quadrature with eight to 
twelve quadrature points. 
 
In MLwiN, RIGLS and MQL were used to estimate normal response models. Logistic 
and negative binomial models were based on RIGLS and second order PQL, after 
deriving MQL-based starting values [164: 111·169: 39]. In these cases, the likelihood 
statistic was only available and the AIC could only be calculated for the gllamm-
based models. Likelihood ratio tests for the variance parameters were thus 
postponed until the final gllamm models were available. In MLwiN, Wald tests were 
alternatively used. The results of both approaches were compared. Assessments of 
the ability of groups of fixed parameters (i.e., sets of predictor variables or interaction 
terms) to significantly improve the model were based on Wald tests only, although 
known to be sub-optimal [186:261], in order to keep computation time requirements 
within realistic limits. (NOTE: Stata uses the variant of the Wald test which is based 
on the standard normal distribution and z statistic, while MLwiN uses the chi squared-
based equivalent [116: 647]. This lead to differences in test statistics, but not in the 
resulting p values.) 
 
Non-parametric bootstrap-based parameter re-estimation for each model was based 
on five sets of 500 replicates per set, and bias-corrected estimates were derived (if 
no numerical problems occurred). 
 
Cross-validation was programmed in Stata and as Stata's gllamm procedure is very 
slow, bootstrap-based cross-validation could not realistically be used with the 
multilevel models. Therefore, only ten-fold cross-validation was used with the 
multilevel models. 
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